0001628280-23-015236.txt : 20230503 0001628280-23-015236.hdr.sgml : 20230503 20230503162209 ACCESSION NUMBER: 0001628280-23-015236 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230503 DATE AS OF CHANGE: 20230503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 23884356 BUSINESS ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 10-Q 1 cort-20230331.htm 10-Q cort-20230331
false2023Q1000108885612/3100010888562023-01-012023-03-3100010888562023-04-26xbrli:shares00010888562023-03-31iso4217:USD00010888562022-12-3100010888562022-01-012022-03-31iso4217:USDxbrli:shares00010888562021-12-3100010888562022-03-310001088856us-gaap:CommonStockMember2022-12-310001088856us-gaap:AdditionalPaidInCapitalMember2022-12-310001088856us-gaap:TreasuryStockCommonMember2022-12-310001088856us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001088856us-gaap:RetainedEarningsMember2022-12-310001088856us-gaap:CommonStockMember2023-01-012023-03-310001088856us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001088856us-gaap:TreasuryStockCommonMember2023-01-012023-03-310001088856us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001088856us-gaap:RetainedEarningsMember2023-01-012023-03-310001088856us-gaap:CommonStockMember2023-03-310001088856us-gaap:AdditionalPaidInCapitalMember2023-03-310001088856us-gaap:TreasuryStockCommonMember2023-03-310001088856us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001088856us-gaap:RetainedEarningsMember2023-03-310001088856us-gaap:CommonStockMember2021-12-310001088856us-gaap:AdditionalPaidInCapitalMember2021-12-310001088856us-gaap:TreasuryStockCommonMember2021-12-310001088856us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001088856us-gaap:RetainedEarningsMember2021-12-310001088856us-gaap:CommonStockMember2022-01-012022-03-310001088856us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001088856us-gaap:TreasuryStockCommonMember2022-01-012022-03-310001088856us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001088856us-gaap:RetainedEarningsMember2022-01-012022-03-310001088856us-gaap:CommonStockMember2022-03-310001088856us-gaap:AdditionalPaidInCapitalMember2022-03-310001088856us-gaap:TreasuryStockCommonMember2022-03-310001088856us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001088856us-gaap:RetainedEarningsMember2022-03-31cort:series0001088856srt:MinimumMember2023-01-012023-03-31cort:compound0001088856us-gaap:FurnitureAndFixturesMember2023-03-310001088856us-gaap:FurnitureAndFixturesMember2022-12-310001088856us-gaap:ComputerSoftwareIntangibleAssetMember2023-03-310001088856us-gaap:ComputerSoftwareIntangibleAssetMember2022-12-310001088856us-gaap:LeaseholdImprovementsMember2023-03-310001088856us-gaap:LeaseholdImprovementsMember2022-12-310001088856us-gaap:CashEquivalentsMember2023-03-310001088856us-gaap:CashEquivalentsMember2022-12-310001088856cort:ShortTermMarketableSecuritiesMember2023-03-310001088856cort:ShortTermMarketableSecuritiesMember2022-12-310001088856cort:LongTermMarketableSecuritiesMember2023-03-310001088856cort:LongTermMarketableSecuritiesMember2022-12-310001088856us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001088856us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001088856us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CommercialPaperMember2023-03-310001088856us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CommercialPaperMember2022-12-310001088856us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001088856us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001088856us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001088856us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001088856us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001088856us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001088856us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001088856us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001088856us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001088856us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001088856us-gaap:SettledLitigationMembercort:MelucciMember2023-02-082023-02-080001088856us-gaap:SettledLitigationMembercort:MelucciMember2022-10-012022-12-310001088856us-gaap:SettledLitigationMembercort:MelucciMember2023-03-31xbrli:purecort:plan0001088856us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001088856us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001088856us-gaap:EmployeeStockOptionMember2023-03-310001088856us-gaap:EmployeeStockOptionMember2022-12-310001088856us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001088856us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001088856us-gaap:RestrictedStockMember2023-01-012023-03-310001088856us-gaap:EmployeeStockMember2022-02-280001088856us-gaap:EmployeeStockMember2023-01-012023-03-310001088856us-gaap:EmployeeStockMember2022-01-012022-03-310001088856cort:RestrictedStockAwardsRSAsMember2023-01-012023-03-310001088856cort:RestrictedStockAwardsRSAsMember2022-01-012022-12-310001088856us-gaap:CostOfSalesMember2023-01-012023-03-310001088856us-gaap:CostOfSalesMember2022-01-012022-03-310001088856us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001088856us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001088856us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310001088856us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310001088856us-gaap:RestrictedStockUnitsRSUMember2023-03-310001088856us-gaap:RestrictedStockMember2023-03-310001088856us-gaap:EmployeeStockOptionMember2022-03-310001088856us-gaap:RestrictedStockUnitsRSUMember2022-03-310001088856us-gaap:RestrictedStockMember2022-03-310001088856cort:RestrictedStockUnitsAndStockOptionsMember2023-01-012023-03-310001088856cort:RestrictedStockUnitsAndStockOptionsMember2022-01-012022-03-310001088856srt:ScenarioForecastMember2023-04-010001088856us-gaap:SubsequentEventMember2023-04-010001088856us-gaap:SubsequentEventMember2023-04-012023-04-010001088856cort:TenderOfferMember2023-03-060001088856us-gaap:SubsequentEventMembercort:TenderOfferMember2023-04-052023-04-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________________________________
FORM 10-Q
_______________________________________________________
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2023
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from             to             
Commission File Number:
000-50679
_______________________________________________________
CORCEPT THERAPEUTICS INCORPORATED
(Exact Name of Corporation as Specified in Its Charter)
_______________________________________________________
Delaware77-0487658
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
149 Commonwealth Drive
Menlo Park, CA 94025
(Address of principal executive offices, including zip code)
_______________________________________________________
(650) 327-3270
(Registrant’s telephone number, including area code)
_______________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par valueCORTThe Nasdaq Stock Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  
On April 26, 2023, there were 101,577,897 shares of common stock outstanding at a par value of $0.001 per share.



TABLE OF CONTENTS
2


PART I. FINANCIAL INFORMATION
ITEM 1.  FINANCIAL STATEMENTS
CORCEPT THERAPEUTICS INCORPORATED
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
March 31,
2023
December 31,
2022
 (Unaudited)(See Note 1)
ASSETS  
Current assets:  
Cash and cash equivalents$299,942 $66,329 
Short-term marketable securities165,115 365,343 
Trade receivables, net of allowances32,557 31,057 
Insurance recovery receivable related to Melucci litigation (Note 4)14,000 14,000 
Inventory6,409 6,100 
Prepaid expenses and other current assets15,870 16,424 
Total current assets533,893 499,253 
Strategic inventory10,156 10,931 
Operating lease right-of-use asset575 1,143 
Property and equipment, net461 633 
Long-term marketable securities 4,947 
Other assets4,764 5,058 
Deferred tax assets, net67,999 61,465 
Total assets$617,848 $583,430 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$11,216 $11,976 
Accrued research and development expenses13,981 14,573 
Accrued and other liabilities39,093 30,799 
Accrued settlement related to Melucci litigation (Note 4)14,000 14,000 
Short-term operating lease liability575 1,143 
Total current liabilities78,865 72,491 
Long-term accrued income taxes payable9,399 9,097 
Total liabilities88,264 81,588 
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock  
Common stock131 131 
Treasury stock(462,507)(456,148)
Additional paid-in capital679,848 662,342 
Accumulated other comprehensive loss(153)(869)
Retained earnings312,265 296,386 
Total stockholders’ equity529,584 501,842 
Total liabilities and stockholders’ equity$617,848 $583,430 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3


CORCEPT THERAPEUTICS INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(In thousands, except per share data)
Three Months Ended March 31,
 20232022
Product revenue, net$105,654 $93,688 
Operating expenses:
Cost of sales1,386 1,250 
Research and development40,851 28,120 
Selling, general and administrative48,564 37,549 
Total operating expenses90,801 66,919 
Income from operations14,853 26,769 
Interest and other income3,581 80 
Income before income taxes18,434 26,849 
Income tax expense(2,555)(4,052)
Net income$15,879 $22,797 
Net income attributable to common stockholders15,807 22,797 
Basic net income per common share$0.15 $0.22 
Diluted net income per common share$0.14 $0.20 
Weighted-average shares outstanding used in computing net income per common share
Basic107,885 106,012 
Diluted115,425 115,037 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4



CORCEPT THERAPEUTICS INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
(In thousands)
Three Months Ended March 31,
20232022
Net income$15,879 $22,797 
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale investments, net of tax effect of $(192) and $323, respectively
605 (1,019)
Foreign currency translation gain (loss), net of tax111 (105)
Total comprehensive income$16,595 $21,673 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5


CORCEPT THERAPEUTICS INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
 Three Months Ended March 31,
 20232022
Cash flows from operating activities:  
Net income$15,879 $22,797 
Adjustments to reconcile net income to net cash provided by operations:
Stock-based compensation11,141 10,761 
(Accretion) amortization of interest income(1,503)1,106 
Depreciation and amortization of property and equipment172 288 
Deferred income taxes(6,726)(9,935)
Non-cash amortization of right-of-use asset568 514 
Changes in operating assets and liabilities:
Trade receivables(1,500)447 
Inventory558 (163)
Prepaid expenses and other assets848 (9)
Accounts payable(649)2,256 
Accrued research and development expenses(592)609 
Accrued and other liabilities8,027 4,995 
Long-term accrued income taxes302 2,107 
Operating lease liability(568)(526)
Net cash provided by operating activities25,957 35,247 
Cash flows from investing activities:
Purchases of property and equipment (12)
Proceeds from maturities of marketable securities207,475 42,127 
Purchases of marketable securities (92,611)
Net cash provided by (used in) investing activities207,475 (50,496)
Cash flows from financing activities:
Proceeds from issuance of common stock under our incentive award plan, net of issuance costs1,409 1,382 
Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants(1,228)(1,888)
Net cash provided by (used in) financing activities181 (506)
Net increase (decrease) in cash and cash equivalents233,613 (15,755)
Cash and cash equivalents, at beginning of period66,329 77,617 
Cash and cash equivalents, at end of period$299,942 $61,862 
Supplemental disclosure:
Exercise cost of shares repurchased for net settlement of cashless option exercises$5,246 $5,149 
Recognition of right-of-use asset and lease liability$ $2,816 
The accompanying notes are an integral part of these condensed consolidated financial statements.
6


CORCEPT THERAPEUTICS INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
(In thousands)
Common StockAdditional Paid-in CapitalTreasury StockAccumulated Other Comprehensive (Loss) IncomeRetained EarningsTotal Stockholders’ Equity
SharesAmount
Balance at December 31, 2022107,835 $131 $662,342 $(456,148)$(869)$296,386 $501,842 
Issuance of common stock under our incentive award plan618 — 6,540 — — — 6,540 
Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises(297)— — (6,359)— — (6,359)
Stock-based compensation— — 10,966 — — — 10,966 
Other comprehensive gain, net of tax— — — — 716 — 716 
Net income— — — — — 15,879 15,879 
Balance at March 31, 2023108,156 $131 $679,848 $(462,507)$(153)$312,265 $529,584 
Common StockAdditional Paid-in CapitalTreasury StockAccumulated Other Comprehensive LossRetained EarningsTotal Stockholders’ Equity
SharesAmount
Balance at December 31, 2021105,940 $127 $591,349 $(410,411)$(227)$194,968 $375,806 
Issuance of common stock upon exercise of options586 1 6,543 — — — 6,544 
Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises(305)— — (7,037)— — (7,037)
Stock-based compensation— — 10,825 — — — 10,825 
Other comprehensive loss, net of tax— — — — (1,124)— (1,124)
Net income— — — — — 22,797 22,797 
Balance at March 31, 2022106,221 $128 $608,717 $(417,448)$(1,351)$217,765 $407,811 
The accompanying notes are an integral part of these condensed consolidated financial statements
7


CORCEPT THERAPEUTICS INCORPORATED
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. Basis of Presentation and Summary of Significant Accounting Policies
Description of Business and Basis of Presentation
Corcept Therapeutics Incorporated (collectively, “Corcept,” the “Company,” “we,” “us,” and “our”) is a commercial-stage pharmaceutical company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. In 2012, the United States Food and Drug Administration (“FDA”) approved Korlym (“mifepristone”) 300 mg tablets, as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. We have discovered and patented four structurally distinct series of selective cortisol modulators, consisting of more than 1,000 compounds. We are developing compounds from these series as potential treatments for a broad range of serious disorders.
We were incorporated in the State of Delaware in May 1998. Our headquarters are located in Menlo Park, California.
Basis of Presentation
We have prepared the following in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X: (i) condensed consolidated balance sheet as of March 31, 2023 and (ii) condensed consolidated statements of income, comprehensive income, cash flows and stockholders’ equity for the three-month periods ended March 31, 2023 and 2022. These do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation (which in the applicable periods consist only of normal, recurring adjustments) have been included. Operating results for the three-month period ended March 31, 2023 are not necessarily indicative of the results for the remainder of 2023 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2022 included in our Annual Report on Form 10-K. The December 31, 2022 balance sheet was derived from audited financial statements at that date.
There have been no material changes to the significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2022.
2. Composition of Certain Balance Sheet Items
Inventory
March 31,
2023
December 31,
2022
 (in thousands)
Work in progress$8,514 $7,827 
Finished goods8,051 9,204 
Total inventory16,565 17,031 
Less strategic inventory classified as non-current(10,156)(10,931)
Total inventory classified as current$6,409 $6,100 
Because we rely on a single manufacturer to produce Korlym’s active pharmaceutical ingredient (“API”), we have purchased and hold significant quantities of API, included in work in progress inventory. We classify inventory we do not expect to sell within 12 months of the balance sheet date as “Strategic inventory,” a long-term asset.
8


Property and equipment, net
March 31,
2023
December 31,
2022
(in thousands)
Furniture and equipment$1,235 $1,235 
Software1,508 1,508 
Leasehold improvements1,597 1,597 
Total property and equipment4,340 4,340 
Less accumulated depreciation and amortization(3,879)(3,707)
Property and equipment, net$461 $633 
Accrued and other liabilities
March 31,
2023
December 31,
2022
 (in thousands)
Government rebates$15,478 $11,098 
Income taxes payable8,589 89 
Accrued compensation7,806 15,511 
Legal fees3,421 2,673 
Professional fees1,498 211 
Accrued selling and marketing costs1,081 434 
Other1,220 783 
Total accrued and other liabilities$39,093 $30,799 
Other assets
As of March 31, 2023 and December 31, 2022, other assets included $4.6 million and $4.9 million of deposits for clinical trials, respectively.
3. Available-for-Sale Securities and Fair Value Measurements
The available-for-sale securities in our condensed consolidated balance sheets are as follows:
March 31,
2023
December 31,
2022
(in thousands)
Cash equivalents$259,936 $36,380 
Short-term marketable securities165,115 365,343 
Long-term marketable securities 4,947 
Total marketable securities$425,051 $406,670 
9


The following table presents our available-for-sale securities grouped by asset type:
 Fair Value
Hierarchy
Level
March 31, 2023December 31, 2022
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueAmortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
  (in thousands)
Corporate bondsLevel 2$30,832 $ $(134)$30,698 $151,069 $ $(625)$150,444 
Commercial paperLevel 294,301   94,301 136,132   136,132 
U.S. government agency securitiesLevel 225,398  (2)25,396 25,113 23  25,136 
Asset-backed securitiesLevel 2    185   185 
U.S. Treasury securitiesLevel 114,723  (3)14,720 58,536  (142)58,394 
Money market fundsLevel 1259,936   259,936 36,379   36,379 
Total marketable securities$425,190 $ $(139)$425,051 $407,414 $23 $(767)$406,670 
We estimate the fair value of marketable securities classified as Level 1 using quoted market prices obtained from a commercial pricing service for these or identical investments. We estimate the fair value of marketable securities classified as Level 2 using inputs that may include benchmark yields, reported trades, broker/dealer quotes and issuer spreads.
We periodically review our debt securities to determine if any of our investments is impaired due to the issuer’s poor credit or other reasons. If the fair value of our investment is less than our amortized cost, we evaluate quantitative and subjective factors – including, but not limited to, the nature of security, changes in credit ratings and analyst reports concerning the security’s issuer and industry, and interest rate fluctuations and general market conditions to determine whether an allowance for credit losses is appropriate.
None of our investments, including those with unrealized losses, are impaired. Unrealized losses on our investments are due to interest rate fluctuations. We do not intend to sell investments that currently have unrealized losses and it is highly unlikely that we will sell any investment before recovery of its amortized cost basis, which may be at maturity. Accordingly, we have not recorded an allowance for credit losses for these investments.
We classified accrued interest on our marketable securities of $1.1 million and $1.8 million as of March 31, 2023 and December 31, 2022, respectively, as prepaid and other current assets on our condensed consolidated balance sheets.
As of March 31, 2023, all our marketable securities had original maturities of less than two years and all our marketable securities classified as short-term have maturities of less than one year. The weighted-average maturity of our holdings was one month. None of our marketable securities changed from one fair value hierarchy to another during the three months ended March 31, 2023.
4. Commitments and Contingencies
There have been no material changes in our obligations under contractual agreements described in our Annual Report on Form 10-K for the year ended December 31, 2022.
In the ordinary course of business, we may be subject to legal claims and regulatory actions that could have a material adverse effect on our business or financial position. We assess our potential liability in such situations by analyzing potential outcomes under various litigation, regulatory and settlement strategies. If we determine a loss is probable and its amount can be reasonably estimated, we accrue an amount equal to the estimated loss.
Melucci Litigation and Settlement
On March 14, 2019, a purported securities class action complaint was filed in the United States District Court for the Northern District of California by Nicholas Melucci (Melucci v. Corcept Therapeutics Incorporated, et al., Case No. 5:19-cv-01372-LHK) (the “Melucci litigation”). The complaint named us and certain of our executive officers as defendants asserting violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder and alleges that the defendants made false and materially misleading statements and failed to disclose adverse facts about our business, operations and prospects. The complaint asserts a putative class period extending from August 2, 2017 to February 5, 2019 and seeks unspecified monetary relief, interest and attorneys’ fees. On October 7, 2019, the Court appointed a lead plaintiff and lead counsel. The lead plaintiff’s consolidated complaint was filed on December 6, 2019. With respect to these allegations, we have stated, from the beginning, that we have done nothing wrong.
10


On February 8, 2023, we reached an agreement in principle (the “Proposed Settlement”) to resolve all claims in the Melucci litigation. Under the Proposed Settlement, we have agreed to make a one-time payment of $14.0 million, which will be covered in full by our insurers. In connection with the Proposed Settlement, we recorded a settlement expense of $14.0 million and corresponding insurance recovery of $14.0 million in operating expenses on our consolidated statement of income in the fourth quarter of 2022. Accordingly, we recorded an accrued liability of $14.0 million and a corresponding insurance recovery receivable of $14.0 million on our condensed consolidated balance sheet as of March 31, 2023. The Proposed Settlement is subject to the final approval of the Court.
No losses and no provision for a loss contingency have been recorded to date. For further information about our ongoing legal matters, see Part II. Item 1, Legal Proceedings.
5. Leases
We lease our office facilities in Menlo Park, California. On April 1, 2023, we signed an amendment to extend our lease through June 30, 2024. Refer to Note 9 “Subsequent Events” for further details.
As the operating lease for our facilities does not expressly state an interest rate, we calculated the present value of remaining lease payments using a discount rate equal to the interest rate we would pay on a collateralized loan with monthly payments and a term equal to the monthly payments and remaining term of our lease. We recognize operating lease payments as expenses using the straight-line method over the term of the lease.
Operating lease expense for the three months ended March 31, 2023 and 2022 was $0.6 million and $0.5 million, respectively.
Our right-of-use assets and related lease liabilities were as follows (in thousands, except weighted average amounts):
Three Months Ended March 31,
20232022
Cash paid for operating lease liabilities$578 $530 
Right-of-use assets obtained in connection with new operating lease obligations$ $2,816 
Weighted-average remaining lease term3 months15 months
Weighted-average discount rate4.0 %4.0 %
As of March 31, 2023, future minimum lease payments under non-cancelable operating leases were as follows (in thousands):
2023 (remainder)578 
Total operating lease payments578 
Less imputed interest(3)
Present value of operating lease liabilities$575 
6. Stockholders’ Equity
Incentive Award Plan
We have one stock option plan – the Corcept Therapeutics Incorporated 2012 Incentive Award Plan (the “2012 Plan”).
Stock Options
During the three months ended March 31, 2023, we issued 0.5 million shares of our common stock upon the exercise of stock options. Some option holders exercised their options on a “net exercise” basis, pursuant to which they surrendered to us, and we purchased from them, at the current market price, shares equal in value to the associated exercise price and tax withholding obligations. During the three months ended March 31, 2023, we purchased 0.3 million shares in connection with option net exercises and paid $1.1 million to satisfy associated tax withholding obligations.
During the three months ended March 31, 2022, we issued 0.6 million shares of our common stock upon the exercise of stock options. We purchased 0.3 million shares in connection with option net exercises and paid $1.9 million to satisfy associated tax withholding obligations.
11


We recorded purchased shares as treasury stock on our condensed consolidated balance sheets at cost. As of March 31, 2023 and December 31, 2022, we had 23.4 million and 23.1 million treasury shares outstanding, respectively.
Restricted Stock Units (“RSUs”)
During the three months ended March 31, 2022, we granted employees 0.2 million RSUs with a weighted-average grant date fair value of $19.34 per share. No RSUs were granted during the three months ended March 31, 2023.
Restricted Stock Awards (“RSAs”)
During the three months ended March 31, 2023, we granted employees 0.3 million RSAs with a weighted-average grant date fair value of $22.39 per share. No RSAs were granted during the three months ended March 31, 2022. RSAs include voting and dividend rights and are therefore “participating” shares for the purpose of calculating basic and diluted net income per share. See “Note 7” below.
Employee Stock Purchase Plan (“ESPP”)
In February 2022 we adopted an ESPP that allows employees to set aside, by means of payroll deductions, up to ten percent of their annual compensation for the purchase of our common stock. Shares are issued to participating employees from the 2012 Plan on March 1st and September 1st of each year (or, if those dates fall on holidays or weekends, on the first business day thereafter) at the then-current fair market value of our stock, as determined at the close of trading on those days. Payroll deductions for participating employees began April 1, 2022, and the first purchase under the plan took place on September 1, 2022.
In January 2023, we increased the number of ESPP purchase dates to occur quarterly on March 1st, June 1st, September 1st and December 1st (or, if those dates fall on holidays or weekends, on the first business day thereafter).
For each purchased share, the participating employee will receive one matching share, also issued from the 2012 Plan if certain conditions are met. There is no vesting requirement for shares issued pursuant to the ESPP purchase. The matching share will be granted in the form of a RSA that will vest on the one-year anniversary of the respective ESPP purchase date, net of applicable tax withholding. The vesting condition on the RSA is that the participating employee hold the corresponding share purchased under the ESPP for one year from the purchase date. Shares purchased pursuant to the ESPP and any matching shares issued upon satisfaction of the one-year holding requirement may be held, sold or transferred at the employee’s sole discretion.
During the three months ended March 31, 2023 and 2022, we issued 0.1 million and no shares of our common stock in connection with our ESPP, respectively. As of March 31, 2023 and December 31, 2022, we had a liability of $0.5 million and $0.2 million, respectively, related to RSAs granted in connection with our ESPP in “Accrued and other liabilities” on our condensed consolidated balance sheets.
Stock-based Compensation
Stock-based compensation expense associated with stock options and awards of restricted stock is measured at the grant date based on the fair value of the award, and is recognized, net of forfeitures, as expense over the remaining requisite service period on a straight-line basis.
We value restricted stock at the closing market price of the our common stock on the date of grant.
The following table summarizes our stock-based compensation by account:
Three Months Ended March 31,
 20232022
 (in thousands)
Stock-based compensation capitalized in inventory$92 $64 
Cost of sales23 16 
Research and development3,484 3,371 
Selling, general and administrative7,634 7,374 
Total stock-based compensation$11,233 $10,825 
12


7. Net Income Per Share
We compute our basic and diluted net income per share in conformity with the two-class method required for companies with participating shares. Under the two-class method, net income is determined by allocating net income between common stock and unvested RSAs. We compute basic net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. We compute diluted net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period, including potentially dilutive stock options and unvested RSUs, less unvested RSAs. We use the treasury stock method to determine the number of dilutive shares of common stock resulting from stock options and unvested RSUs.
The following table shows the computation of net income per share for each period:
Three Months Ended March 31,
 20232022
 (in thousands)
Numerator:  
Net income attributable to common stockholders$15,807 $22,797 
Denominator:
Weighted-average shares used to compute basic net income per common share107,885 106,012 
Dilutive effect of employee stock options and unvested RSUs7,540 9,025 
Weighted-average shares used to compute diluted net income per common share115,425 115,037 
Net income per share attributable to common stockholders
Basic$0.15 $0.22 
Diluted$0.14 $0.20 
As of March 31, 2023, we had 24.6 million stock options, 0.1 million RSUs and 0.6 million RSAs outstanding. As of March 31, 2022, we had 26.0 million stock options, 0.2 million RSUs and no RSAs outstanding.
We excluded from the computation of diluted net income per share, on a weighted-average basis, 10.4 million stock options and unvested RSUs outstanding during the three months ended March 31, 2023 and 6.9 million stock options outstanding and unvested RSUs during the three months ended March 31, 2022, because including them would have reduced dilution.
8. Income Taxes
We recorded income tax expense of $2.6 million for the three months ended March 31, 2023, compared to $4.1 million for the comparable period in 2022. The decrease during the three months ended March 31, 2023 was primarily due to decreased income before income taxes compared to the corresponding period in 2022.
Our effective tax rate differs from the federal statutory rate due to state income taxes and the non-deductible portion of our stock-based compensation, which increased our tax expense, offset by research and development credits and the excess tax deduction arising from the exercise of employee stock options, which reduced our taxable income.
During the three months ended March 31, 2023, unrecognized tax benefits increased by $0.4 million. As of March 31, 2023, the Company had unrecognized tax benefits of $9.3 million that, if recognized, would affect the Company’s effective tax rate and approximately $2.5 million of unrecognized tax benefits that would not impact the effective tax rate as they would be offset by a corresponding change in valuation allowance.
13


Each quarter, we assess the likelihood that we will generate sufficient taxable income to use our federal and state deferred tax assets. Except for the valuation allowances that offset the value of our California net deferred tax assets, we have determined that it is more likely than not we will realize the benefit related to all other deferred tax assets. To the extent we increase a valuation allowance, we will include an expense in the Condensed Consolidated Statement of Income in the period in which such determination is made.
Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the right to deduct research and development expenditures for tax purposes in the period the expenses were incurred and instead requires all U.S. and foreign research and development expenditures to be amortized over five and fifteen tax years, respectively. Congress has considered legislation that would defer the amortization requirement to later years, but as of March 31, 2023, the requirement has not been modified.
9. Subsequent Events
Lease Amendment
On April 1, 2023, we amended our office lease to extend its terms from July 1, 2023 through June 30, 2024 and we leased an additional space beginning April 1, 2023 through June 30, 2024. As a result of the amendment, we expect to record a right-of-use asset and corresponding lease liability of approximately $0.3 million related to the additional space. The remaining space has an extended lease term of 12 months, for which we do not expect to record an additional right of use asset. We will record $2.5 million of rent expense on a straight-line basis throughout the lease term in connection with this lease amendment.
Tender Offer
On March 6, 2023, we announced that our Board of Directors approved a tender offer to purchase up to 7.5 million shares of our common stock. The tender offer commenced on March 6, 2023 and expired on March 31, 2023. On April 5, 2023, we repurchased 6.6 million shares through the tender offer at a price of $22.00 per share for an aggregate purchase price of $145.4 million, excluding related fees and expenses. We recorded purchased shares as treasury stock on our condensed consolidated balance sheet at cost.
14


ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand our results of operations and financial condition and is provided as a supplement to, and should be read in conjunction with our condensed consolidated financial statements and the accompanying notes to financial statements, risk factors and other disclosures included in this Form 10-Q. Our condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”).
We make statements in this section that are “forward-looking” within the meaning of the federal securities laws. For a complete discussion of such statements and the potential risks and uncertainties that may affect their accuracy, see the “Risk Factors” section of this Form 10-Q and the “Overview” and “Liquidity and Capital Resources” sections of this MD&A.
Overview
We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. Since 2012, we have marketed Korlym (mifepristone) for the treatment of patients suffering from Cushing’s syndrome. Our portfolio of proprietary selective cortisol modulators consists of four structurally distinct series totaling more than 1,000 compounds.
Cushing’s Syndrome
Korlym. We sell Korlym in the United States, using experienced sales representatives to call on physicians caring for patients with endogenous Cushing’s syndrome (hypercortisolism). Because many people who suffer from Cushing’s syndrome are undiagnosed or inadequately treated, we have developed and continue to refine and expand programs to educate physicians and patients about screening for hypercortisolism and the role Korlym can play in treating patients with the disorder. We also have a field-based force of medical science liaisons.
We use one specialty pharmacy and one specialty distributor to distribute Korlym and provide logistical support to physicians and patients. Our policy is that no patient with Cushing’s syndrome will be denied access to Korlym for financial reasons. To help us achieve that goal, we fund our own patient support programs and donate money to independent charitable foundations that help patients pay for all aspects of their Cushing’s syndrome care, whether or not that care includes taking Korlym.
Relacorilant. We are conducting two Phase 3 trials (named GRACE and GRADIENT) of our proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with Cushing’s syndrome. Relacorilant was well-tolerated in its Phase 1 and Phase 2 trials. Patients in the Phase 2 trial exhibited meaningful improvements in glucose control, hypertension, weight, liver function, coagulopathy, cognition, mood, insulin resistance and quality of life measures. Relacorilant shares Korlym’s affinity for the glucocorticoid receptor (“GR”), but, unlike Korlym, has no affinity for the progesterone receptor (“PR”), and so is not the “abortion pill” and does not cause other effects associated with PR affinity, including endometrial thickening and vaginal bleeding. Relacorilant also does not appear to cause hypokalemia (low potassium), a potentially serious condition that is a leading cause of patients stopping treatment with Korlym. Forty-four percent of patients in Korlym’s pivotal trial experienced hypokalemia. Relacorilant does not affect any electrocardiogram parameters and does not cause prolongation of the QT interval, unlike all other medications used to treat Cushing’s syndrome.
In the GRACE trial, each patient receives relacorilant for 22 weeks. Patients who exhibit pre-specified improvements in hypertension and/or glucose metabolism enter a 12-week, double-blind, “randomized withdrawal” phase, in which half of the patients continue receiving relacorilant and half receive placebo. The trial’s primary endpoint is the rate and degree of relapse of hypertension in patients receiving placebo measured against the rate and degree of relapse of hypertension in those continuing relacorilant. GRACE has a planned enrollment of 130 patients with Cushing’s syndrome at sites in the United States, Canada, Europe and Israel. If successful, GRACE will provide the basis for a new drug application (“NDA”) for relacorilant as a treatment for patients with any etiology of endogenous Cushing’s syndrome.
Our second Phase 3 trial of relacorilant, GRADIENT, is studying patients whose Cushing’s syndrome is caused by a benign adrenal tumor. These patients often exhibit less severe symptoms or have a more gradual course of disease than patients with other etiologies of Cushing’s syndrome, although their health outcomes are ultimately poor. Half of the patients in GRADIENT will receive relacorilant for 22 weeks and half will receive placebo. The trial’s primary endpoints are improvements in glucose metabolism and hypertension. The planned enrollment for this study is 130 patients. Many of the clinical sites in GRACE are participating in GRADIENT.
15


The United States Food and Drug Administration (“FDA”) and the European Commission (“EC”) have designated relacorilant as an orphan drug for the treatment of Cushing’s syndrome. In the United States, relacorilant’s orphan designation confers tax credits, reduced regulatory fees and, provided we obtain approval for the treatment of patients with Cushing’s syndrome, seven years of exclusive marketing rights. Benefits of orphan drug designation by the EC are similar, but also include protocol assistance from the European Medicines Agency (“EMA”), access to the centralized marketing authorization procedure in the European Union (“EU”) and, if we obtain approval, ten years of exclusive marketing rights in the EU for the treatment of patients with Cushing’s syndrome.
Oncology
There is substantial evidence that cortisol activity at the GR reduces the efficacy of certain anti-cancer therapies and that modulating cortisol’s activity may help anti-cancer treatments achieve their intended effect. In some cancers, cortisol retards cellular apoptosis – the tumor-killing effect many treatments are meant to stimulate. In other cancers, cortisol activity promotes tumor growth. Cortisol also suppresses the body’s immune response; activating – not suppressing – the immune system is beneficial in fighting certain cancers. Many types of solid tumors express the GR and are potential targets for cortisol modulation therapy, among them ovarian, adrenal and prostate cancer.
Relacorilant in Patients with Advanced Ovarian Cancer. In May 2021, we announced preliminary results from our 178-patient, controlled, multi-center, Phase 2 trial of relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer. Study participants were randomized to one of three treatment arms: 60 women received 150 mg of relacorilant intermittently (the day before, the day of and the day after their weekly nab-paclitaxel infusion) and 58 women received a daily relacorilant dose of 100 mg per day in addition to nab-paclitaxel. Sixty women received nab-paclitaxel alone. The trial’s primary endpoint was progression-free survival (i.e., the time from random assignment in a clinical trial to disease progression or death from any cause or “PFS”).
Patients in both of the relacorilant plus nab-paclitaxel treatment arms experienced longer PFS than did the patients who received nab-paclitaxel alone. Patients who received a higher dose of relacorilant intermittently exhibited a statistically significant improvement in median PFS (5.6 months versus 3.8 months, hazard ratio: 0.66; p-value: 0.038). Patients who received a lower dose of relacorilant daily exhibited a median PFS that was 1.5 months longer than did the patients who received nab-paclitaxel alone (5.3 months versus 3.8 months, hazard ratio: 0.83; p-value: not significant). Patients who received relacorilant intermittently also had a longer median duration of response (“DoR”) (5.6 months versus 3.7 months, hazard ratio: 0.36; p-value: 0.006) compared to those who received nab-paclitaxel alone. Patients who received relacorilant intermittently also lived longer (median OS: 13.9 months versus 12.2 months, hazard ratio: 0.67; p-value: 0.066) compared to those who received nab-paclitaxel alone.
Safety and tolerability of relacorilant plus nab-paclitaxel were comparable to nab-paclitaxel monotherapy.
In June 2022, we initiated a pivotal Phase 3 trial (“ROSELLA”) that seeks to replicate the positive results observed in our Phase 2 study. ROSELLA has a planned enrollment of 360 women with recurrent, platinum-resistant ovarian cancer, randomized 1:1 to receive either 150 mg of relacorilant intermittently in addition to nab-paclitaxel or nab-paclitaxel monotherapy. The primary endpoint is PFS, with overall survival as a key secondary endpoint. Patients in ROSELLA will have received prior bevacizumab therapy, which is the standard of care in the United States for patients with platinum-resistant ovarian cancer. Women with a history of tumors that do not respond to initial platinum-based treatments (i.e., women with “primary platinum-refractory” disease) and those who have received more than three prior lines of therapy will be excluded.
In our Phase 2 trial, women who met the entry criteria for ROSELLA and received relacorilant intermittently experienced significantly improved PFS (median: 7.3 months versus 3.7 months, hazard ratio: 0.40; p-value: 0.005) and OS (median: 17.9 months versus 12.6 months, hazard ratio: 0.38; p-value: 0.011) relative to patients in the comparator arm. The patients in the intermittent arm also experienced a significant improvement in DoR relative to those in the comparator arm (median: 5.6 months versus 3.1 months, hazard ratio: 0.29; p-value: 0.016).
Relacorilant in Patients with Adrenal Cancer with Cortisol Excess. We are conducting an open-label, Phase 1b trial of relacorilant plus the PD-1 checkpoint inhibitor pembrolizumab in patients with metastatic or unresectable adrenal cancer whose tumors produce cortisol. The trial is examining whether adding relacorilant to pembrolizumab therapy reduces cortisol-activated immune suppression sufficiently to help pembrolizumab achieve its intended tumor-killing effect. Relacorilant is also expected to treat the patients’ Cushing’s syndrome generated by their tumors’ excess production of cortisol.
Relacorilant in Patients with Prostate Cancer. Androgen deprivation is the standard treatment for prostate cancer because androgens stimulate prostate tumor growth. Tumors often escape androgen deprivation therapy when cortisol’s activity at the GR stimulates tumor growth. Combining a cortisol modulator with an androgen modulator may block this escape route. Our collaborators at the University of Chicago plan to initiate a randomized, placebo-controlled Phase 2 trial of relacorilant plus
16


enzalutamide in patients with prostate cancer, pre-prostatectomy. We are providing relacorilant and placebo for the study and have licensed patents covering the use of relacorilant combined with anticancer agents such as enzalutamide in the treatment of patients with this indication.
Amyotrophic Lateral Sclerosis (“ALS”)
ALS, also known as Lou Gehrig’s disease, is a devastating neuromuscular illness. Our selective cortisol modulator dazucorilant improved motor performance and reduced neuroinflammation and muscular atrophy in animal models of ALS. Following these compelling results, in October 2022 we initiated a Phase 2 trial of dazucorilant (the “DAZALS” trial) in patients with ALS. DAZALS has a planned enrollment of 198 patients, randomized 1:1:1 to receive either 150 mg or 300 mg of dazucorilant or placebo daily for 24 weeks. The primary endpoint is the difference between dazucorilant and placebo demonstrated by patients on the ALS Functional Rating Scale-Revised (ALSFRS-R).
Metabolic Diseases
Liver Disease. NASH is an advanced form of nonalcoholic fatty liver disease that afflicts millions of patients and is a leading cause of liver-related mortality. In April 2021, we suspended our Phase 2a trial of our selective cortisol modulator miricorilant as a potential treatment for NASH after four of the five patients who received miricorilant exhibited both elevated liver enzymes and large, rapid reductions in liver fat. Liver enzyme levels in all affected patients returned to baseline or below baseline after miricorilant was withdrawn. Our ongoing Phase 1b dose-finding trial in patients with presumed NASH has identified a range of doses that appear to cause large reductions in liver fat without causing excessive liver irritation. We plan to start a Phase 2 trial in the fourth quarter of 2023.
Antipsychotic-Induced Weight Gain (“AIWG”). In the United States, six million people take antipsychotic medications such as olanzapine and risperidone to treat illnesses such as schizophrenia, bipolar disorder and depression. While these drugs are very effective, they often cause rapid and sustained weight gain, other metabolic disturbances and, ultimately, cardiovascular disease. Patients taking these medications experience a 10 to 25-year reduction in life expectancy, due largely to increased cardiovascular events, such as heart attacks and strokes. Patients in our two double-blind, placebo-controlled, Phase 2 trials of miricorilant (GRATITUDE and GRATITUDE II) did not experience reversal of AIWG. However, multiple replicated pre-clinical results as well as the results of our double-blind, placebo-controlled trial (published in the Journal of Clinical Psychopharmacology (Hunt et al., 2021)) suggest that miricorilant has the potential to significantly reduce weight gain caused by the administration of olanzapine. Accordingly, we plan to further study miricorilant’s potential to prevent AIWG.
COVID-19 Pandemic
Public health restrictions put in place to reduce the impact of the global COVID-19 pandemic, as well as measures voluntarily undertaken by patients, physicians, hospitals and medical clinics, have reduced our revenue growth and make it difficult to grow our Korlym business.
The pandemic’s impact on the pace of our clinical development programs has been variable. Some of our trials of indications not considered immediately life-threatening, such as Cushing’s syndrome, have experienced slower enrollment. In addition, some clinical sites have reduced the frequency with which physicians see study participants. Our trials in patients with immediately life-threatening diseases, such as our Phase 2 trial in women with platinum-resistant ovarian cancer, have not encountered delays.
We expect that pandemic-related impediments to our business will continue so long as there are COVID-19 public health restrictions or risk-reducing behavior by physicians and patients.
Please see the risk factor under Item 1A of this Quarterly Report, “The COVID-19 pandemic has adversely affected and is continuing to adversely affect our business.”
Inflation Reduction Act of 2022
The Inflation Reduction Act of 2022 (“IRA”) was enacted on August 16, 2022. The IRA includes provisions imposing a 1 percent excise tax on certain share repurchases that occur after December 31, 2022 and introduces a 15 percent corporate alternative minimum tax (“CAMT”) on adjusted financial statement income. The CAMT will be effective for us beginning on January 1, 2024. We do not expect the CAMT to have a significant effect on our consolidated financial statements.
Additionally, the IRA permits CMS to negotiate prices for certain high-expenditure Medicare Part B or Part D drugs. The IRA also requires manufacturers to pay a rebate to CMS if the price of a Medicare Part B or Part D drug increases faster than the rate of inflation. Beginning in 2025, the IRA will also shift to manufacturers a significant portion of the Medicare beneficiary costs currently borne by the government and beneficiaries. We anticipate that this provision will significantly limit
17


the revenue Corcept receives from Medicare patients and may materially reduce our profits. Please see the risk factor under Item 1A of this Quarterly Report, New laws, government regulations, or changes to existing laws and regulations could make it difficult or impossible for us to obtain acceptable prices or adequate insurance coverage and reimbursement for Korlym, which would adversely affect our results of operations and financial position.”
Results of Operations
Net Product Revenue Net product revenue is gross product revenue from sales to our customers less deductions for estimated government rebates and chargebacks.
Net product revenue was $105.7 million for the three months ended March 31, 2023, compared to $93.7 million for the comparable period in 2022. For the three months ended March 31, 2023, higher sales volumes accounted for 42.9 percent of the increase, with the remaining growth due to a price increase effective January 1, 2023.
Cost of sales Cost of sales includes the cost of API, tableting, packaging, personnel, overhead, stability testing and distribution.
Cost of sales was $1.4 million for the three months ended March 31, 2023, compared to $1.3 million for the comparable period in 2022. Cost of sales as a percentage of revenue was 1.3 percent for each of the three months ended March 31, 2023 and 2022.
Research and development expense – Research and development expense includes the cost of (1) recruiting and compensating development personnel, (2) clinical trials, (3) drug product and preclinical studies in support of clinical trials and regulatory submissions, (4) discovery research and (5) the development of drug formulations and manufacturing processes.
Research and development expense was $40.9 million for the three months ended March 31, 2023, compared to $28.1 million for the comparable period in 2022. The increase was primarily due to increased spending on the advancement of our development programs and employee compensation expenses.
Three Months Ended March 31,
 20232022
(in thousands)
Development programs:  
Oncology$7,250 $3,823 
Cushing’s syndrome10,974 7,107 
Metabolic diseases7,172 5,377 
Pre-clinical and early-stage selective cortisol modulators and ALS7,464 5,306 
Unallocated activities, including manufacturing and regulatory activities4,507 3,136 
Stock-based compensation3,484 3,371 
Total research and development expense$40,851 $28,120 
It is difficult to predict the timing and cost of development activities, which are subject to many uncertainties and risks, including inconclusive or negative results, slow patient enrollment, adverse side effects and difficulties in the formulation or manufacture of study drugs and lack of drug-candidate efficacy. In addition, clinical development is subject to government oversight and regulations that may change without notice. We expect our research and development expense to be higher in 2023 than in 2022 as our clinical programs advance. Research and development spending in future years will depend on the outcome of our pre-clinical and clinical trials and our development plans.
Selling, general and administrative expense Selling, general and administrative expense includes (1) compensation of employees, consultants and contractors engaged in commercial and administrative activities, (2) the cost of vendors supporting commercial activities and (3) legal and accounting fees.
Selling, general and administrative expense was $48.6 million for the three months ended March 31, 2023, compared to $37.5 million for the comparable period in 2022. The increase was primarily due to increased sales and marketing activities and employee compensation expenses.
We expect our selling, general and administrative expense to be higher in 2023 than in 2022 due to increased commercial and administrative activities, including litigation and administrative support for increased research and development and marketing efforts.
18


Interest and other income Interest and other income was $3.6 million for the three months ended March 31, 2023, compared to $0.1 million for the comparable period in 2022. The increase was due to a higher cash and investment balance and market-wide increases in interest rates.
Income tax expense Income tax expense was $2.6 million for the three months ended March 31, 2023, compared to $4.1 million for the comparable period in 2022. The change was primarily due to a decrease in income before income taxes.
Liquidity and Capital Resources
Since 2015, we have relied on revenues from the sale of Korlym to fund our operations.
Based on our current plans and expectations, we expect to fund our operations and planned research and development activities over the next 12 months and beyond without needing to raise additional funds, although we may choose to raise additional funds for other reasons. If we were to raise funds, equity financing would be dilutive, debt financing could involve restrictive covenants and funds raised through collaborations with other companies may require us to relinquish certain rights in our product candidates.
As of March 31, 2023, we had cash, cash equivalents and marketable securities of $465.1 million, consisting of cash and cash equivalents of $299.9 million and marketable securities of $165.1 million, compared to cash, cash equivalents and marketable securities of $436.6 million, consisting of cash and cash equivalents of $66.3 million and marketable securities of $370.3 million as of December 31, 2022.
The cash in our bank accounts and our marketable securities could be reduced or our access to them restricted if the financial institutions holding them were to fail or severely adverse conditions were to arise in the markets for public or private debt securities. We have never experienced a material lack of access to cash or material realized losses.
Net cash provided by operating activities was $26.0 million for the three months ended March 31, 2023, compared to $35.2 million for the comparable period in 2022. This decrease was primarily due to increases in operating expenses supporting advancement of our development programs.
Net cash provided by investing activities was $207.5 million for the three months ended March 31, 2023, compared to net cash used in investing activities of $50.5 million for the comparable period in 2022. The increase was primarily due to allocation of cash proceeds from maturities of marketable securities towards cash equivalents in anticipation of the closing of our tender offer in April 2023.
Net cash provided by financing activities was $0.2 million for the three months ended March 31, 2023, compared to net cash used in financing activities of $0.5 million for the comparable period in 2022. In the three months ended March 31, 2023, we spent $1.1 million acquiring shares of our common stock in connection with the net exercise of employee and director stock options and $0.1 million to satisfy tax withholding requirements from vesting of restricted stock grants, offset by $0.2 million received from the exercise of stock options and $1.2 million received in connection with our ESPP. In the comparable period in 2022, we spent $1.9 million acquiring shares of our common stock in connection with the net exercise of employee and director stock options, offset by $1.4 million received from the exercise of stock options.
As of March 31, 2023, we had retained earnings of $312.3 million.
Contractual Obligations and Commitments
Our contractual payment obligations and purchase commitments are disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022. Our payment obligations and purchase commitments did not change materially during the three months ended March 31, 2023. See Note 4 to our Unaudited Condensed Consolidated Financial Statements for more information regarding our purchase commitments.
Off-Balance Sheet Arrangements
None.
Critical Accounting Policies and Estimates
Our condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, which requires us to make estimates and judgments that affect the amount of assets, liabilities and expenses we report. We base our estimates on historical experience and on other assumptions we believe to be reasonable. Actual results may differ from our estimates. Our significant accounting policies are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.
19


There were no changes that occurred during the fiscal quarter covered by this report that materially affected, or are reasonably likely to materially affect, our critical accounting policies and estimates.
ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our market risks as of March 31, 2023 are disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022. The market risks associated with our cash, cash equivalents and marketable securities, which consist entirely of debt instruments with original maturities of less than 24 months, did not change materially during the three months ended March 31, 2023.
ITEM 4.  CONTROLS AND PROCEDURES
Evaluation of disclosure controls and procedures. As of March 31, 2023, our management conducted an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2023, our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to the officers who certify our financial reports and to the members of the Company’s senior management and board of directors as appropriate to allow timely decisions regarding required disclosure at the reasonable assurance level.
Changes in internal control over financial reporting. Our Chief Financial Officer and other members of management evaluated the changes in our internal control over financial reporting during the quarter ended March 31, 2023 and concluded that there was no change during the quarter that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
20


PART II. OTHER INFORMATION
ITEM 1.  LEGAL PROCEEDINGS
Teva Litigation
In February 2018, we received a Paragraph IV Notice Letter advising that Teva Pharmaceuticals USA, Inc. (“Teva”) had submitted an Abbreviated New Drug Application (“ANDA”) to the FDA seeking authorization to manufacture and sell a generic version of Korlym prior to the expiration of patents related to Korlym that are listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). In March 2018, we filed a lawsuit in the United States District Court for the District of New Jersey against Teva for infringement of our patents. In August 2020, Teva received final approval from the FDA for its ANDA in accordance with the Hatch-Waxman Act. The patents currently at issue in the original lawsuit against Teva are U.S. Patent No. 10,195,214 (the “ʼ214 patent”) and U.S. Patent Nos. 10,500,216 (the “ʼ216 patent”). The parties completed briefing on cross-motions for summary judgment regarding infringement of the ’214 patent in July 2021. On February 27, 2023, the Court denied both motions without prejudice.
In May 2019, Teva submitted to the Patent Trial and Appeal Board (“PTAB”) a petition for post-grant review (“PGR”) of the ’214 patent. The PTAB agreed to initiate the PGR, and, in November 2020, issued a decision upholding the validity of the ’214 patent in its entirety. Teva appealed its loss to the Federal Circuit Court of Appeals, which in December 2021, ruled in our favor. The time for Teva to appeal or seek reconsideration of these adverse decisions has passed. This matter is closed.
On March 17, 2023, we filed a separate lawsuit in the United States District Court for the District of New Jersey against Teva for infringement of U.S. patents 10,842,800 and 10,842,801.
The Court has set a trial date of September 27, 2023 for both pending matters.
We will vigorously enforce our intellectual property rights relating to Korlym but cannot predict the outcome of these matters.
Hikma ANDA Litigation and Settlement
In February 2021, we received a Paragraph IV Notice Letter advising that Hikma Pharmaceuticals USA Inc. (“Hikma”) had submitted an ANDA to the FDA seeking authorization to manufacture, use or sell a generic version of Korlym in the United States.
The Notice Letter contains Paragraph IV certifications against certain of our patents related to Korlym, alleging that these patents will not be infringed by Hikma’s proposed product, are invalid and/or are unenforceable.
In March 2021, we filed a lawsuit in the United States District Court for the District of New Jersey against Hikma for infringement of the ’214 patent, the ʼ216 patent, U.S. Patent Nos. 10,842,800 and U.S. Patent Nos. 10,842,801.
On December 7, 2022, we entered into an agreement with Hikma resolving this litigation. Pursuant to the agreement, we have granted Hikma the right to sell a generic version of Korlym in the United States beginning October 1, 2034 or earlier under circumstances customary for settlement agreements of this type. As required by law, we and Hikma have submitted the settlement agreement to the United States Federal Trade Commission and the United States Department of Justice for review.
Other Matters
In March 2019, a purported securities class action complaint was filed in the United States District Court for the Northern District of California by Nicholas Melucci (Melucci v. Corcept Therapeutics Incorporated, et al., Case No. 5:19-cv-01372-LHK) (the “Melucci litigation”). The complaint named us and certain of our executive officers as defendants asserting violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder and alleges that the defendants made false and materially misleading statements and failed to disclose adverse facts about our business, operations and prospects. The complaint asserts a putative class period extending from August 2, 2017 to February 5, 2019 and seeks unspecified monetary relief, interest and attorneys’ fees. In October 2019, the Court appointed a lead plaintiff and lead counsel. The lead plaintiff’s consolidated complaint was filed in December 2019. With respect to these allegations, we have stated, from the beginning, that we have done nothing wrong.
On February 8, 2023, we reached an agreement in principle (the “Proposed Settlement”) to resolve all claims in the Melucci litigation. Under the Proposed Settlement, we have agreed to make a one-time payment of $14.0 million, which will be covered in full by our insurers. The Proposed Settlement does not include an admission of liability on our part. The Proposed Settlement is subject to the final approval of the Court.
21


In September 2019, a purported shareholder derivative complaint was filed in the United States District Court for the District of Delaware by Lauren Williams, captioned Lauren Williams v. G. Leonard Baker, et al., Civil Action No. 1:19-cv-01830. The complaint named our board of directors, Chief Executive Officer and current Chief Business Officer as defendants, and us as nominal defendant. The complaint alleges breach of fiduciary duty, violation of Section 14(a) of the Exchange Act, insider selling, misappropriation of insider information and waste of corporate assets and seeks damages in an amount to be proved at trial. In October 2019, this action was stayed pending a resolution of our motions to dismiss the Melucci litigation. In December 2020, the case was further stayed pending a resolution of our motion to dismiss the third amended complaint in the Melucci litigation. In September 2021, the case was further stayed pending a resolution of the Melucci litigation.
In December 2019, a second purported shareholder derivative complaint was filed in the United States District Court for the District of Delaware by Jeweltex Pension Plan, captioned Jeweltex Pension Plan v. James N. Wilson, et al., Civil Action No. 1:19-cv-02308. The complaint named our board of directors, Chief Executive Officer and current Chief Business Officer as defendants, and us as nominal defendant. The complaint alleges causes of action for breach of fiduciary duty, violation of Section 14(a) of the Exchange Act, waste of corporate assets, contribution and indemnification, aiding and abetting, and gross mismanagement. The complaint seeks damages in an amount to be proved at trial. In April 2020, this action was stayed pending a resolution of our motions to dismiss the Melucci litigation. In December 2020, the case was further stayed pending a resolution of our motion to dismiss the third amended complaint in the Melucci litigation. In September 2021, the case was further stayed pending a resolution of the Melucci litigation.
In January 2022, a purported shareholder derivative complaint was filed in the Delaware Court of Chancery by Joel B. Ritchie, captioned Joel B. Ritchie v. G. Leonard Baker, et al., Case No. 2022-0102-SG. The complaint named our board of directors, Chief Executive Officer, current Chief Business Officer and President of Corcept Endocrinology as defendants, and us as nominal defendant. The complaint alleges a single cause of action for breach of fiduciary duty. The complaint seeks damages in an amount to be proved at trial. In April 2022, the case was further stayed pending a resolution of the Melucci litigation.
We will respond vigorously to the above allegations but cannot predict the outcome of these matters.
In November 2021, we received a records subpoena from the United States Attorney’s Office for the District of New Jersey (the “NJ USAO”) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) seeking information relating to the sale and promotion of Korlym, our relationships with and payments to health care professionals who can prescribe or recommend Korlym and prior authorizations and reimbursement for Korlym. The NJ USAO has informed us that it is investigating whether any criminal or civil violations by us occurred in connection with the matters referenced in the subpoena. It has also informed us that it does not currently consider us a defendant but rather an entity whose conduct is within the scope of the government’s investigation.
In addition to the above-described matters, we are involved from time-to-time in other legal proceedings arising in the ordinary course of our business. Although the outcome of any such matters and the amount, if any, of our liability with respect to them cannot be predicted with certainty, we do not believe that they will have a material adverse effect on our business, results of operations or financial position.
ITEM 1A.  RISK FACTORS
Investing in our common stock involves significant risks. Before investing, carefully consider the risks described below and the other information in this quarterly report, including our condensed consolidated financial statements and related notes. The risks and uncertainties described below are the ones we believe may materially affect us. Many of them have been or may become exacerbated by the COVID-19 pandemic. There may be others of which we are unaware that could materially harm our business or financial condition and cause the price of our stock to decline, in which case you could lose all or part of your investment.
Summary of Principal Risks
The following bullet points summarize the principal risks we face, each of which could adversely affect our business, operations and financial results. For clarity of presentation, we have arranged these risks by the part of our business they most directly affect – (i) commercial operations, (ii) research and development, (iii) capital need and financial results, (iv) intellectual property and (v) our stock price. A sixth group of “general risks” lists risks that affect our business as a whole.
22


Risks Related to our Commercial Activities
Failure to generate sufficient revenue from the sale of Korlym would harm our financial results and would likely cause our stock price to decline.
The COVID-19 pandemic has adversely affected and is continuing to adversely affect our business.
If generic versions of Korlym are successfully commercialized, our business, results of operations and financial position would be adversely affected.
New laws, government regulations, or changes to existing laws and regulations could make it difficult or impossible for us to obtain acceptable prices or adequate insurance coverage and reimbursement for Korlym, which would adversely affect our results of operations and financial position.
Risks Related to our Research and Development Activities
Our efforts to discover, develop and commercialize our product candidates may not succeed. Clinical drug development is lengthy, expensive and often unsuccessful. Results of early studies and trials are often not predictive of later trial results. Failure can occur at any time. Even if we deem our product candidates’ clinical trial results to demonstrate safety and efficacy, regulatory authorities may not agree. Failure to obtain or maintain regulatory approvals for our product candidates would prevent us from commercializing them.
The COVID-19 pandemic has lengthened the time it takes to initiate and advance some of our clinical trials.
Vendors perform many of the activities necessary to carry out our clinical trials, including drug product distribution, trial management and oversight and data collection and analysis. Failure of these vendors to perform their duties or meet expected timelines may prevent or delay approval of our product candidates.
Risks Relating to our Intellectual Property
To succeed, we must secure, maintain and effectively assert adequate patent protection for the composition and methods of use of our proprietary, selective cortisol modulators and for the use of Korlym to treat Cushing’s syndrome.
Risks Related to our Stock
The price of our common stock fluctuates widely and is likely to continue to do so. Opportunities for investors to sell shares may be limited.
Our stock price may decline if our financial performance does not meet the guidance we have provided to the public, estimates published by research analysts or other investor expectations.
General Risks
We rely on information technology to conduct our business. A breakdown or breach of our information technology systems or our failure to protect confidential information concerning our business, patients or employees could interrupt the operation of our business and subject us to liability.
Risk Factors – Discussion
The following section discusses the principal risks listed above, as well as other risks we believe to be material.
Risks Related to our Commercial Activities
Failure to generate sufficient revenue from the sale of Korlym would harm our financial results and would likely cause our stock price to decline.
Our ability to generate revenue and to fund our commercial operations and development programs is dependent on the sale of Korlym to treat patients with Cushing’s syndrome. Physicians will prescribe Korlym only if they determine that it is preferable to other treatments, even if those treatments are not approved for Cushing’s syndrome. Because Cushing’s syndrome is rare, most physicians are inexperienced diagnosing or caring for patients with the illness and it can be hard to persuade them to identify appropriate patients and treat them with Korlym.
Many factors could limit our Korlym revenue, including:
the preference of some physicians for competing treatments for Cushing’s syndrome, including off-label treatments and generic versions of Korlym, should any such generic versions be introduced;
23


natural disasters or other catastrophes, such as the COVID-19 pandemic, that reduce the ability or willingness of physicians to see patients or of patients to bear the risk of leaving their homes to seek medical care; and
lack of availability of government or private insurance, the shift of a significant number of patients to Medicaid, which reimburses Korlym at a significantly lower price, or the introduction of government price controls or other price-reducing regulations, such as the IRA, that may significantly limit Medicare reimbursement rates.
Failure to generate sufficient Korlym revenue could prevent us from fully funding our planned commercial and clinical activities and would likely cause our stock price to decline.
The COVID-19 pandemic has adversely affected and is continuing to adversely affect our business.
COVID-19, a serious and sometimes fatal illness, has spread to every country in the world and throughout the United States. Many countries, including most states of the United States, reacted by instituting quarantines, “lockdowns” and other public health restrictions on leisure activities, work and travel. Although pandemic-related restrictions have been eased or removed in some places, including California, our business remains subject to pandemic-related controls, which may become more restrictive at any time. We rely on third-party manufacturers, distributors (including the specialty pharmacy that dispenses Korlym), information technology and software service providers, law and accounting firms, clinical research organizations and consultants who are subject to, or may become subject to, pandemic-related controls. If these third parties cannot perform the services we require in a timely way and we cannot successfully implement replacements or workarounds, our business, results of operations and financial condition could be harmed.
COVID-19 has made it difficult to grow our commercial business. Many physicians have reduced the frequency of patient office visits and barred office visits by third parties, including our clinical specialists and medical science liaisons. In addition, many patients have postponed visits to their physicians or testing at clinical laboratories or imaging centers. These precautions have made it harder for physicians to identify patients who may benefit from Korlym, begin their treatment, arrive at an optimum dose and maintain their patients’ regimens.
We cannot predict the duration of these impacts on our business or how severe future impacts may be, including supply-chain disruptions and inflationary impacts. If physicians do not prescribe Korlym to new patients or have difficulty increasing a patient’s Korlym dose to its optimal level, or if patients already receiving Korlym discontinue treatment, our revenue will be unlikely to grow and may decline.
If generic versions of Korlym are successfully commercialized, our business, results of operations and financial position would be adversely affected.
The marketing exclusivity provided by Korlym’s orphan drug designation expired in February 2019, which means other companies may now seek to introduce generic equivalents of Korlym for Korlym’s approved indication, provided such parties receive FDA approval and can show that they would not infringe our applicable patents or that those patents are invalid or unenforceable. If our patents are successfully challenged and a generic version of Korlym becomes available, our sales of Korlym tablets and their price could decline rapidly and significantly, which would reduce our revenue and materially harm our results of operations and financial position. Competition from a generic version of Korlym may also cause our revenue to be materially less than the public guidance we have provided, which would likely cause the price of our common stock to decline.
Legal action to enforce or defend intellectual property rights is complex, costly and involves significant commitments of management time. There can be no assurance of a successful outcome. We have sued Teva in Federal District Court with respect to their proposed generic versions of Korlym. In November 2020, the PTAB ruled against Teva in a challenge Teva had brought to one of our patents, a ruling which the Federal Circuit Court of Appeals has affirmed. We had also sued Sun and Hikma with respect to their proposed generic version of Korlym, although we settled those lawsuits in June 2021 and December 2022, respectively. The terms of our settlement with Sun and Hikma are subject to customary review by the Federal Trade Commission and Department of Justice. Please see “Part II, Item 1, Legal Proceedings.” Because Teva has received FDA approval, Teva may choose to begin marketing its generic product at any time, notwithstanding our ongoing litigation. We would seek a court order stopping such a course of action, but even if we were to prevail and Teva were to withdraw its product and pay us damages the temporary availability of a generic version of Korlym might materially harm our results of operations and financial condition.
It is likely that other companies will seek FDA approval to market a generic version of Korlym. While we will vigorously protect our intellectual property, there can be no assurance our efforts will be successful.
24


Other companies offer or are attempting to develop different medications to treat patients with Cushing’s syndrome. The availability of competing treatments could limit our revenue from Korlym.
Since 2012, a medication owned by the Italian pharmaceutical company Recordati-S.p.A., the somatostatin analogue Signifor® (pasireotide) Injection, has been marketed in both the United States and the EU for adult patients with Cushing’s disease (a subset of Cushing’s syndrome). On March 6, 2020, the FDA granted Recordati approval to market another cortisol synthesis inhibitor, Isturisa® (osilodrostat) tablets, to treat patients with Cushing’s disease. Osilodrostat is approved in the EU for the treatment of patients with Cushing’s syndrome.
On December 30, 2021, Xeris Biopharma Holdings, Inc. received FDA approval to market the cortisol synthesis inhibitor Recorlev® (levoketoconazole) to treat patients with Cushing’s syndrome in the United States. Levoketoconazole is an enantiomer of the generic anti-fungal medication, ketoconazole, that is prescribed off-label to treat patients with Cushing’s syndrome.
Osilodrostat and levoketoconazole have been designated orphan drugs in both the EU and the United States.
Physician preference for any of these medications, or for the off-label use of generic medications such as ketoconazole, to treat patients with Cushing’s syndrome could reduce our revenue materially and harm our results of operations, which would cause our stock price to decline.
New laws, government regulations, or changes to existing laws and regulations could make it difficult or impossible for us to obtain acceptable prices or adequate insurance coverage and reimbursement for Korlym, which would adversely affect our results of operations and financial position.
The commercial success of Korlym depends on the availability of acceptable pricing and adequate insurance coverage and reimbursement. Government payers, including Medicare, Medicaid and the Veterans Administration, as well as private insurers and health maintenance organizations, are increasingly attempting to contain healthcare costs by limiting reimbursement for medicines. In many foreign markets, drug prices and the profitability of prescription medications are subject to government control. In the United States, we expect that there will continue to be federal and state proposals for similar controls. Also, the trends toward managed health care in the United States and recent laws and legislation intended to increase the public visibility of drug prices and reduce the cost of government and private insurance programs could significantly influence the purchase of health care services and products and may result in lower prices for Korlym. If government or private payers cease to provide adequate and timely coverage, pricing and reimbursement for Korlym, physicians may not prescribe the medication and patients may not purchase it, even if it is prescribed, or the price we receive may be reduced, which would reduce our revenue.
In the United States, there have been and continue to be legislative initiatives to contain healthcare costs. The Patient Protection and Affordable Care Act (“ACA”) which was passed in 2010, substantially changed the way health care is financed by both governmental and private insurers. The IRA introduced some of the most significant changes to Medicare payment for prescription drugs since the ACA. Among its many provisions, the IRA requires the Secretary of the U.S. Department of Health and Human Services (“HHS”) to negotiate Medicare prices for selected drugs and biologicals, including both physician-administered products covered under Medicare’s Part B benefit and self-administered drugs covered under the Part D benefit. Each year, the Secretary will select for price negotiation a specified number of negotiation-eligible drugs with the highest total Part B or D expenditures over a preceding 12-month period. To be eligible for price negotiation a drug must have been on the market for at least seven years without generic competition. Orphan drugs indicated for only one rare disease or condition and drugs with less than $200 million in annual Medicare expenditures are exempt from the negotiation program. For the first two years of the program, 2026 and 2027, only Part D drugs are eligible. The Secretary will publish the negotiated price, known as the “Maximum Fair Price”, or MFP, for each of the selected products. Manufacturers of selected drugs would be required to offer the drug for Medicare recipients at the MFP. Manufacturers who fail to negotiate or offer the MFP can face significant civil money penalties or excise tax liability on sales of that drug. Depending on the share of Medicare spending each year that is attributed to Korlym or any other drug candidate that we develop and whether or not those drugs become eligible for Medicare negotiation, those drugs and our revenue may be adversely impacted by this provision.
The IRA also establishes an inflation rebate program that requires manufacturers to pay rebates to the Medicare program if any of the medications they provide Medicare recipients increase in price faster than the rate of inflation. The Part D inflation rebate provision went into effect on October 1, 2022. Although manufacturers are generally familiar with inflation rebates under the Medicaid program, where they have existed for decades, the IRA represents the first time that inflation rebates have been extended to the Medicare program.
25


Beginning in 2025, the IRA will also shift a significant portion of the Medicare beneficiary costs from the government and beneficiaries to manufacturers. We anticipate that this provision will significantly limit the revenue Corcept receives and may materially reduce our revenue and profits.
There continues to be federal and state initiatives to contain healthcare costs, in part informed by the current atmosphere of mounting criticism of prescription drug costs in the United States. We expect governmental oversight and scrutiny of pharmaceutical companies will continue to increase and there will continue to be proposals to change the healthcare system in ways that could harm our ability to sell Korlym profitably. We anticipate that the United States Congress, state legislatures, and regulators may implement healthcare policies intended to curb healthcare costs, such as federal and state controls on reimbursement for drugs (including under Medicare and commercial health plans), new or increased requirements to pay prescription drug rebates and penalties to government health care programs and policies that require drug companies to disclose and justify the prices they charge.
Recently enacted laws and the regulations and policies implementing them, as well as other healthcare-related measures that may be adopted in the future, could materially reduce our Korlym revenues and our ability to develop and commercialize our product candidates.
We depend on vendors to manufacture Korlym’s active ingredient, form it into tablets, package it and dispense it to patients. We also depend on vendors to manufacture the active pharmaceutical ingredient (“API”) and capsules or tablets for our product candidates. If our suppliers become unable or unwilling to perform these functions and we cannot transfer these activities to replacement vendors in a timely manner, our business will be harmed.
A single third-party manufacturer, Produits Chimiques Auxiliaires et de Synthese SA (“PCAS”), supplies the API in Korlym. Two other third-party manufacturers are approved to produce and bottle Korlym tablets. The current term of our agreement with PCAS continues until December 31, 2023. We use a single specialty pharmacy, Optime, to dispense Korlym and perform related pharmacy operations, patient support and related services, including the collection of payments from insurers representing approximately 99 percent of our revenue. If Optime does not adhere to its agreements with payers, it may not be able to collect some or all of the payments due to us. Our agreement with Optime extends to March 31, 2024, subject to customary termination provisions, including the right of Optime to terminate in the event of a material breach by us that we do not cure in a reasonable period of time after receiving written notice. In addition, we may terminate the agreement for convenience.
In the event any of our vendors fails to perform its contractual obligations to us or is materially impaired in its performance by the COVID-19 pandemic or for any other reason, we may experience disruptions and delays in our supply chain and our ability to deliver Korlym to patients, which would adversely affect our business, results of operations and financial position.
The facilities used by our vendors to manufacture and package the API and drug product for Korlym and our product candidates must be approved by the FDA and, in some cases, the European Medicines Agency (“EMA”) or the Medicines and Healthcare products Regulatory Agency (“MHRA”). We do not control the activities of these vendors, including whether they maintain adequate quality control and hire qualified personnel. We are dependent on them for compliance with the regulatory requirements known as current good manufacturing practices (“cGMPs”). If our vendors cannot manufacture material that conforms to our specifications and the strict requirements of the FDA or others, they will not be able to maintain regulatory authorizations for their facilities and we could be prohibited from using the API or drug product they have provided. If the FDA, EMA, MHRA or other regulatory authorities withdraw regulatory authorizations of these facilities, we may need to find alternative vendors or facilities, which would be time-consuming, complex and expensive and could significantly hamper our ability to develop, obtain regulatory approval for and market our products. Sanctions could be imposed on us, including fines, injunctions, civil penalties, refusal of regulators to approve our product candidates, delays, suspensions or withdrawals of approvals, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business.
The unfavorable public perception of mifepristone may limit our ability to sell Korlym.
The active ingredient in Korlym, mifepristone, is approved by the FDA in another drug for the termination of early pregnancy. On June 24, 2022, the United States Supreme Court published its decision in the case of Dobbs v. Jackson Women’s Health Organization (“Dobbs”), which overturned Roe v. Wade, the 1973 Supreme Court decision establishing a woman’s right to terminate her pregnancy, subject to certain limitations. Dobbs has stimulated many states to enact laws making abortion illegal in virtually every circumstance, including during early pregnancy. More laws banning or heavily restricting termination of pregnancy may be adopted and existing laws may be made more restrictive. Two highly publicized cases regarding mifepristone have been filed in the U.S. since the Dobbs decision, one of which seeks to invalidate the FDA’s approval of mifepristone and the other of which seeks to uphold the FDA’s approval in certain jurisdictions. On April 7, 2023, the United
26


States District Court for the Northern District of Texas Amarillo Division issued a preliminary injunction blocking the FDA’s approval of mifepristone, and on the same day, the United States District Court in the Eastern District of Washington issued a ruling ordering the FDA to maintain the current availability of mifepristone in 17 states and Washington, D.C. On April 21, 2023, the U.S. Supreme Court granted an emergency request from the U.S. Department of Justice and the manufacturer of mifepristone to permit the continued availability of mifepristone. The ultimate outcome of these cases and any further consideration by the U.S. Supreme Court, as well as the timing of any outcome, is uncertain. In addition, heightened public perception of mifepristone as an abortifacient may draw the attention of hostile state government officials or political activists to Korlym – even though Korlym is not approved for the termination of pregnancy, we do not promote it for that use and we have taken measures to minimize the chance that it will accidentally be prescribed to a pregnant woman. In addition, physicians and patients may choose not to use Korlym as a treatment for Cushing’s syndrome simply to avoid the risk of terminating a pregnancy.
Natural disasters, some possibly related to the increasing effects of climate change, could damage or destroy clinical trial sites, our office spaces, the residences of our employees or the facilities or residences of our vendors, contractors or consultants, which could significantly harm our operations.
We are vulnerable to natural disasters, including earthquakes, fires, hurricanes, floods, blizzards and the extended periods of extreme heat, cold and precipitation made more frequent and severe by global warming. For example, our headquarters are in the San Francisco Bay Area, which experiences earthquakes, wildfires and flooding. Our specialty pharmacy, tablet manufacturers and warehouses are in areas subject to hurricanes and tornadoes. All our activities, as well as the activities of our vendors, consultants, clinical investigators, patients, physicians and regulators, are subject to the risks posed by global warming.
The loss of life, property damage and disruptions to electrical power distribution, communications, travel and shipping caused by natural disasters could make it difficult or impossible to conduct our commercial activities or complete our drug discovery activities or clinical trials. Patients may be unwilling or unable to travel to clinical trial sites, for example, or clinical materials or data may be lost.
Our insurance, if available at all, would likely be insufficient to cover losses resulting from disasters or other business interruptions.
We may not have adequate insurance to cover our exposure to product liability claims.
We may be subject to product liability or other claims based on allegations that Korlym or one of our product candidates has harmed a patient. Such a claim may damage our reputation by raising questions about Korlym or our product candidates’ safety and could prevent or interfere with product development or commercialization. Less common adverse effects of a pharmaceutical product are sometimes not known until long after the product is approved for marketing. Because the active ingredient in Korlym is used to terminate pregnancy, clinicians using Korlym in clinical trials and physicians prescribing the medicine to women must take strict precautions to ensure that it is not administered to pregnant women. Failure to observe these precautions could result in significant product liability claims.
Our insurance may not fully cover our potential product liabilities. Inability to obtain adequate insurance coverage could inhibit development of our product candidates or result in significant uninsured liability. Defending a lawsuit could be costly and divert management from productive activities.
If we are unable to maintain regulatory approval of Korlym or if we fail to comply with other requirements, we will be unable to generate revenue and may be subject to penalties.
We are subject to oversight by the FDA and other regulatory authorities in the United States and elsewhere with respect to our research, testing, manufacturing, labeling, distribution, adverse event reporting, storage, advertising, promotion, recordkeeping and sales and marketing activities. These requirements include submissions of safety information, annual updates on manufacturing activities and continued compliance with FDA regulations, including cGMPs, good laboratory practices and good clinical practices (“GCPs”). The FDA enforces these regulations through inspections of us and the laboratories, manufacturers and clinical sites we use. Foreign regulatory authorities have comparable requirements and enforcement mechanisms. Discovery of previously unknown problems with a product or product candidate, such as adverse events of unanticipated severity or frequency or deficiencies in manufacturing processes or management, as well as failure to comply with FDA or other U.S. or foreign regulatory requirements, may subject us to substantial civil and criminal penalties, injunctions, holds on clinical trials, product seizure, refusal to permit the import or export of products, restrictions on product marketing, withdrawal of the product from the market, product recalls, total or partial suspension of production, refusal to approve pending new drug applications (“NDAs”) or supplemental NDAs, and suspension or revocation of product approvals.
27


We may be subject to civil or criminal penalties if our marketing of Korlym violates FDA regulations or health care fraud and abuse laws.
We are subject to FDA regulations governing the promotion and sale of medications. Although physicians are permitted to prescribe drugs for any indication they choose, manufacturers may only promote products for their FDA-approved use. All other uses are referred to as “off-label,” manufacturers are prohibited from engaging in any of “off-label” promotion. In the United States, we market Korlym to treat hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and for whom surgery has failed or is not an option. Among other activities, we provide promotional materials and training programs to physicians covering the use of Korlym for this indication. The FDA may change its policies or enact new regulations at any time that may restrict our ability to promote our products, which could adversely impact our business.
If the FDA were to determine that we engaged in off-label promotion, the FDA could require us to change our practices and subject us to regulatory enforcement actions, including issuance of a public “warning letter,” untitled letter, injunction, seizure, civil fine or criminal penalties. Other federal or state enforcement authorities might act if they believe that the alleged improper promotion led to the submission and payment of claims for an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. Even if it is determined that we are not in violation of these laws, we may receive negative publicity, incur significant expenses and be forced to devote management time to defending our position.
In addition to laws prohibiting off-label promotion, we are also subject to federal and state healthcare fraud and abuse laws and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive practices. The United States healthcare laws and regulations that may affect our ability to operate include, but are not limited to:
the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal health care programs such as Medicare and Medicaid. And, although we structure our applicable business arrangements in accordance with the safe harbors, it is difficult to determine exactly how the law will be applied in specific circumstances. Accordingly, it is possible that certain practices of ours may be challenged under the federal Anti-Kickback Statute. From a liability perspective, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
federal false claims laws, including, without limitation, the False Claims Act, which prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. The federal False Claims Act is unique in that it allows private individuals (whistleblowers) to bring actions on behalf of the federal government via qui tam actions. Importantly, under the False Claims Act the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;
the federal Civil Monetary Penalties law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary’s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;
HIPAA, which created federal criminal laws that prohibit executing a scheme to defraud any health care benefit program or making false statements relating to health care matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
federal “sunshine” laws, including the federal Physician Payment Sunshine Act (or sometimes referred to as the Open PaymentsTM Program), that require transparency regarding financial arrangements with health care providers, such as the reporting and disclosure requirements imposed by the ACA on drug manufacturers regarding any “transfer of value” made or distributed to physicians, certain non-physician practitioners, teaching hospitals, and ownership or investment interests held by physicians and their immediate family members;
federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and
state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers; state laws that require
28


pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; and state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information.
The risk of being found in violation of these laws and regulations is increased by the fact that many of them have not been definitively interpreted by regulatory authorities or the courts and their provisions are open to a variety of interpretations. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under them, it is possible that some of our business activities, including our relationships with physicians and other healthcare providers (some of whom recommend, purchase and/or prescribe our products) and the manner in which we promote our products, could be subject to challenge and scrutiny. We are also exposed to the risk that our employees, independent contractors, principal investigators, consultants, vendors, distributors and contract research organizations (“CROs”) may engage in fraudulent or other illegal activity. Although we have policies and procedures prohibiting such activity, it is not always possible to identify and deter misconduct and the precautions we take may not be effective in controlling unknown risks or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with applicable laws and regulations.
In November 2021, we received a records subpoena from the United States Attorney’s Office for the District of New Jersey (the “NJ USAO”) seeking information relating to the sale and promotion of Korlym, our relationships with and payments to health care professionals who can prescribe or recommend Korlym and prior authorizations and reimbursement for Korlym. The NJ USAO has informed us that it is investigating whether any criminal or civil violations by us occurred in connection with the matters referenced in the subpoena. It has also informed us that it does not currently consider us a defendant but rather an entity whose conduct is within the scope of the government’s investigation. We are cooperating with the investigation. Please see “Part II, Item 1, Legal Proceedings.”
If we are found in violation of any of the laws described above or any other government regulations, we may be subject to civil and criminal penalties, damages, fines, exclusion from governmental health care programs, a corporate integrity agreement or other agreement to resolve allegations of non-compliance, individual imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our financial results and ability to operate.
Risks Related to our Research and Development Activities
Our efforts to discover, develop and commercialize our product candidates may not succeed. Clinical drug development is lengthy, expensive and often unsuccessful. Results of early studies and trials are often not predictive of later trial results. Failure can occur at any time.
Clinical development is costly, time-consuming and unpredictable. Positive data from clinical trials are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The results from early clinical trials are often not predictive of results in later clinical trials. Product candidates may fail to show the desired safety and efficacy traits despite having produced positive results in preclinical studies and initial clinical trials. Many companies have suffered significant setbacks in late-stage clinical trials due to lack of efficacy or unanticipated or unexpectedly severe adverse events.
Our current clinical trials may prove inadequate to support marketing approvals. Even trials that generate positive results may have to be confirmed in much larger, more expensive and lengthier trials before we could seek regulatory approval.
Clinical trials may take longer to complete, cost more than expected and fail for many reasons, including:
failure to show efficacy or acceptable safety;
slow patient enrollment or delayed activation of clinical trial sites due to the COVID-19 pandemic or other factors;
delays obtaining regulatory permission to start a trial, changes to the size or design of a trial or changes in regulatory requirements for a trial already underway;
inability to secure acceptable terms with vendors and an appropriate number of clinical trial sites;
delays or inability to obtain institutional review board (“IRB”) approval at prospective trial sites;
failure of patients or investigators to comply with the clinical trial protocol;
unforeseen safety issues; and
29


negative findings of inspections of clinical sites or manufacturing operations by us, the FDA or other authorities.
A trial may also be suspended or terminated by us, the trial’s data safety monitoring board, the IRBs governing the sites where the trial is being conducted or the FDA for many reasons, including failure to comply with regulatory requirements or clinical protocols, negative findings in an inspection of our clinical trial operations or trial sites by the FDA or other authorities, unforeseen safety issues, failure to demonstrate a benefit or changes in government regulations. Disruptions caused by the COVID-19 pandemic increase the likelihood of delays in initiating or completing our planned and ongoing clinical trials, thereby increasing their costs. Please see the risk factor, “The COVID-19 pandemic has lengthened the time it takes to initiate and advance some of our clinical trials.”
During the development of a product candidate, we may decide, or the FDA or other regulatory authorities may require us, to conduct more pre-clinical or clinical studies or to change the size or design of a trial already underway, thereby delaying or preventing the completion of development and increase its cost. Even if we conduct the clinical trials and supportive studies that we consider appropriate and the results are positive, we may not receive regulatory approval. Following regulatory approval, there are significant risks to its commercial success, such as development of competing products by other companies or the reluctance of physicians to prescribe it.
The COVID-19 pandemic has lengthened the time it takes to initiate and advance some of our clinical trials.
We conduct clinical trials at sites in the United States, Canada, Europe and Israel. In the United States, Canada and Europe, authorities have imposed significant public health restrictions of varying degrees of severity which are likely to persist as long as COVID-19 public health concerns remain. In addition, physicians, patients and medical institutions have changed their behavior in an attempt to reduce the risk of infection, which makes clinical trials more expensive, time-consuming and risky to initiate and conduct.
Some of the sites where we are conducting clinical trials have, from time-to-time, stopped enrolling new patients or reduced the frequency with which enrolled patients see their physicians. Some clinical sites have temporarily stopped initiating new trials. Many patients are reluctant to participate in procedures required by our clinical trial protocols because they fear infection. In general, COVID-19 has slowed the pace of our clinical trials, including our studies in Cushing’s syndrome. Studies of diseases perceived to be acutely life-threatening, such as our Phase 2 trial in women with platinum-resistant ovarian cancer, did not experience delay or disruption.
We may continue to experience disruptions from the COVID-19 pandemic, which could have a material adverse impact on our clinical trial plans and timelines, including:
delays in enrolling patients or the loss of enrolled patients due to COVID-19 related restrictions;
delays in clinical site initiation, including difficulties in recruiting clinical investigators and staff;
delays in receiving authorizations from local regulatory authorities and internal review boards to initiate clinical trials or amend existing protocols;
delays in clinical sites receiving necessary supplies and materials due to interruptions in local and global shipping;
changes in local regulations that require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs or cause us to suspend or discontinue a trial in the affected jurisdiction;
diversion of healthcare resources, including facilities, supplies and staff, away from the conduct of clinical trials;
interruption of key clinical trial activities, such as clinical trial site monitoring, patient visits and follow-up, study procedures and data collection, that could affect the integrity of clinical trial data, due to limitations on travel;
the infection of patients enrolled in our clinical trials with COVID-19, which could affect the results of the clinical trial, including by increasing the number of observed adverse events or by causing patients to drop out of the study;
patient discontinuations due to fear of infection with COVID-19 or public health restrictions implemented by clinical trial sites which make trial participation more time consuming or difficult;
interruptions or delays in preclinical studies due to restricted or limited operations at laboratory facilities;
delays in necessary interactions with local regulators, ethics committees and other third parties and contractors due to limitations in employee resources or the furlough of government employees; and
30


limitations caused by the sickness of our employees or their families or the desire of employees to avoid contact with large groups of people.
The extent to which the COVID-19 pandemic affects our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence.
Vendors perform many of the activities necessary to carry out our clinical trials, including drug product distribution, trial management and oversight and data collection and analysis. Failure of these vendors to perform their duties or meet expected timelines may prevent or delay approval of our product candidates.
Third-party clinical investigators and clinical sites enroll patients and CROs manage many of our trials and perform data collection and analysis. Although we control only certain aspects of these third parties’ activities, we are responsible for ensuring that every study adheres to its protocol and meets regulatory and scientific standards. If any of our vendors does not perform its duties or meet expected deadlines or fails to adhere to applicable GCPs, or if the quality or accuracy of the data it produces is compromised, affected clinical trials may be extended, delayed or terminated and we may be unable to obtain approval for our product candidates. Outside parties may have staffing difficulties, may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct our clinical trials. Problems with the timeliness or quality of the work of a CRO may lead us to seek to terminate the relationship and use an alternative service provider. However, making this change may be costly and may delay our trials, and it may be challenging to find a replacement organization that can conduct our trials in an acceptable manner and at an acceptable cost. Failure of our manufacturing vendors to perform their duties or comply with cGMPs may require us to recall drug product or repeat clinical trials, which would delay regulatory approval. If our agreements with any of these vendors terminate, we may not be able to enter into alternative arrangements in a timely manner or on reasonable terms.
Our ability to physically inspect our vendors and clinical sites has been limited by the COVID-19 pandemic and associated public health restrictions, which increases the risk that failures to meet applicable requirements will go undetected.
We may be unable to obtain or maintain regulatory approvals for our product or product candidates, which would prevent us from commercializing our product candidates.
We cannot sell a product without the approval of the FDA or comparable foreign regulatory authority. Obtaining such approval is difficult, uncertain, lengthy and expensive. Failure can occur at any stage. In order to receive FDA approval for a new drug, we must demonstrate to the FDA’s satisfaction that the new drug is safe and effective for its intended use and that our manufacturing processes comply with cGMPs. Our inability or the inability of our vendors to comply with applicable FDA and other regulatory requirements can result in delays in or denials of new product approvals, warning letters, untitled letters, fines, consent decrees restricting or suspending manufacturing operations, injunctions, civil penalties, recall or seizure of products, total or partial suspension of product sales and criminal prosecution. We may seek to commercialize our products in international markets, which would require us to receive a marketing authorization and, in many cases, pricing approval, from the appropriate regulatory authorities. Approval procedures vary between countries and can require additional pre-clinical or clinical studies. Obtaining approval may take longer than it does in the United States. Although approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by others, failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Any of these or other regulatory actions could materially harm our business and financial condition.
If we receive regulatory approval for a product candidate, we will be subject to ongoing requirements and oversight by the FDA and other regulatory authorities, such as continued safety and other reporting requirements and possibly post-approval marketing restrictions and additional costly clinical trials. If we are not able to maintain regulatory compliance, we may be required to stop development of a product candidate or to stop selling a product that has already been approved. We may also be subject to product recalls or seizures. Future governmental action or changes in regulatory authority policy or personnel may also result in delays or rejection of pending or anticipated product approvals.
Our products and product candidates may cause undesirable side effects that halt their clinical development, prevent their regulatory approval, limit their commercial potential or cause us significant liability.
Patients in clinical trials report changes in their health, including new illnesses, injuries and discomforts, to their study doctor. Often, it is not possible to determine whether or not these conditions were caused by the drug candidate being studied or something else. As we test our product candidates in larger, longer and more extensive clinical trials, or as use of them becomes more widespread if we receive regulatory approval, patients may report serious adverse events that did not occur or went undetected in previous trials. Many times, serious side effects are only detected in large-scale, Phase 3 clinical trials or following commercial approval.
31


Adverse events reported in clinical trials can slow or stop patient recruitment, prevent enrolled patients from completing a trial and could give rise to liability claims. Regulatory authorities could respond to reported adverse events by interrupting or halting our clinical trials or limiting the scope of, delaying or denying marketing approval. If we elect, or are required by authorities, to delay, suspend or terminate a clinical trial or commercialization efforts, the commercial prospects of the affected product candidates or products may be harmed and our ability to generate product revenues from them may be delayed or eliminated.
If one of our product candidates receives marketing approval, and we or others later identify undesirable side effects or adverse events, potentially significant negative consequences could result, including but not limited to:
regulatory authorities may suspend, limit or withdraw approvals of such product;
regulatory authorities may require additional warnings on the label, including “boxed” warnings, or issue safety alerts and other safety information about the product;
we may be required to change the way the product is administered or conduct additional studies or clinical trials;
we may be required to create a Risk Evaluation and Mitigation Strategy, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use;
the product may become less competitive;
we may be subject to fines, injunctions or the imposition of criminal penalties; and
we could be sued and held liable for harm caused to patients;
Any of these events could seriously harm our business.
Risks Related to our Capital Needs and Financial Results
We may need additional capital to fund our operations or for strategic reasons. Such capital may not be available on acceptable terms or at all.
We are dependent on revenue from the sale of Korlym and our cash reserves to fund our commercial operations and development programs. If Korlym revenue declines significantly, we may need to curtail our operations or raise funds to support our plans. We may also choose to raise funds for strategic reasons. We cannot be certain funding will be available on acceptable terms or at all. Equity financing would cause dilution, debt financing may involve restrictive covenants. Neither type of financing may be available to us on attractive terms or at all. If we obtain funds through collaborations with other companies, we may have to relinquish rights to one or more of our product candidates. If our revenue declines and our cash reserves are depleted, and if adequate funds are not available from other sources, we may have to delay, reduce the scope of, or eliminate one or more of our development programs.
Risks Relating to our Intellectual Property
To succeed, we must secure, maintain and effectively assert adequate patent protection for the composition and methods of use of our proprietary, selective cortisol modulators and for the use of Korlym to treat Cushing’s syndrome.
Patents are uncertain, involve complex legal and factual questions and are frequently the subject of litigation. The patents issued or licensed to us may be challenged at any time. Competitors may take actions we believe infringe our intellectual property, causing us to take legal action to defend our rights. Intellectual property litigation is lengthy, expensive and requires significant management attention. Outcomes are uncertain. If we do not protect our intellectual property, competitors may erode our competitive advantage. Please see “Part II, Item 1, Legal Proceedings.”
Our patent applications may not result in issued patents and patents issued to us may be challenged, invalidated, held unenforceable or circumvented. Our patents may not prevent third parties from producing competing products. The foreign countries where we may someday operate may not protect our intellectual property to the extent the laws of the United States do. If we fail to obtain adequate patent protection in other countries, others may produce products in those countries based on our technology.
32


Risks Related to our Stock
The price of our common stock fluctuates widely and is likely to continue to do so. Opportunities for investors to sell shares may be limited.
We cannot assure investors that a liquid trading market for our common stock will exist at any particular time. As a result, holders of our common stock may not be able to sell shares quickly or at the current market price. During the 52-week period ended April 26, 2023, our average daily trading volume was approximately 740,650 shares and the intra-day sales prices per share of our common stock on The Nasdaq Stock Market ranged from $17.19 to $30.14. As of April 26, 2023, our officers, directors and principal stockholders beneficially owned approximately 20 percent of our common stock.
Our stock price can experience extreme price and volume fluctuations that are unrelated or disproportionate to our operating performance or prospects. Securities class action lawsuits are often instituted against companies following periods of stock market volatility. Such litigation is costly and diverts management’s attention from productive efforts.
Factors that may cause the price of our common stock to fluctuate rapidly and widely include:
actual or anticipated variations in our operating results or changes to any public guidance we have provided;
actual or anticipated timing and results of our clinical trials;
changes in the expected or actual timing of our competitors’ development programs;
general market and economic conditions, including the effects of the COVID-19 pandemic;
disputes or other developments relating to our intellectual property, including developments in ANDA litigation;
short-selling of our common stock, the publication of speculative opinions about our business or other market manipulation activities that are intended to lower our stock price or increase its volatility;
changes in estimates or recommendations by securities analysts or the failure of our performance to meet the published expectations of those analysts or public guidance we have provided;
actual or anticipated regulatory approvals of our product candidates or competing products;
purchases or sales of our common stock by our officers, directors or stockholders;
changes in laws or regulations applicable to Korlym, our product candidates or our competitors’ products;
technological innovations by us, our collaborators or our competitors;
conditions in the pharmaceutical industry, including the market valuations of companies similar to ours;
additions or departures of key personnel;
announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; and
additional financing activities.
Our stock price may decline if our financial performance does not meet the guidance we have provided to the public, estimates published by research analysts or other investor expectations.
The guidance we provide as to our expected revenue is only an estimate of what we believe is realizable at the time we give such guidance. It is difficult to predict our revenue and our actual results may vary materially from our guidance. The effect on our business of the COVID-19 pandemic is difficult to forecast. In addition, the rate of physician adoption of Korlym and the actions of government and private payers is uncertain. We may experience competition from generic versions of Korlym, which our public revenue guidance does not anticipate. We may not meet our financial guidance or other investor expectations for other reasons, including those arising from the risks and uncertainties described in this report and in our other public filings and public statements. Research analysts publish estimates of our future revenue and earnings based on their own analysis. The revenue guidance we provide may be one factor they consider when determining their estimates.
33


General Risk Factors
We need to increase the size of our organization and may experience difficulties in managing growth.
Our commercial and research and development efforts are constrained by our limited administrative, operational and management resources. To date, we have relied on a small management team. Growth will impose significant added responsibilities on members of management, including the need to recruit and retain additional employees. Our financial performance and ability to compete will depend on our ability to manage growth effectively. To that end, we must:
manage our sales and marketing efforts, clinical trials, research and manufacturing activities effectively;
hire more management, clinical development, administrative and sales and marketing personnel; and
continue to develop our administrative systems and controls.
Failure to accomplish any of these tasks, which are more difficult during the COVID-19 pandemic, could harm our business.
If we lose key personnel or are unable to attract more skilled personnel, we may be unable to pursue our product development and commercialization goals.
Our ability to operate successfully and manage growth depends upon hiring and retaining skilled managerial, scientific, sales, marketing and financial personnel. The job market for qualified personnel is intensely competitive and turnover rates have reached record highs within our industry and the geographical areas from which we recruit. We depend on the principal members of our management and scientific staff. Any officer or employee may terminate his or her relationship with us at any time and work for a competitor. We do not have employment insurance covering any of our personnel. The loss of key individuals could delay our research, development and commercialization efforts.
We are subject to government regulation and other legal obligations relating to privacy and data protection. Compliance with these requirements is complex and costly. Failure to comply could materially harm our business.
We and our partners are subject to federal, state and foreign laws and regulations concerning data privacy and security, including HIPAA and the EU General Data Protection Regulation, or the GDPR. These and other regulatory frameworks are evolving rapidly as new rules are enacted and existing ones updated and made more stringent.
In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy, laws, and federal and state consumer protection laws and regulations (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.
Even when HIPAA does not apply, according to the Federal Trade Commission (the “FTC”), violating consumers’ privacy or failing to take appropriate steps to keep consumers’ personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. In 2022, the FTC also began a rulemaking proceeding to develop additional data privacy rules and requirements, which may add additional complexity to compliance obligations going forward.
In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, the California Confidentiality of Medical Information Act imposes restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. Further, the California Consumer Privacy Act, or the CCPA, which took effect on January 1, 2020, created individual privacy rights for California consumers and increased the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential
34


liability. Further, the California Privacy Rights Act, or CPRA, revised and expanded the CCPA, adding additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The CPRA is in full effect as of January 1, 2023, and similar laws passed in Virginia, Colorado, Connecticut and Utah will take effect starting in 2023. As a result, additional compliance investment and potential business process changes may be required. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. Additional legislation proposed at the federal level and in other states, along with increased regulatory action, reflect a trend toward more stringent privacy legislation in the United States.
Outside the United States, many jurisdictions have or are in the process of enacting sweeping data privacy regulatory regimes. In Europe, the GDPR took effect in 2018, and is imposing stringent requirements for controllers and processors of personal data of individuals within the EEA, particularly with respect to clinical trials. The GDPR provides that EEA member states may make their own further laws and regulations limiting the processing of health data, which could limit our ability to use and share personal data or could cause our costs to increase and harm our business and financial condition. In addition, the GDPR increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. Recent legal developments have added complexity and compliance uncertainty regarding certain transfers of information from the EEA to the United States. Following EU court decisions, updated standard contractual clauses (“SCCs”) were adopted to account for these judicial decisions, imposing new requirements on data transfers. The revised SCCs must be used for relevant new data transfers from September 27, 2021, and existing SCC arrangements were required to be migrated by December 27, 2022. There is some uncertainty around whether the revised clauses can be used for all types of data transfers, particularly whether they can be relied on for data transfers to non-EEA entities subject to the GDPR. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. The GDPR imposes substantial fines for breaches of data protection requirements, which can be up to four percent of global revenue for the preceding financial year or €20 million, whichever is greater, and it also confers a private right of action on data subjects for breaches of data protection requirements. Compliance with European data protection laws is a rigorous and time intensive process that may increase our cost of doing business, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation and reputational harm in connection with our European activities. From January 1, 2021, we have had to comply with the GDPR and separately the United Kingdom GDPR, which, together with the amended United Kingdom Data Protection Act 2018, retains the GDPR in United Kingdom national law, each regime having the ability to fine up to the greater of €20 million/ £17.5 million or 4 percent of global turnover. It is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term and these changes may lead to additional costs and increase our overall risk exposure. On June 28, 2021, the EC adopted an adequacy decision in favor of the United Kingdom, enabling data transfers from EU member states to the United Kingdom without additional safeguards. However, the United Kingdom adequacy decision will automatically expire in June 2025 unless the EC renews or extends that decision and remains under review by the Commission during this period.
Complying with U.S. and foreign privacy and security laws and regulations is complex and costly. Failure to comply by us or our vendors could subject us to litigation, government enforcement actions and substantial penalties and fines, which could harm our business.
We rely on information technology to conduct our business. A breakdown or breach of our information technology systems or our failure to protect confidential information concerning our business, patients or employees could interrupt the operation of our business and subject us to liability.
We store valuable confidential information relating to our business, patients and employees on our computer networks and on the networks of our vendors. In addition, we rely heavily on internet technology, including video conference, teleconference and file-sharing services, to conduct business. Despite our security measures, our networks and the networks of our vendors are at risk of break-ins, installation of malware or ransomware, denial-of-service attacks, data theft and other forms of malfeasance by persons seeking to commit fraud or theft, which could result in unauthorized access to, and/or misuse of, our clinical data or other confidential information, including confidential information relating to our patients or employees. COVID-19 may continue to increase our cybersecurity risks, due to our reliance on internet technology and the number of our employees that are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities.
35


We and our vendors have experienced data breaches, theft, “phishing” attacks and other unauthorized access to confidential data and information. Russia’s invasion of Ukraine or another war of international dispute may cause an increase in the number and severity of such malicious incidents. There can be no assurance that our cybersecurity systems and processes will prevent unauthorized access in the future that causes serious harm to us, our patients or employees. We may also experience security breaches that remain undetected for an extended period.
Disruptions or security breaches that result in the disclosure of confidential or proprietary information could cause us to incur liability and delay or otherwise harm our research, development and commercialization efforts. We may be liable for losses suffered by patients or employees or other individuals whose confidential information is stolen as a result of a breach of the security of the systems that we or third parties and our vendors store this information on, and any such liability could be material. Even if we are not liable for such losses, any breach of these systems could expose us to material costs in notifying affected individuals, as well as regulatory fines or penalties. In addition, any breach of these systems could disrupt our normal business operations and expose us to reputational damage and harm our business, operating results and financial condition. Any insurance we maintain against the risk of this type of loss may not be sufficient to cover actual losses or may not apply to the circumstances relating to any particular loss.
Changes in federal, state and local tax laws may reduce our net earnings.
Our earnings are subject to federal, state and local taxes. We offset a portion of our earnings using net operating losses and our taxes using research and development tax credits, which reduces the amount of tax we pay. Some jurisdictions require that we pay taxes or fees calculated as a percentage of sales, payroll expense, or other indicia of our activities. Please see “Part I, Item 1, Notes to Unaudited Condensed Consolidated Financial Statements – Income Taxes.” Certain provisions of the recently enacted IRA, effective January 1, 2023, including a 1 percent excise tax on share repurchases and a 15 percent corporate alternative minimum tax, may impact our income tax expense, profitability and capital allocation decisions. In April 2023, we completed an issuer tender offer pursuant to which we accepted for tender 6,610,369 shares of our common stock for an aggregate purchase price of $145,428,118. Changes to existing tax laws could materially increase the amounts we pay, which would reduce our after tax net income.
We may face competition from companies with greater financial, technical and marketing resources than our own.
The pharmaceutical industry is competitive and subject to rapid technological change. Our potential competitors include large pharmaceutical companies and innovative biotechnology companies, many of which have greater clinical, marketing and sales resources than our own and may develop and commercialize medications that are superior to and less expensive than ours, which could negatively affect our financial results and the prospects of our product candidates.
Research analysts may not continue to provide or initiate coverage of our common stock or may issue negative reports.
The market for our common stock may be affected by the reports financial analysts publish about us. If any of the analysts covering us downgrades or discontinues coverage of our stock, the price of our common stock could decline rapidly and significantly. Paucity of research coverage may also adversely affect our stock price.
Sale of a substantial number of shares of our common stock may cause its price to decline.
Sales of a substantial number of shares of our stock in the public market could reduce its price. As additional shares of our stock become available for public resale, whether by the exercise of stock options by employees or directors or because of an equity financing by us, the supply of our stock will increase, which could cause its price to fall. Substantially all of our outstanding shares are eligible for sale, subject to applicable volume and certain other resale restrictions.
Changes in laws and regulations may significantly increase our costs or reduce our revenue, which could harm our financial results.
New laws and regulations, as well as changes to existing laws and regulations, including statutes and regulations concerning taxes and the development, approval, marketing and pricing of medications, the provisions of the ACA requiring the reporting of aggregate spending related to health care professionals, the provisions of the Sarbanes-Oxley Act of 2002, the Dodd Frank Act of 2010 and rules adopted by the SEC and by The Nasdaq Stock Market have and will likely continue to increase our cost of doing business and divert management’s attention from revenue-generating activities.
We may fail to comply with our public company obligations, including securities laws and regulations. Such compliance is costly and requires significant management attention.
The federal securities laws and regulations, including the corporate governance and other requirements of the Sarbanes-Oxley Act of 2002 and the governance and other requirements of the Dodd Frank Act of 2010, impose complex and continually
36


changing regulatory requirements on our operations and reporting. These developing requirements will continue to increase our compliance costs. Section 404 of the Sarbanes-Oxley Act of 2002 requires that we evaluate the effectiveness of, and provide a management report with respect to, our internal controls over financial reporting. It also requires that the independent registered public accounting firm auditing our consolidated financial statements must attest to and report on the effectiveness of our internal controls over financial reporting. If we are unable to complete the required assessment and report or if our independent registered public accounting firm is unable to issue an unqualified opinion as to the effectiveness of our internal control over financial reporting, investors could lose confidence in our financial reporting and our stock price would likely decline.
Anti-takeover provisions in our charter and bylaws and under Delaware law may make an acquisition of us or a change in our management more expensive or difficult, even if an acquisition or a management change would be beneficial to our stockholders.
Provisions in our charter and bylaws may delay or prevent an acquisition of us or a change in our management. Some of these provisions allow us to issue preferred stock without any vote or further action by the stockholders, require advance notification of stockholder proposals and nominations of candidates for election as directors and prohibit stockholders from acting by written consent. In addition, a supermajority vote of stockholders is required to amend our bylaws. Our bylaws provide that special meetings of the stockholders may be called only by our Chairman, President or the Board of Directors and that the authorized number of directors may be changed only by resolution of the Board of Directors. These provisions may prevent or delay a change in our Board of Directors or our management, which our Board of Directors appoints. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law. Section 203 may prohibit large stockholders, in particular those owning 15 percent or more of our outstanding voting stock, from merging or combining with us. These provisions in our charter and bylaws and under Delaware law could reduce the price that investors would be willing to pay for shares of our common stock.
Our officers, directors and principal stockholders, acting as a group, could significantly influence corporate actions.
As of April 26, 2023, our officers and directors beneficially owned approximately 20 percent of our common stock. Acting together, these stockholders could significantly influence any matter requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combinations. The interests of this group may not always coincide with our interests or the interests of other stockholders and may prevent or delay a change in control. This significant concentration of share ownership may adversely affect the trading price of our common stock because many investors perceive disadvantages to owning stock in companies with controlling stockholders.
We have in the past and may in the future be subject to short selling strategies that may drive down the market price of our common stock.
Short sellers have in the past and may attempt in the future to drive down the market price of our common stock. Short selling is the practice of selling securities that the seller does not own but may have borrowed with the intention of buying identical securities back at a later date. The short seller hopes to profit from a decline in the value of the securities between the time the securities are borrowed and the time they are replaced. As it is in the short seller’s best interests for the price of the stock to decline, many short sellers (sometime known as “disclosed shorts”) publish, or arrange for the publication of, negative opinions regarding the relevant issuer and its business prospects to create negative market momentum. Although traditionally these disclosed shorts were limited in their ability to access mainstream business media or to otherwise create negative market rumors, the rise of the Internet and technological advancements regarding document creation, videotaping and publication by weblog (“blogging”) have allowed many disclosed shorts to publicly attack a company’s credibility, strategy and veracity by means of so-called “research reports” that mimic the type of investment analysis performed by large Wall Street firms and independent research analysts. These short attacks have, in the past, led to selling of shares in the market. Further, these short seller publications are not regulated by any governmental, self-regulatory organization or other official authority in the U.S. and they are not subject to certification requirements imposed by the SEC. Accordingly, the opinions they express may be based on distortions, omissions or fabrications. Companies that are subject to unfavorable allegations, even if untrue, may have to expend a significant amount of resources to investigate such allegations and/or defend themselves, including shareholder suits against the company that may be prompted by such allegations. We may in the future be the subject of shareholder suits that we believe were prompted by allegations made by short sellers.
ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
There were no unregistered sales of equity securities during the period covered by this report.
37


Issuer Purchases of Equity Securities
The following table contains information relating to the purchases of our common stock in the three months ended March 31, 2023 as part of the cashless net exercises of stock options (in thousands, except average price per share):
Fiscal Period
Total Number of Shares Purchased(1)
Average Price Per Share
Total Purchase Price of Shares(2)
January 1, 2023 to January 31, 202340 $22.10 $887 
February 1, 2023 to February 28, 202311 23.03 244 
March 1, 2023 to March 31, 2023246 21.21 5,228 
Total297 $21.40 $6,359 
(1) In January 2023, we issued 76,066 shares of common stock as part of net-share settlement of cashless option exercises, of which 40,146 shares were surrendered to us in satisfaction of related exercise cost and tax obligations. In February 2023, we issued 16,168 shares of common stock as part of net-share settlement of cashless option exercises, of which 10,584 shares were surrendered to us. In March 2023, we issued 378,456 shares of common stock as part of net-share settlement of cashless option exercises, of which 246,463 shares were surrendered to us.
(2) We paid $1.1 million to satisfy the tax withholding obligations associated with the net-share settlement of these cashless option exercises.
ITEM 3.  DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4.  MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5.  OTHER INFORMATION
None.
38


ITEM 6.  EXHIBITS
Exhibit
Number
 Description of Document
3.1 
3.2 
10.1
31.1 
31.2 
32.1 
32.2 
101 
The following materials from the registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, formatted in Extensible Business Reporting Language (XBRL): (i) Unaudited Condensed Consolidated Balance Sheets at March 31, 2023 and December 31, 2022, (ii) Unaudited Condensed Consolidated Statements of Income for the three month periods ended March 31, 2023 and 2022, (iii) Unaudited Condensed Consolidated Statements of Comprehensive Income for the three month periods ended March 31, 2023 and 2022, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the three month periods ended March 31, 2023 and 2022, (v) Unaudited Condensed Consolidated Statement of Stockholders’ Equity and (vi) Notes to Unaudited Condensed Consolidated Financial Statements.
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

39


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 CORCEPT THERAPEUTICS INCORPORATED
  
Date: May 3, 2023/s/ Joseph K. Belanoff
 Joseph K. Belanoff, M.D.
Chief Executive Officer
  
Date:
May 3, 2023/s/ Atabak Mokari
 Atabak Mokari
 Chief Financial Officer
Date:May 3, 2023/s/ Joseph D. Lyon
Joseph D. Lyon
Chief Accounting Officer
40
EX-10.1 2 cort33123ex101eighthamendm.htm EX-10.1 Document

Exhibit 10.1
EIGHTH AMENDMENT TO LEASE
THIS EIGHTH AMENDMENT TO LEASE (the “Eighth Amendment”) is made and entered into as of April 1, 2023 by and between Exponent Realty, LLC, a Delaware limited liability company (“Landlord”), and Corcept Therapeutics Incorporated, a Delaware corporation (“Tenant”).
RECITALS
A.    Landlord and Tenant are parties to that certain lease dated April 1, 2016 (the “Lease”), the first amendment (the “First Amendment”) dated June 1, 2017, the second amendment (the “Second Amendment”) dated March 12, 2018, the third amendment (the “Third Amendment”) dated November 8, 2018, the Fourth Amendment dated October 23, 2019 (the “Fourth Amendment”) the Fifth Amendment dated June 17, 2020 (the “Fifth Amendment”), the Sixth Amendment dated July 22, 2020 (the “Sixth Amendment”), and the Seventh Amendment (the “Seventh Amendment”) dated March 18, 2022. Pursuant to the Lease, the First Amendment, the Second Amendment, the Third Amendment, the Fourth Amendment, the Fifth Amendment, the Sixth Amendment, and the Seventh Amendment, Landlord has leased to Tenant space currently containing approximately 47,022 rentable square feet (the “Premises”) on the first and second floor of the building, located at 149 Commonwealth Dr., Menlo Park, CA 94025 (the "Building”).
B.    Tenant and Landlord now desire to amend the Lease on the following terms and conditions:
NOW, THEREFORE, in consideration of the above recitals which by this reference are incorporated herein, the mutual covenants and conditions contained herein and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows:
1.    Tenant Improvements. Landlord shall not provide any allowance for Tenant Improvements in the Premises.
2.    Lease Term. The Term of the Lease shall be extended through June 30, 2024.
3.    Revision of Premises. The Premises shall be revised as follows:
a.Effective June 30, 2023, Suite 1014 (2,617 rentable square feet), shown on Exhibit A, shall no longer be part of the Premises and all rights to that portion of the Premises shall revert to Landlord.
b.Effective immediately, Suite 2060 (6,372 rentable square feet), shown on Exhibit A, shall be added to the Premises, provided, however, that no base rent shall be due with respect to that portion of the Premises until July 1, 2023.
4.    Base Rent. The Base Rent for the Premises shall be as shown in the schedule below. Tenant shall continue to pay its proportionate share of the Operating Expenses and Real Estate Taxes on the Premises. As of July 1, 2023, the schedule of Base Rent payable with respect to the Premises is the following:
DATEPERIODRENTABLE
SQ. FT.
BASE RENT PER RSF* PER YEARMONTHLY
AMOUNT
PERIODIC
AMOUNT
07/01/2023 to 06/30/202412 months50,777$48.60$205,646.85$2,467,762.20
*RSF is defined as Rentable Square Foot/Feet
5.    Option to Extend Lease. Tenant shall have one option to extend the Term of the Lease by 12 months. In order to extend the Term, Tenant must notify Landlord in writing, by September 30, 2023 of Tenant’s exercise of this option. In the event that Tenant exercises this option, Tenant shall continue to pay its proportionate share of the Operating Expenses and Real Estate Taxes on the Premises through the extended Term and the schedule of Base Rent payable with respect to the Premises shall be the following:
DATEPERIODRENTABLE
SQ. FT.
BASE RENT PER RSF* PER YEARMONTHLY
AMOUNT
PERIODIC
AMOUNT
07/01/2024 to 06/30/202512 months50,777$48.60$205,646.85$2,467,762.20



6.    Miscellaneous.
6.1 This Eighth Amendment, which is hereby incorporated into and made a part of the Lease, sets forth the entire agreement between the parties with respect to the matters herein. There have been no additional oral or written representations or agreements. Under no circumstances shall Tenant be entitled to any Rent abatement, improvement allowance, leasehold improvements, or other work to the Premises, or any similar economic incentives that may have been provided Tenant in connection with entering into the Lease, unless specifically set forth in this Eighth Amendment. Tenant agrees that neither Tenant nor its agents or any other parties acting on behalf of Tenant shall disclose any matters set forth in this Eighth Amendment or disseminate or distribute any information concerning the terms, details or conditions hereof to any person, firm, entity, broker or other tenants in the Building without obtaining the express written consent of Landlord.
6.2 Except as herein modified or amended, the provisions, conditions and terms of the Lease shall remain unchanged and in full force and effect.
6.3 In the case of any inconsistency between the provisions of the Lease and the Eighth Amendment, the provisions of this Eighth Amendment shall govern and control.
6.4 Submission of this Eighth Amendment by Landlord is not an offer to enter into this Eighth Amendment but rather is a solicitation for such an offer by Tenant. Landlord shall not be bound by this Eighth Amendment until Tenant and Landlord have executed and Landlord delivered the same to Tenant.
6.5 Tenant hereby represents to Landlord that Tenant has dealt with no real estate brokers or agents in connection with this Eighth Amendment. Tenant agrees to indemnify and hold Landlord, its members, principals, beneficiaries, partners, officers, directors, employees, mortgagee(s) and agents, and the respective principals and members of any such real estate brokers or agents (collectively, the “Landlord Related Parties”) harmless from all claims of any real estate brokers or agents claiming to have represented Tenant in connection with this Eighth Amendment. Landlord hereby represents to Tenant that Landlord has dealt with no real estate brokers or agents in connection with this Eighth Amendment. Landlord agrees to indemnify and hold Tenant, its members, principals, beneficiaries, partners, officers, directors, employees, and agents, and the respective principals and members of any such real estate brokers or agents (collectively, the “Tenant Related Parties”) harmless from all claims of any real estate brokers or agents claiming to have represented Landlord in connection with this Eighth Amendment.
6.6 Each signatory of this Eighth Amendment represents hereby that he or she has the authority to execute and deliver the same on behalf of the party hereto for which such signatory is acting.
SIGNATURES APPEAR ON NEXT PAGE



IN WITNESS WHEREOF, Landlord and Tenant have duly executed this Eighth Amendment as of the day and year first above written.
LANDLORD:
EXPONENT REALTY, L.L.C.,
a Delaware limited liability company
Date: April 1, 2023By: /s/ Richard L. Schlenker
Name: Richard L. Schlenker
Title: Executive Vice President & CFO
TENANT:
Corcept Therapeutics Incorporated,
a Delaware corporation
Date: April 1, 2023By: /s/ J.D. Lyon
Name: J.D. Lyon
Title: Chief Accounting Officer



EXHIBIT A
capture.gif

EX-31.1 3 cort33123ex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, Joseph K. Belanoff, M.D., certify that:
1.I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2023 of Corcept Therapeutics Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/ Joseph K. Belanoff
Joseph K. Belanoff, M.D.
Chief Executive Officer and President
(Principal Executive Officer)
May 3, 2023


EX-31.2 4 cort33123ex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, Atabak Mokari, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2023 of Corcept Therapeutics Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/ Atabak Mokari
Atabak Mokari
Chief Financial Officer
(Principal Financial Officer)
May 3, 2023


EX-32.1 5 cort33123ex321.htm EX-32.1 Document

Exhibit 32.1
Corcept Therapeutics Incorporated
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Corcept Therapeutics Incorporated (the “Company”) on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph K. Belanoff, M.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Joseph K. Belanoff
Joseph K. Belanoff, M.D.
Chief Executive Officer and President
(Principal Executive Officer)
May 3, 2023
This certification is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Corcept Therapeutics Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in such filing.


EX-32.2 6 cort33123ex322.htm EX-32.2 Document

Exhibit 32.2
Corcept Therapeutics Incorporated
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Corcept Therapeutics Incorporated (the “Company”) on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Atabak Mokari, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Atabak Mokari
Atabak Mokari
Chief Financial Officer
(Principal Financial Officer)
May 3, 2023
This certification is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Corcept Therapeutics Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in such filing.

EX-101.SCH 7 cort-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Composition of Certain Balance Sheet Items link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Available-for-Sale Securities and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Composition of Certain Balance Sheet Items (Tables) link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Available-for-Sale Securities and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Composition of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Composition of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Other Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Composition of Certain Balance Sheet Items - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Summary of the Classification of Available-for-Sale Securities in Condensed Consolidated Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Leases - Right-of-use Assets and Related Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Stockholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Stockholders' Equity - Summary of Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Net Income Per Share - Schedule of Computation of Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Net Income Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Subsequent Events - Lease Amendment (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Subsequent Events - Tender Offer (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 cort-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 cort-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 cort-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Adjustments to reconcile net income to net cash provided by operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Total operating lease payments Lessee, Operating Lease, Liability, to be Paid Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Income tax expense Income tax expense Income Tax Expense (Benefit) Deferred tax assets, net Deferred Income Tax Assets, Net Entity Address, Postal Zip Code Entity Address, Postal Zip Code Additional Paid-in Capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Cost of sales Cost of Goods and Services Sold Diluted (in shares) Weighted-average shares used to compute diluted net income per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted average maturity period Marketable Securities Weighted Average Maturity Period Marketable securities weighted-average maturity period. Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of composition of inventory, current Schedule of Inventory, Current [Table Text Block] (Accretion) amortization of interest income Accretion Expense (Income) Accretion Expense (Income) Number of stock option plans Number Of Stock Option Plans Number of stock option plans. Loss Contingencies [Line Items] Loss Contingencies [Line Items] Total property and equipment Property, Plant and Equipment, Gross Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Schedule of available-for-sale securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Government rebates Accrued Government Rebate Current Accrued government rebate current. Common stock Common Stock, Value, Issued Proceeds from issuance of common stock under our incentive award plan, net of issuance costs Proceeds from Issuance or Sale of Equity Financial Instruments Financial Instruments [Domain] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Recognition of right-of-use asset and lease liability Non Cash Transaction, Recognition Of Right Of Use Asset And Lease Liability Non Cash Transaction, Recognition Of Right Of Use Asset And Lease Liability Weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Statistical Measurement [Domain] Statistical Measurement [Domain] Issuance of common stock upon exercise of options (in shares) Common shares issued upon exercise of options (in share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Proceeds from maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Estimated Fair Value Available For Sale Securities Including Cash Equivalents Available for sale securities including cash equivalents. Additional paid-in capital Additional Paid in Capital, Common Stock Cash and cash equivalents, at beginning of period Cash and cash equivalents, at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Foreign currency translation gain (loss), net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Net income per share attributable to common stockholders Earnings Per Share, Basic and Diluted EPS [Abstract] Earnings Per Share, Basic and Diluted EPS Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Net income attributable to common stockholders, basic Net Income (Loss) Available to Common Stockholders, Basic Net income Net income Net Income (Loss) Attributable to Parent Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Weighted average options excluded from the computation of diluted net income per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Cash equivalents Cash Equivalents [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Available For Sale Securities And Fair Value Measurements [Abstract] Available For Sale Securities And Fair Value Measurements [Abstract] Available for sale securities and fair value measurements. Income Statement Location Income Statement Location [Domain] Share Repurchase Program Share Repurchase Program [Domain] Unrecognized tax benefits that would be offset by a change in valuation allowance Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance Equity Component Equity Component [Domain] Amendment Flag Amendment Flag Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Subsequent Event Type [Domain] Subsequent Event Type [Domain] Scenario [Axis] Scenario [Axis] Total comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] Leases Lessee, Operating Leases [Text Block] Number of series of selective cortisol modulators Number Of Series Of Selective Cortisol Modulators Number Of Series Of Selective Cortisol Modulators Number of compounds (more than) Number Of Compounds Number Of Compounds Treasury stock Treasury Stock, Common, Value Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Long-term accrued income taxes Increase (Decrease) in Accrued Taxes Payable Other assets Other Assets, Noncurrent Long-term marketable securities Long Term Marketable Securities [Member] Long Term Marketable Securities [Member] Total marketable securities Debt Securities, Available-for-Sale Award holding period Employee Stock Purchase Plan, Award Holding Period Employee Stock Purchase Plan, Award Holding Period Supplemental disclosure: Supplemental Cash Flow Information [Abstract] Depreciation and amortization of property and equipment Depreciation, Depletion and Amortization 2023 (remainder) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Extended lease term Lessee, Operating Lease, Term of Contract Employee Stock Employee Stock [Member] Stock options outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Award Type [Axis] Award Type [Axis] Total inventory Inventory Current Noncurrent Total inventory. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Accrued selling and marketing costs Accrued Marketing Costs, Current Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Short-term operating lease liability Operating Lease, Liability, Current Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Summary of the classification of available-for-sale securities in condensed consolidated balance sheets Debt Securities, Available-for-Sale [Table Text Block] Cash paid for operating lease liabilities Operating Lease, Payments Accounting Policies [Table] Accounting Policies [Table] Accounting Policies [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Stock Options Stock Options to Purchase Common Stock Share-Based Payment Arrangement, Option [Member] Operating expenses: Costs and Expenses [Abstract] Issuance of common stock upon exercise of options Stock Issued During Period, Value, Stock Options Exercised Balance Sheet Location [Axis] Balance Sheet Location [Axis] Unrealized gain (loss) on available-for-sale investments, net of tax effect of $(192) and $323, respectively OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Total liabilities Liabilities Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Income taxes payable Accrued Income Taxes, Current Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Schedule of property and equipment Property, Plant and Equipment [Table Text Block] Accrued settlement related to Melucci litigation (Note 4) Accrued liability, litigation Loss Contingency, Accrual, Current Document Type Document Type Settled Litigation Settled Litigation [Member] Entity Small Business Entity Small Business Measurement Basis [Axis] Measurement Basis [Axis] Stockholders’ Equity Stockholders' Equity Note Disclosure [Text Block] Non-cash amortization of right-of-use asset Operating Lease, Right-of-Use Asset, Amortization Expense Shares issued in period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Software Computer Software, Intangible Asset [Member] Entity Shell Company Entity Shell Company Deferred income taxes Deferred Income Tax Expense (Benefit) Restricted Stock Awards (RSAs) Restricted Stock Awards (RSAs) [Member] Restricted Stock Awards (RSAs) Financial Instrument [Axis] Financial Instrument [Axis] Trade receivables Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Subsequent event Subsequent Event [Member] Document Period End Date Document Period End Date Total operating expenses Costs and Expenses Interest receivable, current Interest Receivable, Current Subsequent Event [Line Items] Subsequent Event [Line Items] Work in progress Inventory Work In Process Current And Noncurrent Inventory, work in process. current and noncurrent. Shareholders Equity [Line Items] Class of Stock [Line Items] Present value of operating lease liabilities Operating Lease, Liability U.S. government agency securities US Government Agencies Debt Securities [Member] Total assets Assets Selling, general and administrative Selling, General and Administrative Expenses [Member] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Accrued and other liabilities Increase (Decrease) in Other Accrued Liabilities Income Statement Location Income Statement Location [Axis] Antidilutive Securities Antidilutive Securities [Axis] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Estimate of fair value measurement Estimate of Fair Value Measurement [Member] Total accrued and other liabilities Total accrued and other liabilities Accrued Liabilities, Current U.S. Treasury securities US Treasury Securities [Member] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Payment awarded to other party Litigation Settlement, Amount Awarded to Other Party Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Legal fees Accrued Legal Fees Current Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to legal services. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Inventory Total inventory classified as current Inventory, Net Asset-backed securities Asset-Backed Securities [Member] Accounts payable Accounts Payable, Current Finished goods Inventory Finished Goods Current And Noncurrent Inventory, finished goods, current and noncurrent. Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Net Income Per Share Earnings Per Share [Text Block] Unrealized gain (loss) on available-for-sale investments, tax expense (benefit) OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax Composition of Certain Balance Sheet Items Supplemental Balance Sheet Disclosures [Text Block] Operating lease liability Increase (Decrease) in Operating Lease Liability Entity Filer Category Entity Filer Category Basic (in shares) Weighted-average shares used to compute basic net income per share (in shares) Weighted Average Number of Shares Outstanding, Basic Award Type [Domain] Award Type [Domain] Melucci Melucci [Member] Melucci Allocated share-based compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies (Note 4) Commitments and Contingencies Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Accounting Policies [Line Items] Accounting Policies [Line Items] Accounting Policies [Line Items] Subsequent Events Subsequent Events [Text Block] Preferred stock Preferred Stock, Value, Issued Restricted Stock Awards (RSAs) Restricted Stock [Member] Accrued compensation Accrued Compensation, Current Accrued Compensation, Current Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Product revenue, net Revenue from Contract with Customer, Excluding Assessed Tax Corporate bonds Corporate Bond Securities [Member] Entity Address, City or Town Entity Address, City or Town Leases [Abstract] Leases [Abstract] Cover page. Cover [Abstract] Unrecognized tax benefits, period increase Unrecognized Tax Benefits, Period Increase (Decrease) Minimum Minimum [Member] Maximum maturity period, short-term securities Short Term Marketable Securities Maximum Maturity Period Short Term Marketable Securities Maximum Maturity Period Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Deposits for clinical trials Deposits For Clinical Trials Deposits For Clinical Trials Weighted-average shares outstanding used in computing net income per common share Weighted Average Number of Shares Outstanding, Basic and Diluted [Abstract] Weighted Average Number of Shares Outstanding, Basic and Diluted Forecast Forecast [Member] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Treasury Stock Treasury Stock, Common [Member] Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants Payment tax withholding share-based payment arrangement Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and stockholders’ equity Liabilities and Equity Trading Symbol Trading Symbol Entity File Number Entity File Number Common stock repurchased, average price (in dollars per share) Treasury Stock Acquired, Average Cost Per Share Short-term marketable securities Short Term Marketable Securities [Member] Short Term Marketable Securities [Member] Exercise cost of shares repurchased for net settlement of cashless option exercises Shares Repurchased In Net Settlement Of Cashless Option Exercise Shares Repurchased In Net Settlement Of Cashless Option Exercise Number of treasury shares outstanding (in shares) Treasury Stock, Common, Shares Dilutive effect of employee stock options and unvested RSUs (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Research and development Research and Development Expense Accrued research and development expenses Accrued Clinical Expenses Current Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are associated with clinical research and related activities, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of clinical accrued liabilities (due within one year or within the normal operating cycle if longer). Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Level 2 Fair Value, Inputs, Level 2 [Member] Accrued research and development expenses Increase Decrease In Accrued Clinical Expenses Increase (decrease) in accrued clinical expenses. Grants in period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Current Fiscal Year End Date Current Fiscal Year End Date Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Short-term marketable securities Marketable Securities, Current Diluted net income per share (in dollars per share) Diluted (in dollars per share) Earnings Per Share, Diluted Net income attributable to common stockholders, diluted Net Income (Loss) Available to Common Stockholders, Diluted Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Subsequent Events [Abstract] Total current liabilities Liabilities, Current Total stock-based compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount Income Taxes Income Tax Disclosure [Text Block] Long-term accrued income taxes payable Accrued Income Taxes, Noncurrent Schedule of Available-for-sale Securities [Table] Schedule of Available-for-Sale Securities [Table] Basic net income per share (in dollars per share) Basic (in dollars per share) Earnings Per Share, Basic Share Repurchase Program Share Repurchase Program [Axis] Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Schedule of future minimum lease payments under non-cancelable operating leases Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Tender Offer Tender Offer [Member] Tender Offer Stock-based compensation capitalized in inventory Share-Based Payment Arrangement, Amount Capitalized Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Entity Interactive Data Current Entity Interactive Data Current Insurance recoveries Insurance Recoveries Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Strategic inventory Less strategic inventory classified as non-current Inventory, Noncurrent Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Schedule of other accrued liabilities Schedule of Accrued Liabilities [Table Text Block] Other comprehensive income (loss), net of tax Marketable Securities, Unrealized Gain (Loss) Money market funds Money Market Funds [Member] Equity [Abstract] Equity [Abstract] Portion at fair value measurement Portion at Fair Value Measurement [Member] Retained Earnings Retained Earnings [Member] Subsequent Event [Table] Subsequent Event [Table] Entity Tax Identification Number Entity Tax Identification Number Litigation Status [Domain] Litigation Status [Domain] Common Stock Common Stock [Member] ESPP maximum employee subscription rate Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Summary of stock-based compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Purchase price of stock repurchase Payments for Repurchase of Common Stock Schedule of information of leases asset and liabilities Lease, Cost [Table Text Block] Statement [Table] Statement [Table] Other losses for contingent liability Loss Contingency Accrual, Other Loss Contingency Accrual, Other Long-term marketable securities Marketable Securities, Noncurrent Document Quarterly Report Document Quarterly Report Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises (in shares) Shares withheld for tax withholding obligation (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Furniture and equipment Furniture and Fixtures [Member] Current assets: Assets, Current [Abstract] Litigation settlement, expense Litigation Settlement, Expense Statistical Measurement [Axis] Statistical Measurement [Axis] Treasury stock shares acquired (in shares) Treasury Stock, Shares, Acquired Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Insurance recovery receivable related to Melucci litigation (Note 4) Insurance recovery receivable Loss Contingency, Receivable, Current Leasehold improvements Leasehold Improvements [Member] Retained earnings Retained Earnings (Accumulated Deficit) Available-for-Sale Securities and Fair Value Measurements Available For Sale Securities And Fair Value Measurements Disclosure [Text Block] Available for sale securities and fair value measurements disclosure. Commercial paper Commercial Paper [Member] Trade receivables, net of allowances Accounts Receivable, after Allowance for Credit Loss, Current Purchases of marketable securities Payments to Acquire Marketable Securities Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Equity Components Equity Components [Axis] Scenario [Domain] Scenario [Domain] Other provisions for a loss contingency Loss Contingency Accrual, Provision, Other Loss Contingency Accrual, Provision, Other Litigation Case [Domain] Litigation Case [Domain] Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Other Other Accrued Liabilities, Current Number of shares repurchased (in shares) Stock Repurchase Program, Number of Shares Authorized to be Repurchased Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] City Area Code City Area Code Professional fees Accrued Professional Fees, Current Statement [Line Items] Statement [Line Items] ASSETS Assets [Abstract] Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Interest and other income Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Selling, general and administrative Selling, General and Administrative Expense Loss Contingencies [Table] Loss Contingencies [Table] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Restricted Stock Units and Stock Options Restricted Stock Units and Stock Options [Member] Restricted Stock Units and Stock Options Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Schedule of composition of inventory, noncurrent Schedule of Inventory, Noncurrent [Table Text Block] Operating lease expenses Rent expense Operating Lease, Expense Document Transition Report Document Transition Report Local Phone Number Local Phone Number Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Income from operations Operating Income (Loss) Research and development Research and Development Expense [Member] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset Inventory Increase (Decrease) in Inventories Litigation Status [Axis] Litigation Status [Axis] Schedule of computation of net income per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Maximum maturity period Marketable Securities Maximum Maturity Period Marketable securities maximum original maturity period. Right-of-use assets obtained in connection with new operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Cost of sales Cost of Sales [Member] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] EX-101.PRE 11 cort-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 capture.gif begin 644 capture.gif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htm IDEA: XBRL DOCUMENT v3.23.1
Cover Page - shares
3 Months Ended
Mar. 31, 2023
Apr. 26, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Document Transition Report false  
Entity File Number 000-50679  
Entity Registrant Name CORCEPT THERAPEUTICS INC  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 77-0487658  
Entity Address, Address Line One 149 Commonwealth Drive  
Entity Address, City or Town Menlo Park  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94025  
City Area Code 650  
Local Phone Number 327-3270  
Title of 12(b) Security Common Stock, $0.001 par value  
Trading Symbol CORT  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   101,577,897
Amendment Flag false  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0001088856  
Current Fiscal Year End Date --12-31  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 299,942 $ 66,329
Short-term marketable securities 165,115 365,343
Trade receivables, net of allowances 32,557 31,057
Insurance recovery receivable related to Melucci litigation (Note 4) 14,000 14,000
Inventory 6,409 6,100
Prepaid expenses and other current assets 15,870 16,424
Total current assets 533,893 499,253
Strategic inventory 10,156 10,931
Operating lease right-of-use asset 575 1,143
Property and equipment, net 461 633
Long-term marketable securities 0 4,947
Other assets 4,764 5,058
Deferred tax assets, net 67,999 61,465
Total assets 617,848 583,430
Current liabilities:    
Accounts payable 11,216 11,976
Accrued research and development expenses 13,981 14,573
Total accrued and other liabilities 39,093 30,799
Accrued settlement related to Melucci litigation (Note 4) 14,000 14,000
Short-term operating lease liability 575 1,143
Total current liabilities 78,865 72,491
Long-term accrued income taxes payable 9,399 9,097
Total liabilities 88,264 81,588
Commitments and contingencies (Note 4)
Stockholders’ equity:    
Preferred stock 0 0
Common stock 131 131
Treasury stock (462,507) (456,148)
Additional paid-in capital 679,848 662,342
Accumulated other comprehensive loss (153) (869)
Retained earnings 312,265 296,386
Total stockholders’ equity 529,584 501,842
Total liabilities and stockholders’ equity $ 617,848 $ 583,430
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Statement of Comprehensive Income [Abstract]    
Product revenue, net $ 105,654 $ 93,688
Operating expenses:    
Cost of sales 1,386 1,250
Research and development 40,851 28,120
Selling, general and administrative 48,564 37,549
Total operating expenses 90,801 66,919
Income from operations 14,853 26,769
Interest and other income 3,581 80
Income before income taxes 18,434 26,849
Income tax expense (2,555) (4,052)
Net income 15,879 22,797
Net income attributable to common stockholders, basic 15,807 22,797
Net income attributable to common stockholders, diluted $ 15,807 $ 22,797
Basic net income per share (in dollars per share) $ 0.15 $ 0.22
Diluted net income per share (in dollars per share) $ 0.14 $ 0.20
Weighted-average shares outstanding used in computing net income per common share    
Basic (in shares) 107,885 106,012
Diluted (in shares) 115,425 115,037
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Statement of Comprehensive Income [Abstract]    
Net income $ 15,879 $ 22,797
Other comprehensive income (loss):    
Unrealized gain (loss) on available-for-sale investments, net of tax effect of $(192) and $323, respectively 605 (1,019)
Foreign currency translation gain (loss), net of tax 111 (105)
Total comprehensive income $ 16,595 $ 21,673
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Statement of Comprehensive Income [Abstract]    
Unrealized gain (loss) on available-for-sale investments, tax expense (benefit) $ 192 $ (323)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:    
Net income $ 15,879 $ 22,797
Adjustments to reconcile net income to net cash provided by operations:    
Stock-based compensation 11,141 10,761
(Accretion) amortization of interest income (1,503) 1,106
Depreciation and amortization of property and equipment 172 288
Deferred income taxes (6,726) (9,935)
Non-cash amortization of right-of-use asset 568 514
Changes in operating assets and liabilities:    
Trade receivables (1,500) 447
Inventory 558 (163)
Prepaid expenses and other assets 848 (9)
Accounts payable (649) 2,256
Accrued research and development expenses (592) 609
Accrued and other liabilities 8,027 4,995
Long-term accrued income taxes 302 2,107
Operating lease liability (568) (526)
Net cash provided by operating activities 25,957 35,247
Cash flows from investing activities:    
Purchases of property and equipment 0 (12)
Proceeds from maturities of marketable securities 207,475 42,127
Purchases of marketable securities 0 (92,611)
Net cash provided by (used in) investing activities 207,475 (50,496)
Cash flows from financing activities:    
Proceeds from issuance of common stock under our incentive award plan, net of issuance costs 1,409 1,382
Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants (1,228) (1,888)
Net cash provided by (used in) financing activities 181 (506)
Net increase (decrease) in cash and cash equivalents 233,613 (15,755)
Cash and cash equivalents, at beginning of period 66,329 77,617
Cash and cash equivalents, at end of period 299,942 61,862
Supplemental disclosure:    
Exercise cost of shares repurchased for net settlement of cashless option exercises 5,246 5,149
Recognition of right-of-use asset and lease liability $ 0 $ 2,816
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Accumulated Other Comprehensive (Loss) Income
Retained Earnings
Beginning balance (in shares) at Dec. 31, 2021   105,940        
Beginning balance at Dec. 31, 2021 $ 375,806 $ 127 $ 591,349 $ (410,411) $ (227) $ 194,968
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of options (in shares)   586        
Issuance of common stock upon exercise of options 6,544 $ 1 6,543      
Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises (in shares)   (305)        
Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises (7,037)     (7,037)    
Stock-based compensation 10,825   10,825      
Other comprehensive income (loss), net of tax (1,124)       (1,124)  
Net income 22,797         22,797
Ending balance (in shares) at Mar. 31, 2022   106,221        
Ending balance at Mar. 31, 2022 407,811 $ 128 608,717 (417,448) (1,351) 217,765
Beginning balance (in shares) at Dec. 31, 2022   107,835        
Beginning balance at Dec. 31, 2022 501,842 $ 131 662,342 (456,148) (869) 296,386
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of options (in shares)   618        
Issuance of common stock upon exercise of options 6,540   6,540      
Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises (in shares)   (297)        
Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises (6,359)     (6,359)    
Stock-based compensation 10,966   10,966      
Other comprehensive income (loss), net of tax 716       716  
Net income 15,879         15,879
Ending balance (in shares) at Mar. 31, 2023   108,156        
Ending balance at Mar. 31, 2023 $ 529,584 $ 131 $ 679,848 $ (462,507) $ (153) $ 312,265
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation and Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Summary of Significant Accounting Policies
Description of Business and Basis of Presentation
Corcept Therapeutics Incorporated (collectively, “Corcept,” the “Company,” “we,” “us,” and “our”) is a commercial-stage pharmaceutical company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. In 2012, the United States Food and Drug Administration (“FDA”) approved Korlym (“mifepristone”) 300 mg tablets, as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. We have discovered and patented four structurally distinct series of selective cortisol modulators, consisting of more than 1,000 compounds. We are developing compounds from these series as potential treatments for a broad range of serious disorders.
We were incorporated in the State of Delaware in May 1998. Our headquarters are located in Menlo Park, California.
Basis of Presentation
We have prepared the following in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X: (i) condensed consolidated balance sheet as of March 31, 2023 and (ii) condensed consolidated statements of income, comprehensive income, cash flows and stockholders’ equity for the three-month periods ended March 31, 2023 and 2022. These do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation (which in the applicable periods consist only of normal, recurring adjustments) have been included. Operating results for the three-month period ended March 31, 2023 are not necessarily indicative of the results for the remainder of 2023 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2022 included in our Annual Report on Form 10-K. The December 31, 2022 balance sheet was derived from audited financial statements at that date.
There have been no material changes to the significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2022.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of Certain Balance Sheet Items
3 Months Ended
Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]  
Composition of Certain Balance Sheet Items Composition of Certain Balance Sheet Items
Inventory
March 31,
2023
December 31,
2022
 (in thousands)
Work in progress$8,514 $7,827 
Finished goods8,051 9,204 
Total inventory16,565 17,031 
Less strategic inventory classified as non-current(10,156)(10,931)
Total inventory classified as current$6,409 $6,100 
Because we rely on a single manufacturer to produce Korlym’s active pharmaceutical ingredient (“API”), we have purchased and hold significant quantities of API, included in work in progress inventory. We classify inventory we do not expect to sell within 12 months of the balance sheet date as “Strategic inventory,” a long-term asset.
Property and equipment, net
March 31,
2023
December 31,
2022
(in thousands)
Furniture and equipment$1,235 $1,235 
Software1,508 1,508 
Leasehold improvements1,597 1,597 
Total property and equipment4,340 4,340 
Less accumulated depreciation and amortization(3,879)(3,707)
Property and equipment, net$461 $633 
Accrued and other liabilities
March 31,
2023
December 31,
2022
 (in thousands)
Government rebates$15,478 $11,098 
Income taxes payable8,589 89 
Accrued compensation7,806 15,511 
Legal fees3,421 2,673 
Professional fees1,498 211 
Accrued selling and marketing costs1,081 434 
Other1,220 783 
Total accrued and other liabilities$39,093 $30,799 
Other assets
As of March 31, 2023 and December 31, 2022, other assets included $4.6 million and $4.9 million of deposits for clinical trials, respectively.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Available-for-Sale Securities and Fair Value Measurements
3 Months Ended
Mar. 31, 2023
Available For Sale Securities And Fair Value Measurements [Abstract]  
Available-for-Sale Securities and Fair Value Measurements Available-for-Sale Securities and Fair Value Measurements
The available-for-sale securities in our condensed consolidated balance sheets are as follows:
March 31,
2023
December 31,
2022
(in thousands)
Cash equivalents$259,936 $36,380 
Short-term marketable securities165,115 365,343 
Long-term marketable securities— 4,947 
Total marketable securities$425,051 $406,670 
The following table presents our available-for-sale securities grouped by asset type:
 Fair Value
Hierarchy
Level
March 31, 2023December 31, 2022
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueAmortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
  (in thousands)
Corporate bondsLevel 2$30,832 $— $(134)$30,698 $151,069 $— $(625)$150,444 
Commercial paperLevel 294,301 — — 94,301 136,132 — — 136,132 
U.S. government agency securitiesLevel 225,398 — (2)25,396 25,113 23 — 25,136 
Asset-backed securitiesLevel 2— — — — 185 — — 185 
U.S. Treasury securitiesLevel 114,723 — (3)14,720 58,536 — (142)58,394 
Money market fundsLevel 1259,936 — — 259,936 36,379 — — 36,379 
Total marketable securities$425,190 $— $(139)$425,051 $407,414 $23 $(767)$406,670 
We estimate the fair value of marketable securities classified as Level 1 using quoted market prices obtained from a commercial pricing service for these or identical investments. We estimate the fair value of marketable securities classified as Level 2 using inputs that may include benchmark yields, reported trades, broker/dealer quotes and issuer spreads.
We periodically review our debt securities to determine if any of our investments is impaired due to the issuer’s poor credit or other reasons. If the fair value of our investment is less than our amortized cost, we evaluate quantitative and subjective factors – including, but not limited to, the nature of security, changes in credit ratings and analyst reports concerning the security’s issuer and industry, and interest rate fluctuations and general market conditions to determine whether an allowance for credit losses is appropriate.
None of our investments, including those with unrealized losses, are impaired. Unrealized losses on our investments are due to interest rate fluctuations. We do not intend to sell investments that currently have unrealized losses and it is highly unlikely that we will sell any investment before recovery of its amortized cost basis, which may be at maturity. Accordingly, we have not recorded an allowance for credit losses for these investments.
We classified accrued interest on our marketable securities of $1.1 million and $1.8 million as of March 31, 2023 and December 31, 2022, respectively, as prepaid and other current assets on our condensed consolidated balance sheets.
As of March 31, 2023, all our marketable securities had original maturities of less than two years and all our marketable securities classified as short-term have maturities of less than one year. The weighted-average maturity of our holdings was one month. None of our marketable securities changed from one fair value hierarchy to another during the three months ended March 31, 2023
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
There have been no material changes in our obligations under contractual agreements described in our Annual Report on Form 10-K for the year ended December 31, 2022.
In the ordinary course of business, we may be subject to legal claims and regulatory actions that could have a material adverse effect on our business or financial position. We assess our potential liability in such situations by analyzing potential outcomes under various litigation, regulatory and settlement strategies. If we determine a loss is probable and its amount can be reasonably estimated, we accrue an amount equal to the estimated loss.
Melucci Litigation and Settlement
On March 14, 2019, a purported securities class action complaint was filed in the United States District Court for the Northern District of California by Nicholas Melucci (Melucci v. Corcept Therapeutics Incorporated, et al., Case No. 5:19-cv-01372-LHK) (the “Melucci litigation”). The complaint named us and certain of our executive officers as defendants asserting violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder and alleges that the defendants made false and materially misleading statements and failed to disclose adverse facts about our business, operations and prospects. The complaint asserts a putative class period extending from August 2, 2017 to February 5, 2019 and seeks unspecified monetary relief, interest and attorneys’ fees. On October 7, 2019, the Court appointed a lead plaintiff and lead counsel. The lead plaintiff’s consolidated complaint was filed on December 6, 2019. With respect to these allegations, we have stated, from the beginning, that we have done nothing wrong.
On February 8, 2023, we reached an agreement in principle (the “Proposed Settlement”) to resolve all claims in the Melucci litigation. Under the Proposed Settlement, we have agreed to make a one-time payment of $14.0 million, which will be covered in full by our insurers. In connection with the Proposed Settlement, we recorded a settlement expense of $14.0 million and corresponding insurance recovery of $14.0 million in operating expenses on our consolidated statement of income in the fourth quarter of 2022. Accordingly, we recorded an accrued liability of $14.0 million and a corresponding insurance recovery receivable of $14.0 million on our condensed consolidated balance sheet as of March 31, 2023. The Proposed Settlement is subject to the final approval of the Court.
No losses and no provision for a loss contingency have been recorded to date. For further information about our ongoing legal matters, see Part II. Item 1, Legal Proceedings.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Leases
3 Months Ended
Mar. 31, 2023
Leases [Abstract]  
Leases Leases
We lease our office facilities in Menlo Park, California. On April 1, 2023, we signed an amendment to extend our lease through June 30, 2024. Refer to Note 9 “Subsequent Events” for further details.
As the operating lease for our facilities does not expressly state an interest rate, we calculated the present value of remaining lease payments using a discount rate equal to the interest rate we would pay on a collateralized loan with monthly payments and a term equal to the monthly payments and remaining term of our lease. We recognize operating lease payments as expenses using the straight-line method over the term of the lease.
Operating lease expense for the three months ended March 31, 2023 and 2022 was $0.6 million and $0.5 million, respectively.
Our right-of-use assets and related lease liabilities were as follows (in thousands, except weighted average amounts):
Three Months Ended March 31,
20232022
Cash paid for operating lease liabilities$578 $530 
Right-of-use assets obtained in connection with new operating lease obligations$— $2,816 
Weighted-average remaining lease term3 months15 months
Weighted-average discount rate4.0 %4.0 %
As of March 31, 2023, future minimum lease payments under non-cancelable operating leases were as follows (in thousands):
2023 (remainder)578 
Total operating lease payments578 
Less imputed interest(3)
Present value of operating lease liabilities$575 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Stockholders’ Equity Stockholders’ Equity
Incentive Award Plan
We have one stock option plan – the Corcept Therapeutics Incorporated 2012 Incentive Award Plan (the “2012 Plan”).
Stock Options
During the three months ended March 31, 2023, we issued 0.5 million shares of our common stock upon the exercise of stock options. Some option holders exercised their options on a “net exercise” basis, pursuant to which they surrendered to us, and we purchased from them, at the current market price, shares equal in value to the associated exercise price and tax withholding obligations. During the three months ended March 31, 2023, we purchased 0.3 million shares in connection with option net exercises and paid $1.1 million to satisfy associated tax withholding obligations.
During the three months ended March 31, 2022, we issued 0.6 million shares of our common stock upon the exercise of stock options. We purchased 0.3 million shares in connection with option net exercises and paid $1.9 million to satisfy associated tax withholding obligations.
We recorded purchased shares as treasury stock on our condensed consolidated balance sheets at cost. As of March 31, 2023 and December 31, 2022, we had 23.4 million and 23.1 million treasury shares outstanding, respectively.
Restricted Stock Units (“RSUs”)
During the three months ended March 31, 2022, we granted employees 0.2 million RSUs with a weighted-average grant date fair value of $19.34 per share. No RSUs were granted during the three months ended March 31, 2023.
Restricted Stock Awards (“RSAs”)
During the three months ended March 31, 2023, we granted employees 0.3 million RSAs with a weighted-average grant date fair value of $22.39 per share. No RSAs were granted during the three months ended March 31, 2022. RSAs include voting and dividend rights and are therefore “participating” shares for the purpose of calculating basic and diluted net income per share. See “Note 7” below.
Employee Stock Purchase Plan (“ESPP”)
In February 2022 we adopted an ESPP that allows employees to set aside, by means of payroll deductions, up to ten percent of their annual compensation for the purchase of our common stock. Shares are issued to participating employees from the 2012 Plan on March 1st and September 1st of each year (or, if those dates fall on holidays or weekends, on the first business day thereafter) at the then-current fair market value of our stock, as determined at the close of trading on those days. Payroll deductions for participating employees began April 1, 2022, and the first purchase under the plan took place on September 1, 2022.
In January 2023, we increased the number of ESPP purchase dates to occur quarterly on March 1st, June 1st, September 1st and December 1st (or, if those dates fall on holidays or weekends, on the first business day thereafter).
For each purchased share, the participating employee will receive one matching share, also issued from the 2012 Plan if certain conditions are met. There is no vesting requirement for shares issued pursuant to the ESPP purchase. The matching share will be granted in the form of a RSA that will vest on the one-year anniversary of the respective ESPP purchase date, net of applicable tax withholding. The vesting condition on the RSA is that the participating employee hold the corresponding share purchased under the ESPP for one year from the purchase date. Shares purchased pursuant to the ESPP and any matching shares issued upon satisfaction of the one-year holding requirement may be held, sold or transferred at the employee’s sole discretion.
During the three months ended March 31, 2023 and 2022, we issued 0.1 million and no shares of our common stock in connection with our ESPP, respectively. As of March 31, 2023 and December 31, 2022, we had a liability of $0.5 million and $0.2 million, respectively, related to RSAs granted in connection with our ESPP in “Accrued and other liabilities” on our condensed consolidated balance sheets.
Stock-based Compensation
Stock-based compensation expense associated with stock options and awards of restricted stock is measured at the grant date based on the fair value of the award, and is recognized, net of forfeitures, as expense over the remaining requisite service period on a straight-line basis.
We value restricted stock at the closing market price of the our common stock on the date of grant.
The following table summarizes our stock-based compensation by account:
Three Months Ended March 31,
 20232022
 (in thousands)
Stock-based compensation capitalized in inventory$92 $64 
Cost of sales23 16 
Research and development3,484 3,371 
Selling, general and administrative7,634 7,374 
Total stock-based compensation$11,233 $10,825 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Net Income Per Share
3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Net Income Per Share Net Income Per Share
We compute our basic and diluted net income per share in conformity with the two-class method required for companies with participating shares. Under the two-class method, net income is determined by allocating net income between common stock and unvested RSAs. We compute basic net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. We compute diluted net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period, including potentially dilutive stock options and unvested RSUs, less unvested RSAs. We use the treasury stock method to determine the number of dilutive shares of common stock resulting from stock options and unvested RSUs.
The following table shows the computation of net income per share for each period:
Three Months Ended March 31,
 20232022
 (in thousands)
Numerator:  
Net income attributable to common stockholders$15,807 $22,797 
Denominator:
Weighted-average shares used to compute basic net income per common share107,885 106,012 
Dilutive effect of employee stock options and unvested RSUs7,540 9,025 
Weighted-average shares used to compute diluted net income per common share115,425 115,037 
Net income per share attributable to common stockholders
Basic$0.15 $0.22 
Diluted$0.14 $0.20 
As of March 31, 2023, we had 24.6 million stock options, 0.1 million RSUs and 0.6 million RSAs outstanding. As of March 31, 2022, we had 26.0 million stock options, 0.2 million RSUs and no RSAs outstanding.
We excluded from the computation of diluted net income per share, on a weighted-average basis, 10.4 million stock options and unvested RSUs outstanding during the three months ended March 31, 2023 and 6.9 million stock options outstanding and unvested RSUs during the three months ended March 31, 2022, because including them would have reduced dilution
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
We recorded income tax expense of $2.6 million for the three months ended March 31, 2023, compared to $4.1 million for the comparable period in 2022. The decrease during the three months ended March 31, 2023 was primarily due to decreased income before income taxes compared to the corresponding period in 2022.
Our effective tax rate differs from the federal statutory rate due to state income taxes and the non-deductible portion of our stock-based compensation, which increased our tax expense, offset by research and development credits and the excess tax deduction arising from the exercise of employee stock options, which reduced our taxable income.
During the three months ended March 31, 2023, unrecognized tax benefits increased by $0.4 million. As of March 31, 2023, the Company had unrecognized tax benefits of $9.3 million that, if recognized, would affect the Company’s effective tax rate and approximately $2.5 million of unrecognized tax benefits that would not impact the effective tax rate as they would be offset by a corresponding change in valuation allowance.
Each quarter, we assess the likelihood that we will generate sufficient taxable income to use our federal and state deferred tax assets. Except for the valuation allowances that offset the value of our California net deferred tax assets, we have determined that it is more likely than not we will realize the benefit related to all other deferred tax assets. To the extent we increase a valuation allowance, we will include an expense in the Condensed Consolidated Statement of Income in the period in which such determination is made.
Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the right to deduct research and development expenditures for tax purposes in the period the expenses were incurred and instead requires all U.S. and foreign research and development expenditures to be amortized over five and fifteen tax years, respectively. Congress has considered legislation that would defer the amortization requirement to later years, but as of March 31, 2023, the requirement has not been modified.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events
3 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
Lease Amendment
On April 1, 2023, we amended our office lease to extend its terms from July 1, 2023 through June 30, 2024 and we leased an additional space beginning April 1, 2023 through June 30, 2024. As a result of the amendment, we expect to record a right-of-use asset and corresponding lease liability of approximately $0.3 million related to the additional space. The remaining space has an extended lease term of 12 months, for which we do not expect to record an additional right of use asset. We will record $2.5 million of rent expense on a straight-line basis throughout the lease term in connection with this lease amendment.
Tender Offer
On March 6, 2023, we announced that our Board of Directors approved a tender offer to purchase up to 7.5 million shares of our common stock. The tender offer commenced on March 6, 2023 and expired on March 31, 2023. On April 5, 2023, we repurchased 6.6 million shares through the tender offer at a price of $22.00 per share for an aggregate purchase price of $145.4 million, excluding related fees and expenses. We recorded purchased shares as treasury stock on our condensed consolidated balance sheet at cost.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
We have prepared the following in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X: (i) condensed consolidated balance sheet as of March 31, 2023 and (ii) condensed consolidated statements of income, comprehensive income, cash flows and stockholders’ equity for the three-month periods ended March 31, 2023 and 2022. These do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation (which in the applicable periods consist only of normal, recurring adjustments) have been included. Operating results for the three-month period ended March 31, 2023 are not necessarily indicative of the results for the remainder of 2023 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2022 included in our Annual Report on Form 10-K. The December 31, 2022 balance sheet was derived from audited financial statements at that date.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of Certain Balance Sheet Items (Tables)
3 Months Ended
Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]  
Schedule of composition of inventory, current
Inventory
March 31,
2023
December 31,
2022
 (in thousands)
Work in progress$8,514 $7,827 
Finished goods8,051 9,204 
Total inventory16,565 17,031 
Less strategic inventory classified as non-current(10,156)(10,931)
Total inventory classified as current$6,409 $6,100 
Schedule of composition of inventory, noncurrent
Inventory
March 31,
2023
December 31,
2022
 (in thousands)
Work in progress$8,514 $7,827 
Finished goods8,051 9,204 
Total inventory16,565 17,031 
Less strategic inventory classified as non-current(10,156)(10,931)
Total inventory classified as current$6,409 $6,100 
Schedule of property and equipment
Property and equipment, net
March 31,
2023
December 31,
2022
(in thousands)
Furniture and equipment$1,235 $1,235 
Software1,508 1,508 
Leasehold improvements1,597 1,597 
Total property and equipment4,340 4,340 
Less accumulated depreciation and amortization(3,879)(3,707)
Property and equipment, net$461 $633 
Schedule of other accrued liabilities
Accrued and other liabilities
March 31,
2023
December 31,
2022
 (in thousands)
Government rebates$15,478 $11,098 
Income taxes payable8,589 89 
Accrued compensation7,806 15,511 
Legal fees3,421 2,673 
Professional fees1,498 211 
Accrued selling and marketing costs1,081 434 
Other1,220 783 
Total accrued and other liabilities$39,093 $30,799 
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Available-for-Sale Securities and Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2023
Available For Sale Securities And Fair Value Measurements [Abstract]  
Summary of the classification of available-for-sale securities in condensed consolidated balance sheets
The available-for-sale securities in our condensed consolidated balance sheets are as follows:
March 31,
2023
December 31,
2022
(in thousands)
Cash equivalents$259,936 $36,380 
Short-term marketable securities165,115 365,343 
Long-term marketable securities— 4,947 
Total marketable securities$425,051 $406,670 
Schedule of available-for-sale securities
The following table presents our available-for-sale securities grouped by asset type:
 Fair Value
Hierarchy
Level
March 31, 2023December 31, 2022
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueAmortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
  (in thousands)
Corporate bondsLevel 2$30,832 $— $(134)$30,698 $151,069 $— $(625)$150,444 
Commercial paperLevel 294,301 — — 94,301 136,132 — — 136,132 
U.S. government agency securitiesLevel 225,398 — (2)25,396 25,113 23 — 25,136 
Asset-backed securitiesLevel 2— — — — 185 — — 185 
U.S. Treasury securitiesLevel 114,723 — (3)14,720 58,536 — (142)58,394 
Money market fundsLevel 1259,936 — — 259,936 36,379 — — 36,379 
Total marketable securities$425,190 $— $(139)$425,051 $407,414 $23 $(767)$406,670 
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Tables)
3 Months Ended
Mar. 31, 2023
Leases [Abstract]  
Schedule of information of leases asset and liabilities
Our right-of-use assets and related lease liabilities were as follows (in thousands, except weighted average amounts):
Three Months Ended March 31,
20232022
Cash paid for operating lease liabilities$578 $530 
Right-of-use assets obtained in connection with new operating lease obligations$— $2,816 
Weighted-average remaining lease term3 months15 months
Weighted-average discount rate4.0 %4.0 %
Schedule of future minimum lease payments under non-cancelable operating leases
As of March 31, 2023, future minimum lease payments under non-cancelable operating leases were as follows (in thousands):
2023 (remainder)578 
Total operating lease payments578 
Less imputed interest(3)
Present value of operating lease liabilities$575 
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Summary of stock-based compensation
The following table summarizes our stock-based compensation by account:
Three Months Ended March 31,
 20232022
 (in thousands)
Stock-based compensation capitalized in inventory$92 $64 
Cost of sales23 16 
Research and development3,484 3,371 
Selling, general and administrative7,634 7,374 
Total stock-based compensation$11,233 $10,825 
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Net Income Per Share (Tables)
3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Schedule of computation of net income per share
The following table shows the computation of net income per share for each period:
Three Months Ended March 31,
 20232022
 (in thousands)
Numerator:  
Net income attributable to common stockholders$15,807 $22,797 
Denominator:
Weighted-average shares used to compute basic net income per common share107,885 106,012 
Dilutive effect of employee stock options and unvested RSUs7,540 9,025 
Weighted-average shares used to compute diluted net income per common share115,425 115,037 
Net income per share attributable to common stockholders
Basic$0.15 $0.22 
Diluted$0.14 $0.20 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation and Summary of Significant Accounting Policies (Details)
compound in Thousands
3 Months Ended
Mar. 31, 2023
compound
series
Accounting Policies [Line Items]  
Number of series of selective cortisol modulators | series 4
Minimum  
Accounting Policies [Line Items]  
Number of compounds (more than) | compound 1
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of Certain Balance Sheet Items - Schedule of Composition of Inventory (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]    
Work in progress $ 8,514 $ 7,827
Finished goods 8,051 9,204
Total inventory 16,565 17,031
Less strategic inventory classified as non-current (10,156) (10,931)
Total inventory classified as current $ 6,409 $ 6,100
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 4,340 $ 4,340
Less accumulated depreciation and amortization (3,879) (3,707)
Property and equipment, net 461 633
Furniture and equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 1,235 1,235
Software    
Property, Plant and Equipment [Line Items]    
Total property and equipment 1,508 1,508
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 1,597 $ 1,597
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of Certain Balance Sheet Items - Schedule of Other Accrued Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]    
Government rebates $ 15,478 $ 11,098
Income taxes payable 8,589 89
Accrued compensation 7,806 15,511
Legal fees 3,421 2,673
Professional fees 1,498 211
Accrued selling and marketing costs 1,081 434
Other 1,220 783
Total accrued and other liabilities $ 39,093 $ 30,799
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of Certain Balance Sheet Items - Narrative (Details) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]    
Deposits for clinical trials $ 4.6 $ 4.9
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Available-for-Sale Securities and Fair Value Measurements - Summary of the Classification of Available-for-Sale Securities in Condensed Consolidated Balance Sheets (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Total marketable securities $ 425,051 $ 406,670
Cash equivalents    
Debt Securities, Available-for-sale [Line Items]    
Total marketable securities 259,936 36,380
Short-term marketable securities    
Debt Securities, Available-for-sale [Line Items]    
Total marketable securities 165,115 365,343
Long-term marketable securities    
Debt Securities, Available-for-sale [Line Items]    
Total marketable securities $ 0 $ 4,947
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Available-for-Sale Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details) - Estimate of fair value measurement - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost $ 425,190 $ 407,414
Gross Unrealized Gains 0 23
Gross Unrealized Losses (139) (767)
Estimated Fair Value 425,051 406,670
Corporate bonds | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 30,832 151,069
Gross Unrealized Gains 0 0
Gross Unrealized Losses (134) (625)
Estimated Fair Value 30,698 150,444
Commercial paper | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 94,301 136,132
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Estimated Fair Value 94,301 136,132
U.S. government agency securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 25,398 25,113
Gross Unrealized Gains 0 23
Gross Unrealized Losses (2) 0
Estimated Fair Value 25,396 25,136
Asset-backed securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 0 185
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Estimated Fair Value 0 185
U.S. Treasury securities | Level 1    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 14,723 58,536
Gross Unrealized Gains 0 0
Gross Unrealized Losses (3) (142)
Estimated Fair Value 14,720 58,394
Money market funds | Level 1    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 259,936 36,379
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Estimated Fair Value $ 259,936 $ 36,379
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Available-for-Sale Securities and Fair Value Measurements - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Available For Sale Securities And Fair Value Measurements [Abstract]    
Interest receivable, current $ 1.1 $ 1.8
Maximum maturity period 2 years  
Maximum maturity period, short-term securities 1 year  
Weighted average maturity period 1 month  
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies (Details) - USD ($)
3 Months Ended
Feb. 08, 2023
Mar. 31, 2023
Dec. 31, 2022
Loss Contingencies [Line Items]      
Accrued liability, litigation   $ 14,000,000 $ 14,000,000
Insurance recovery receivable   14,000,000 14,000,000
Other losses for contingent liability   0  
Other provisions for a loss contingency   0  
Melucci | Settled Litigation      
Loss Contingencies [Line Items]      
Payment awarded to other party $ 14,000,000    
Litigation settlement, expense     14,000,000
Insurance recoveries     $ 14,000,000
Accrued liability, litigation   14,000,000  
Insurance recovery receivable   $ 14,000,000  
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Leases [Abstract]    
Operating lease expenses $ 0.6 $ 0.5
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Right-of-use Assets and Related Liabilities (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Leases [Abstract]    
Cash paid for operating lease liabilities $ 578 $ 530
Right-of-use assets obtained in connection with new operating lease obligations $ 0 $ 2,816
Weighted-average remaining lease term 3 months 15 months
Weighted-average discount rate 4.00% 4.00%
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Future Minimum Lease Payments (Details)
$ in Thousands
Mar. 31, 2023
USD ($)
Leases [Abstract]  
2023 (remainder) $ 578
Total operating lease payments 578
Less imputed interest (3)
Present value of operating lease liabilities $ 575
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' Equity - Narrative (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2023
USD ($)
plan
$ / shares
shares
Mar. 31, 2022
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
shares
Feb. 28, 2022
Shareholders Equity [Line Items]        
Number of stock option plans | plan 1      
Payment tax withholding share-based payment arrangement | $ $ 1,228 $ 1,888    
Stock Options        
Shareholders Equity [Line Items]        
Common shares issued upon exercise of options (in share) 500,000 600,000    
Shares withheld for tax withholding obligation (in shares) 300,000 300,000    
Payment tax withholding share-based payment arrangement | $ $ 1,100 $ 1,900    
Number of treasury shares outstanding (in shares) 23,400,000   23,100,000  
Restricted Stock Units (RSUs)        
Shareholders Equity [Line Items]        
Grants in period (in shares) 0 200,000    
Weighted average grant date fair value (in dollars per share) | $ / shares   $ 19.34    
Restricted Stock Awards (RSAs)        
Shareholders Equity [Line Items]        
Grants in period (in shares) 300,000      
Weighted average grant date fair value (in dollars per share) | $ / shares $ 22.39      
Employee Stock        
Shareholders Equity [Line Items]        
ESPP maximum employee subscription rate       10.00%
Award holding period 1 year      
Shares issued in period (in shares) 100,000 0    
Restricted Stock Awards (RSAs)        
Shareholders Equity [Line Items]        
Allocated share-based compensation expense | $ $ 500   $ 200  
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' Equity - Summary of Stock-Based Compensation (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Stock-based compensation capitalized in inventory $ 92 $ 64
Total stock-based compensation 11,233 10,825
Cost of sales    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Allocated share-based compensation expense 23 16
Research and development    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Allocated share-based compensation expense 3,484 3,371
Selling, general and administrative    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Allocated share-based compensation expense $ 7,634 $ 7,374
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Net Income Per Share - Schedule of Computation of Net Income Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Numerator:    
Net income attributable to common stockholders, basic $ 15,807 $ 22,797
Net income attributable to common stockholders, diluted $ 15,807 $ 22,797
Denominator:    
Weighted-average shares used to compute basic net income per share (in shares) 107,885 106,012
Dilutive effect of employee stock options and unvested RSUs (in shares) 7,540 9,025
Weighted-average shares used to compute diluted net income per share (in shares) 115,425 115,037
Net income per share attributable to common stockholders    
Basic (in dollars per share) $ 0.15 $ 0.22
Diluted (in dollars per share) $ 0.14 $ 0.20
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Net Income Per Share - Narrative (Details) - shares
shares in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Restricted Stock Units and Stock Options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Weighted average options excluded from the computation of diluted net income per share (in shares) 10.4 6.9
Stock Options to Purchase Common Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Stock options outstanding (in shares) 24.6 26.0
Restricted Stock Units (RSUs)    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number (in shares) 0.1 0.2
Restricted Stock Awards (RSAs)    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number (in shares) 0.6 0.0
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Income taxes (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Tax Disclosure [Abstract]    
Income tax expense $ 2,555 $ 4,052
Unrecognized tax benefits, period increase 400  
Unrecognized tax benefits that would impact effective tax rate 9,300  
Unrecognized tax benefits that would be offset by a change in valuation allowance $ 2,500  
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events - Lease Amendment (Details) - USD ($)
$ in Thousands
3 Months Ended
Apr. 01, 2023
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Subsequent Event [Line Items]        
Operating lease right-of-use asset   $ 575   $ 1,143
Short-term operating lease liability   575   $ 1,143
Rent expense   $ 600 $ 500  
Forecast        
Subsequent Event [Line Items]        
Operating lease right-of-use asset $ 300      
Short-term operating lease liability $ 300      
Subsequent event        
Subsequent Event [Line Items]        
Extended lease term 12 months      
Rent expense $ 2,500      
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events - Tender Offer (Details) - Tender Offer - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
Apr. 05, 2023
Mar. 06, 2023
Subsequent Event [Line Items]    
Number of shares repurchased (in shares)   7.5
Subsequent event    
Subsequent Event [Line Items]    
Treasury stock shares acquired (in shares) 6.6  
Common stock repurchased, average price (in dollars per share) $ 22.00  
Purchase price of stock repurchase $ 145.4  
XML 54 cort-20230331_htm.xml IDEA: XBRL DOCUMENT 0001088856 2023-01-01 2023-03-31 0001088856 2023-04-26 0001088856 2023-03-31 0001088856 2022-12-31 0001088856 2022-01-01 2022-03-31 0001088856 2021-12-31 0001088856 2022-03-31 0001088856 us-gaap:CommonStockMember 2022-12-31 0001088856 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001088856 us-gaap:TreasuryStockCommonMember 2022-12-31 0001088856 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001088856 us-gaap:RetainedEarningsMember 2022-12-31 0001088856 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001088856 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001088856 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001088856 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001088856 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001088856 us-gaap:CommonStockMember 2023-03-31 0001088856 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001088856 us-gaap:TreasuryStockCommonMember 2023-03-31 0001088856 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001088856 us-gaap:RetainedEarningsMember 2023-03-31 0001088856 us-gaap:CommonStockMember 2021-12-31 0001088856 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001088856 us-gaap:TreasuryStockCommonMember 2021-12-31 0001088856 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001088856 us-gaap:RetainedEarningsMember 2021-12-31 0001088856 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001088856 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001088856 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0001088856 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001088856 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001088856 us-gaap:CommonStockMember 2022-03-31 0001088856 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001088856 us-gaap:TreasuryStockCommonMember 2022-03-31 0001088856 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001088856 us-gaap:RetainedEarningsMember 2022-03-31 0001088856 srt:MinimumMember 2023-01-01 2023-03-31 0001088856 us-gaap:FurnitureAndFixturesMember 2023-03-31 0001088856 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001088856 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-03-31 0001088856 us-gaap:ComputerSoftwareIntangibleAssetMember 2022-12-31 0001088856 us-gaap:LeaseholdImprovementsMember 2023-03-31 0001088856 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001088856 us-gaap:CashEquivalentsMember 2023-03-31 0001088856 us-gaap:CashEquivalentsMember 2022-12-31 0001088856 cort:ShortTermMarketableSecuritiesMember 2023-03-31 0001088856 cort:ShortTermMarketableSecuritiesMember 2022-12-31 0001088856 cort:LongTermMarketableSecuritiesMember 2023-03-31 0001088856 cort:LongTermMarketableSecuritiesMember 2022-12-31 0001088856 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateBondSecuritiesMember 2023-03-31 0001088856 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001088856 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CommercialPaperMember 2023-03-31 0001088856 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CommercialPaperMember 2022-12-31 0001088856 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0001088856 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001088856 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2023-03-31 0001088856 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001088856 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USTreasurySecuritiesMember 2023-03-31 0001088856 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001088856 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MoneyMarketFundsMember 2023-03-31 0001088856 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001088856 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-03-31 0001088856 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001088856 cort:MelucciMember us-gaap:SettledLitigationMember 2023-02-08 2023-02-08 0001088856 cort:MelucciMember us-gaap:SettledLitigationMember 2022-10-01 2022-12-31 0001088856 cort:MelucciMember us-gaap:SettledLitigationMember 2023-03-31 0001088856 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001088856 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001088856 us-gaap:EmployeeStockOptionMember 2023-03-31 0001088856 us-gaap:EmployeeStockOptionMember 2022-12-31 0001088856 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001088856 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001088856 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0001088856 us-gaap:EmployeeStockMember 2022-02-28 0001088856 us-gaap:EmployeeStockMember 2023-01-01 2023-03-31 0001088856 us-gaap:EmployeeStockMember 2022-01-01 2022-03-31 0001088856 cort:RestrictedStockAwardsRSAsMember 2023-01-01 2023-03-31 0001088856 cort:RestrictedStockAwardsRSAsMember 2022-01-01 2022-12-31 0001088856 us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0001088856 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0001088856 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001088856 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001088856 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0001088856 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0001088856 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001088856 us-gaap:RestrictedStockMember 2023-03-31 0001088856 us-gaap:EmployeeStockOptionMember 2022-03-31 0001088856 us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0001088856 us-gaap:RestrictedStockMember 2022-03-31 0001088856 cort:RestrictedStockUnitsAndStockOptionsMember 2023-01-01 2023-03-31 0001088856 cort:RestrictedStockUnitsAndStockOptionsMember 2022-01-01 2022-03-31 0001088856 srt:ScenarioForecastMember 2023-04-01 0001088856 us-gaap:SubsequentEventMember 2023-04-01 0001088856 us-gaap:SubsequentEventMember 2023-04-01 2023-04-01 0001088856 cort:TenderOfferMember 2023-03-06 0001088856 cort:TenderOfferMember us-gaap:SubsequentEventMember 2023-04-05 2023-04-05 shares iso4217:USD iso4217:USD shares cort:series cort:compound pure cort:plan false 2023 Q1 0001088856 --12-31 10-Q true 2023-03-31 false 000-50679 CORCEPT THERAPEUTICS INC DE 77-0487658 149 Commonwealth Drive Menlo Park CA 94025 650 327-3270 Common Stock, $0.001 par value CORT NASDAQ Yes Yes Large Accelerated Filer false false false 101577897 299942000 66329000 165115000 365343000 32557000 31057000 14000000 14000000 6409000 6100000 15870000 16424000 533893000 499253000 10156000 10931000 575000 1143000 461000 633000 0 4947000 4764000 5058000 67999000 61465000 617848000 583430000 11216000 11976000 13981000 14573000 39093000 30799000 14000000 14000000 575000 1143000 78865000 72491000 9399000 9097000 88264000 81588000 0 0 131000 131000 462507000 456148000 679848000 662342000 -153000 -869000 312265000 296386000 529584000 501842000 617848000 583430000 105654000 93688000 1386000 1250000 40851000 28120000 48564000 37549000 90801000 66919000 14853000 26769000 3581000 80000 18434000 26849000 2555000 4052000 15879000 22797000 15807000 15807000 22797000 22797000 0.15 0.22 0.14 0.20 107885000 106012000 115425000 115037000 15879000 22797000 192000 -323000 605000 -1019000 111000 -105000 16595000 21673000 15879000 22797000 11141000 10761000 -1503000 1106000 172000 288000 -6726000 -9935000 568000 514000 1500000 -447000 -558000 163000 -848000 9000 -649000 2256000 -592000 609000 8027000 4995000 302000 2107000 -568000 -526000 25957000 35247000 0 12000 207475000 42127000 0 92611000 207475000 -50496000 1409000 1382000 1228000 1888000 181000 -506000 233613000 -15755000 66329000 77617000 299942000 61862000 5246000 5149000 0 2816000 107835000 131000 662342000 -456148000 -869000 296386000 501842000 618000 6540000 6540000 297000 6359000 6359000 10966000 10966000 716000 716000 15879000 15879000 108156000 131000 679848000 -462507000 -153000 312265000 529584000 105940000 127000 591349000 -410411000 -227000 194968000 375806000 586000 1000 6543000 6544000 305000 7037000 7037000 10825000 10825000 -1124000 -1124000 22797000 22797000 106221000 128000 608717000 -417448000 -1351000 217765000 407811000 Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Business and Basis of Presentation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corcept Therapeutics Incorporated (collectively, “Corcept,” the “Company,” “we,” “us,” and “our”) is a commercial-stage pharmaceutical company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. In 2012, the United States Food and Drug Administration (“FDA”) approved Korlym (“mifepristone”) 300 mg tablets, as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. We have discovered and patented four structurally distinct series of selective cortisol modulators, consisting of more than 1,000 compounds. We are developing compounds from these series as potential treatments for a broad range of serious disorders.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in the State of Delaware in May 1998. Our headquarters are located in Menlo Park, California.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the following in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X: (i) condensed consolidated balance sheet as of March 31, 2023 and (ii) condensed consolidated statements of income, comprehensive income, cash flows and stockholders’ equity for the three-month periods ended March 31, 2023 and 2022. These do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation (which in the applicable periods consist only of normal, recurring adjustments) have been included. Operating results for the three-month period ended March 31, 2023 are not necessarily indicative of the results for the remainder of 2023 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2022 included in our Annual Report on Form 10-K. The December 31, 2022 balance sheet was derived from audited financial statements at that date.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div> 4 1000 <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the following in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X: (i) condensed consolidated balance sheet as of March 31, 2023 and (ii) condensed consolidated statements of income, comprehensive income, cash flows and stockholders’ equity for the three-month periods ended March 31, 2023 and 2022. These do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation (which in the applicable periods consist only of normal, recurring adjustments) have been included. Operating results for the three-month period ended March 31, 2023 are not necessarily indicative of the results for the remainder of 2023 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2022 included in our Annual Report on Form 10-K. The December 31, 2022 balance sheet was derived from audited financial statements at that date.</span></div> Composition of Certain Balance Sheet Items<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,514 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,565 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less strategic inventory classified as non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,931)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory classified as current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,409 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on a single manufacturer to produce Korlym’s active pharmaceutical ingredient (“API”), we have purchased and hold significant quantities of API, included in work in progress inventory. We classify inventory we do not expect to sell within 12 months of the balance sheet date as “Strategic inventory,” a long-term asset.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment, net</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,340 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,340 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,879)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other liabilities</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government rebates</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,098 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,511 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued selling and marketing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued and other liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,093 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,799 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, other assets included $4.6 million and $4.9 million of deposits for clinical trials, respectively.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,514 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,565 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less strategic inventory classified as non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,931)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory classified as current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,409 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,514 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,565 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less strategic inventory classified as non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,931)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory classified as current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,409 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 8514000 7827000 8051000 9204000 16565000 17031000 10156000 10931000 6409000 6100000 <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment, net</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,340 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,340 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,879)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1235000 1235000 1508000 1508000 1597000 1597000 4340000 4340000 3879000 3707000 461000 633000 <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other liabilities</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government rebates</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,098 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,511 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued selling and marketing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued and other liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,093 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,799 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 15478000 11098000 8589000 89000 7806000 15511000 3421000 2673000 1498000 211000 1081000 434000 1220000 783000 39093000 30799000 4600000 4900000 Available-for-Sale Securities and Fair Value Measurements<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The available-for-sale securities in our condensed consolidated balance sheets are as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,051 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,670 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our available-for-sale securities grouped by asset type:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,832 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,720 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,536 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259,936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259,936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425,190 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425,051 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407,414 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(767)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406,670 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of marketable securities classified as Level 1 using quoted market prices obtained from a commercial pricing service for these or identical investments. We estimate the fair value of marketable securities classified as Level 2 using inputs that may include benchmark yields, reported trades, broker/dealer quotes and issuer spreads.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review our debt securities to determine if any of our investments is impaired due to the issuer’s poor credit or other reasons. If the fair value of our investment is less than our amortized cost, we evaluate quantitative and subjective factors – including, but not limited to, the nature of security, changes in credit ratings and analyst reports concerning the security’s issuer and industry, and interest rate fluctuations and general market conditions to determine whether an allowance for credit losses is appropriate.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our investments, including those with unrealized losses, are impaired. Unrealized losses on our investments are due to interest rate fluctuations. We do not intend to sell investments that currently have unrealized losses and it is highly unlikely that we will sell any investment before recovery of its amortized cost basis, which may be at maturity. Accordingly, we have not recorded an allowance for credit losses for these investments.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classified accrued interest on our marketable securities of $1.1 million and $1.8 million as of March 31, 2023 and December 31, 2022, respectively, as prepaid and other current assets on our condensed consolidated balance sheets.</span></div>As of March 31, 2023, all our marketable securities had original maturities of less than two years and all our marketable securities classified as short-term have maturities of less than one year. The weighted-average maturity of our holdings was one month. None of our marketable securities changed from one fair value hierarchy to another during the three months ended March 31, 2023 <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The available-for-sale securities in our condensed consolidated balance sheets are as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,051 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,670 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 259936000 36380000 165115000 365343000 0 4947000 425051000 406670000 <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our available-for-sale securities grouped by asset type:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,832 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,720 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,536 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259,936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259,936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425,190 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425,051 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407,414 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(767)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406,670 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 30832000 0 134000 30698000 151069000 0 625000 150444000 94301000 0 0 94301000 136132000 0 0 136132000 25398000 0 2000 25396000 25113000 23000 0 25136000 0 0 0 0 185000 0 0 185000 14723000 0 3000 14720000 58536000 0 142000 58394000 259936000 0 0 259936000 36379000 0 0 36379000 425190000 0 139000 425051000 407414000 23000 767000 406670000 1100000 1800000 P2Y P1Y P1M Commitments and Contingencies<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There have been no material changes in our obligations under contractual agreements described in our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we may be subject to legal claims and regulatory actions that could have a material adverse effect on our business or financial position. We assess our potential liability in such situations by analyzing potential outcomes under various litigation, regulatory and settlement strategies. If we determine a loss is probable and its amount can be reasonably estimated, we accrue an amount equal to the estimated loss.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Melucci Litigation and Settlement</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2019, a purported securities class action complaint was filed in the United States District Court for the Northern District of California by Nicholas Melucci (Melucci v. Corcept Therapeutics Incorporated, et al., Case No. 5:19-cv-01372-LHK) (the “Melucci litigation”). The complaint named us and certain of our executive officers as defendants asserting violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder and alleges that the defendants made false and materially misleading statements and failed to disclose adverse facts about our business, operations and prospects. The complaint asserts a putative class period extending from August 2, 2017 to February 5, 2019 and seeks unspecified monetary relief, interest and attorneys’ fees. On October 7, 2019, the Court appointed a lead plaintiff and lead counsel. The lead plaintiff’s consolidated complaint was filed on December 6, 2019. With respect to these allegations, we have stated, from the beginning, that we have done nothing wrong.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2023, we reached an agreement in principle (the “Proposed Settlement”) to resolve all claims in the Melucci litigation. Under the Proposed Settlement, we have agreed to make a one-time payment of $14.0 million, which will be covered in full by our insurers. In connection with the Proposed Settlement, we recorded a settlement expense of $14.0 million and corresponding insurance recovery of $14.0 million in operating expenses on our consolidated statement of income in the fourth quarter of 2022. Accordingly, we recorded an accrued liability of $14.0 million and a corresponding insurance recovery receivable of $14.0 million on our condensed consolidated balance sheet as of March 31, 2023. The Proposed Settlement is subject to the final approval of the Court.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No losses and no provision for a loss contingency have been recorded to date. For further information about our ongoing legal matters, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part II. Item 1, Legal Proceedings.</span></div> 14000000 14000000 14000000 14000000 14000000 0 0 Leases<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease our office facilities in Menlo Park, California. On April 1, 2023, we signed an amendment to extend our lease through June 30, 2024. Refer to Note 9 “Subsequent Events” for further details.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the operating lease for our facilities does not expressly state an interest rate, we calculated the present value of remaining lease payments using a discount rate equal to the interest rate we would pay on a collateralized loan with monthly payments and a term equal to the monthly payments and remaining term of our lease. We recognize operating lease payments as expenses using the straight-line method over the term of the lease.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense for the three months ended March 31, 2023 and 2022 was $0.6 million and $0.5 million, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our right-of-use assets and related lease liabilities were as follows (in thousands, except weighted average amounts):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in connection with new operating lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, future minimum lease payments under non-cancelable operating leases were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 600000 500000 <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our right-of-use assets and related lease liabilities were as follows (in thousands, except weighted average amounts):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in connection with new operating lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 578000 530000 0 2816000 P3M P15M 0.040 0.040 <div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, future minimum lease payments under non-cancelable operating leases were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 578000 578000 3000 575000 Stockholders’ Equity<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incentive Award Plan</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one stock option plan – the Corcept Therapeutics Incorporated 2012 Incentive Award Plan (the “2012 Plan”).</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, we issued 0.5 million shares of our common stock upon the exercise of stock options. Some option holders exercised their options on a “net exercise” basis, pursuant to which they surrendered to us, and we purchased from them, at the current market price, shares equal in value to the associated exercise price and tax withholding obligations. During the three months ended March 31, 2023, we purchased 0.3 million shares in connection with option net exercises and paid $1.1 million to satisfy associated tax withholding obligations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we issued 0.6 million shares of our common stock upon the exercise of stock options. We purchased 0.3 million shares in connection with option net exercises and paid $1.9 million to satisfy associated tax withholding obligations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded purchased shares as treasury stock on our condensed consolidated balance sheets at cost. As of March 31, 2023 and December 31, 2022, we had 23.4 million and 23.1 million treasury shares outstanding, respectively.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units (“RSUs”)</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we granted employees 0.2 million RSUs with a weighted-average grant date fair value of $19.34 per share. No RSUs were granted during the three months ended March 31, 2023.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards (“RSAs”)</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, we granted employees 0.3 million RSAs with a weighted-average grant date fair value of $22.39 per share. No RSAs were granted during the three months ended March 31, 2022. RSAs include voting and dividend rights and are therefore “participating” shares for the purpose of calculating basic and diluted net income per share. See “Note 7” below.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan (“ESPP”)</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022 we adopted an ESPP that allows employees to set aside, by means of payroll deductions, up to ten percent of their annual compensation for the purchase of our common stock. Shares are issued to participating employees from the 2012 Plan on March 1st and September 1st of each year (or, if those dates fall on holidays or weekends, on the first business day thereafter) at the then-current fair market value of our stock, as determined at the close of trading on those days. Payroll deductions for participating employees began April 1, 2022, and the first purchase under the plan took place on September 1, 2022.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we increased the number of ESPP purchase dates to occur quarterly on March 1st, June 1st, September 1st and December 1st (or, if those dates fall on holidays or weekends, on the first business day thereafter).</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each purchased share, the participating employee will receive one matching share, also issued from the 2012 Plan if certain conditions are met. There is no vesting requirement for shares issued pursuant to the ESPP purchase. The matching share will be granted in the form of a RSA that will vest on the one-year anniversary of the respective ESPP purchase date, net of applicable tax withholding. The vesting condition on the RSA is that the participating employee hold the corresponding share purchased under the ESPP for one year from the purchase date. Shares purchased pursuant to the ESPP and any matching shares issued upon satisfaction of the one-year holding requirement may be held, sold or transferred at the employee’s sole discretion.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023 and 2022, we issued 0.1 million and no shares of our common stock in connection with our ESPP, respectively. As of March 31, 2023 and December 31, 2022, we had a liability of $0.5 million and $0.2 million, respectively, related to RSAs granted in connection with our ESPP in “Accrued and other liabilities” on our condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense associated with stock options and awards of restricted stock is measured at the grant date based on the fair value of the award, and is recognized, net of forfeitures, as expense over the remaining requisite service period on a straight-line basis.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value restricted stock at the closing market price of the our common stock on the date of grant.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock-based compensation by account:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation capitalized in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,233 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,825 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1 500000 300000 1100000 600000 300000 1900000 23400000 23100000 200000 19.34 0 300000 22.39 0 0.10 P1Y P1Y 100000 0 500000 200000 <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock-based compensation by account:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation capitalized in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,233 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,825 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 92000 64000 23000 16000 3484000 3371000 7634000 7374000 11233000 10825000 Net Income Per Share<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compute our basic and diluted net income per share in conformity with the two-class method required for companies with participating shares. Under the two-class method, net income is determined by allocating net income between common stock and unvested RSAs. We compute basic net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. We compute diluted net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period, including potentially dilutive stock options and unvested RSUs, less unvested RSAs. We use the treasury stock method to determine the number of dilutive shares of common stock resulting from stock options and unvested RSUs.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of net income per share for each period:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic net income per common share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,885 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of employee stock options and unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,025 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute diluted net income per common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,425 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,037 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, we had 24.6 million stock options, 0.1 million RSUs and 0.6 million RSAs outstanding. As of March 31, 2022, we had 26.0 million stock options, 0.2 million RSUs and no RSAs outstanding.</span></div>We excluded from the computation of diluted net income per share, on a weighted-average basis, 10.4 million stock options and unvested RSUs outstanding during the three months ended March 31, 2023 and 6.9 million stock options outstanding and unvested RSUs during the three months ended March 31, 2022, because including them would have reduced dilution <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of net income per share for each period:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic net income per common share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,885 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of employee stock options and unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,025 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute diluted net income per common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,425 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,037 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 15807000 15807000 22797000 22797000 107885000 106012000 7540000 9025000 115425000 115037000 0.15 0.22 0.14 0.20 24600000 100000 600000 26000000 200000 0 10400000 6900000 Income Taxes<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded income tax expense of $2.6 million for the three months ended March 31, 2023, compared to $4.1 million for the comparable period in 2022. The decrease during the three months ended March 31, 2023 was primarily due to decreased income before income taxes compared to the corresponding period in 2022.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate differs from the federal statutory rate due to state income taxes and the non-deductible portion of our stock-based compensation, which increased our tax expense, offset by research and development credits and the excess tax deduction arising from the exercise of employee stock options, which reduced our taxable income.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, unrecognized tax benefits increased by $0.4 million. As of March 31, 2023, the Company had unrecognized tax benefits of $9.3 million that, if recognized, would affect the Company’s effective tax rate and approximately $2.5 million of unrecognized tax benefits that would not impact the effective tax rate as they would be offset by a corresponding change in valuation allowance.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each quarter, we assess the likelihood that we will generate sufficient taxable income to use our federal and state deferred tax assets. Except for the valuation allowances that offset the value of our California net deferred tax assets, we have determined that it is more likely than not we will realize the benefit related to all other deferred tax assets. To the extent we increase a valuation allowance, we will include an expense in the Condensed Consolidated Statement of Income in the period in which such determination is made.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the right to deduct research and development expenditures for tax purposes in the period the expenses were incurred and instead requires all U.S. and foreign research and development expenditures to be amortized over five and fifteen tax years, respectively. Congress has considered legislation that would defer the amortization requirement to later years, but as of March 31, 2023, the requirement has not been modified.</span></div> 2600000 4100000 400000 9300000 2500000 Subsequent Events<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Amendment</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2023, we amended our office lease to extend its terms from July 1, 2023 through June 30, 2024 and we leased an additional space beginning April 1, 2023 through June 30, 2024. As a result of the amendment, we expect to record a right-of-use asset and corresponding lease liability of approximately $0.3 million related to the additional space. The remaining space has an extended lease term of 12 months, for which we do not expect to record an additional right of use asset. We will record $2.5 million of rent expense on a straight-line basis throughout the lease term in connection with this lease amendment.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tender Offer</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 6, 2023, we announced that our Board of Directors approved a tender offer to purchase up to 7.5 million shares of our common stock. The tender offer commenced on March 6, 2023 and expired on March 31, 2023. On April 5, 2023, we repurchased 6.6 million shares through the tender offer at a price of $22.00 per share for an aggregate purchase price of $145.4 million, excluding related fees and expenses. We recorded purchased shares as treasury stock on our condensed consolidated balance sheet at cost.</span></div> 300000 300000 P12M 2500000 7500000 6600000 22.00 145400000 EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 56 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 97 193 1 false 35 0 false 7 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.corcept.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) Sheet http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Sheet http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (Parenthetical) Sheet http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnauditedParenthetical CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Statements 7 false false R8.htm 0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 8 false false R9.htm 0000009 - Disclosure - Composition of Certain Balance Sheet Items Sheet http://www.corcept.com/role/CompositionofCertainBalanceSheetItems Composition of Certain Balance Sheet Items Notes 9 false false R10.htm 0000010 - Disclosure - Available-for-Sale Securities and Fair Value Measurements Sheet http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurements Available-for-Sale Securities and Fair Value Measurements Notes 10 false false R11.htm 0000011 - Disclosure - Commitments and Contingencies Sheet http://www.corcept.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 11 false false R12.htm 0000012 - Disclosure - Leases Sheet http://www.corcept.com/role/Leases Leases Notes 12 false false R13.htm 0000013 - Disclosure - Stockholders' Equity Sheet http://www.corcept.com/role/StockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 0000014 - Disclosure - Net Income Per Share Sheet http://www.corcept.com/role/NetIncomePerShare Net Income Per Share Notes 14 false false R15.htm 0000015 - Disclosure - Income Taxes Sheet http://www.corcept.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 0000016 - Disclosure - Subsequent Events Sheet http://www.corcept.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 0000017 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 17 false false R18.htm 0000018 - Disclosure - Composition of Certain Balance Sheet Items (Tables) Sheet http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables Composition of Certain Balance Sheet Items (Tables) Tables http://www.corcept.com/role/CompositionofCertainBalanceSheetItems 18 false false R19.htm 0000019 - Disclosure - Available-for-Sale Securities and Fair Value Measurements (Tables) Sheet http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsTables Available-for-Sale Securities and Fair Value Measurements (Tables) Tables http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurements 19 false false R20.htm 0000020 - Disclosure - Leases (Tables) Sheet http://www.corcept.com/role/LeasesTables Leases (Tables) Tables http://www.corcept.com/role/Leases 20 false false R21.htm 0000021 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.corcept.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.corcept.com/role/StockholdersEquity 21 false false R22.htm 0000022 - Disclosure - Net Income Per Share (Tables) Sheet http://www.corcept.com/role/NetIncomePerShareTables Net Income Per Share (Tables) Tables http://www.corcept.com/role/NetIncomePerShare 22 false false R23.htm 0000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) Sheet http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails Basis of Presentation and Summary of Significant Accounting Policies (Details) Details http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies 23 false false R24.htm 0000024 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Composition of Inventory (Details) Sheet http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails Composition of Certain Balance Sheet Items - Schedule of Composition of Inventory (Details) Details 24 false false R25.htm 0000025 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Details) Sheet http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Details) Details 25 false false R26.htm 0000026 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Other Accrued Liabilities (Details) Sheet http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails Composition of Certain Balance Sheet Items - Schedule of Other Accrued Liabilities (Details) Details 26 false false R27.htm 0000027 - Disclosure - Composition of Certain Balance Sheet Items - Narrative (Details) Sheet http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsNarrativeDetails Composition of Certain Balance Sheet Items - Narrative (Details) Details 27 false false R28.htm 0000028 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Summary of the Classification of Available-for-Sale Securities in Condensed Consolidated Balance Sheets (Details) Sheet http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails Available-for-Sale Securities and Fair Value Measurements - Summary of the Classification of Available-for-Sale Securities in Condensed Consolidated Balance Sheets (Details) Details 28 false false R29.htm 0000029 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details) Sheet http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails Available-for-Sale Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details) Details 29 false false R30.htm 0000030 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Narrative (Details) Sheet http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails Available-for-Sale Securities and Fair Value Measurements - Narrative (Details) Details http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsTables 30 false false R31.htm 0000031 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.corcept.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.corcept.com/role/CommitmentsandContingencies 31 false false R32.htm 0000032 - Disclosure - Leases - Narrative (Details) Sheet http://www.corcept.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 32 false false R33.htm 0000033 - Disclosure - Leases - Right-of-use Assets and Related Liabilities (Details) Sheet http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails Leases - Right-of-use Assets and Related Liabilities (Details) Details 33 false false R34.htm 0000034 - Disclosure - Leases - Future Minimum Lease Payments (Details) Sheet http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails Leases - Future Minimum Lease Payments (Details) Details 34 false false R35.htm 0000035 - Disclosure - Stockholders' Equity - Narrative (Details) Sheet http://www.corcept.com/role/StockholdersEquityNarrativeDetails Stockholders' Equity - Narrative (Details) Details 35 false false R36.htm 0000036 - Disclosure - Stockholders' Equity - Summary of Stock-Based Compensation (Details) Sheet http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails Stockholders' Equity - Summary of Stock-Based Compensation (Details) Details 36 false false R37.htm 0000037 - Disclosure - Net Income Per Share - Schedule of Computation of Net Income Per Share (Details) Sheet http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails Net Income Per Share - Schedule of Computation of Net Income Per Share (Details) Details 37 false false R38.htm 0000038 - Disclosure - Net Income Per Share - Narrative (Details) Sheet http://www.corcept.com/role/NetIncomePerShareNarrativeDetails Net Income Per Share - Narrative (Details) Details 38 false false R39.htm 0000039 - Disclosure - Income taxes (Details) Sheet http://www.corcept.com/role/IncometaxesDetails Income taxes (Details) Details 39 false false R40.htm 0000040 - Disclosure - Subsequent Events - Lease Amendment (Details) Sheet http://www.corcept.com/role/SubsequentEventsLeaseAmendmentDetails Subsequent Events - Lease Amendment (Details) Details 40 false false R41.htm 0000041 - Disclosure - Subsequent Events - Tender Offer (Details) Sheet http://www.corcept.com/role/SubsequentEventsTenderOfferDetails Subsequent Events - Tender Offer (Details) Details 41 false false All Reports Book All Reports cort-20230331.htm cort-20230331.xsd cort-20230331_cal.xml cort-20230331_def.xml cort-20230331_lab.xml cort-20230331_pre.xml cort33123ex101eighthamendm.htm cort33123ex311.htm cort33123ex312.htm cort33123ex321.htm cort33123ex322.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 60 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cort-20230331.htm": { "axisCustom": 1, "axisStandard": 14, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 380, "http://xbrl.sec.gov/dei/2022": 29 }, "contextCount": 97, "dts": { "calculationLink": { "local": [ "cort-20230331_cal.xml" ] }, "definitionLink": { "local": [ "cort-20230331_def.xml" ] }, "inline": { "local": [ "cort-20230331.htm" ] }, "labelLink": { "local": [ "cort-20230331_lab.xml" ] }, "presentationLink": { "local": [ "cort-20230331_pre.xml" ] }, "schema": { "local": [ "cort-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 309, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 5, "total": 5 }, "keyCustom": 24, "keyStandard": 169, "memberCustom": 6, "memberStandard": 29, "nsprefix": "cort", "nsuri": "http://www.corcept.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.corcept.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "cort:AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Available-for-Sale Securities and Fair Value Measurements", "menuCat": "Notes", "order": "10", "role": "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurements", "shortName": "Available-for-Sale Securities and Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "cort:AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "11", "role": "http://www.corcept.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Leases", "menuCat": "Notes", "order": "12", "role": "http://www.corcept.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "13", "role": "http://www.corcept.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Net Income Per Share", "menuCat": "Notes", "order": "14", "role": "http://www.corcept.com/role/NetIncomePerShare", "shortName": "Net Income Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "15", "role": "http://www.corcept.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "16", "role": "http://www.corcept.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "17", "role": "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Composition of Certain Balance Sheet Items (Tables)", "menuCat": "Tables", "order": "18", "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables", "shortName": "Composition of Certain Balance Sheet Items (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Available-for-Sale Securities and Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "19", "role": "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsTables", "shortName": "Available-for-Sale Securities and Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "20", "role": "http://www.corcept.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Stockholders' Equity (Tables)", "menuCat": "Tables", "order": "21", "role": "http://www.corcept.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Net Income Per Share (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.corcept.com/role/NetIncomePerShareTables", "shortName": "Net Income Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "cort:NumberOfSeriesOfSelectiveCortisolModulators", "reportCount": 1, "unique": true, "unitRef": "series", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "23", "role": "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "cort:NumberOfSeriesOfSelectiveCortisolModulators", "reportCount": 1, "unique": true, "unitRef": "series", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "cort:InventoryWorkInProcessCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Composition of Inventory (Details)", "menuCat": "Details", "order": "24", "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails", "shortName": "Composition of Certain Balance Sheet Items - Schedule of Composition of Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "cort:InventoryWorkInProcessCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Details)", "menuCat": "Details", "order": "25", "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails", "shortName": "Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "cort:AccruedGovernmentRebateCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Other Accrued Liabilities (Details)", "menuCat": "Details", "order": "26", "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails", "shortName": "Composition of Certain Balance Sheet Items - Schedule of Other Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "cort:AccruedGovernmentRebateCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "cort:DepositsForClinicalTrials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Composition of Certain Balance Sheet Items - Narrative (Details)", "menuCat": "Details", "order": "27", "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsNarrativeDetails", "shortName": "Composition of Certain Balance Sheet Items - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "cort:DepositsForClinicalTrials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Summary of the Classification of Available-for-Sale Securities in Condensed Consolidated Balance Sheets (Details)", "menuCat": "Details", "order": "28", "role": "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails", "shortName": "Available-for-Sale Securities and Fair Value Measurements - Summary of the Classification of Available-for-Sale Securities in Condensed Consolidated Balance Sheets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i1255cd421e7d462e8c66fdf4e30a2a31_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details)", "menuCat": "Details", "order": "29", "role": "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails", "shortName": "Available-for-Sale Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i1255cd421e7d462e8c66fdf4e30a2a31_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)", "menuCat": "Statements", "order": "3", "role": "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InterestReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Narrative (Details)", "menuCat": "Details", "order": "30", "role": "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails", "shortName": "Available-for-Sale Securities and Fair Value Measurements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InterestReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyAccrualCarryingValueCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "31", "role": "http://www.corcept.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "INF", "lang": "en-US", "name": "cort:LossContingencyAccrualOther", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Leases - Narrative (Details)", "menuCat": "Details", "order": "32", "role": "http://www.corcept.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Leases - Right-of-use Assets and Related Liabilities (Details)", "menuCat": "Details", "order": "33", "role": "http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails", "shortName": "Leases - Right-of-use Assets and Related Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Leases - Future Minimum Lease Payments (Details)", "menuCat": "Details", "order": "34", "role": "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails", "shortName": "Leases - Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "cort:NumberOfStockOptionPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Stockholders' Equity - Narrative (Details)", "menuCat": "Details", "order": "35", "role": "http://www.corcept.com/role/StockholdersEquityNarrativeDetails", "shortName": "Stockholders' Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "cort:NumberOfStockOptionPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Stockholders' Equity - Summary of Stock-Based Compensation (Details)", "menuCat": "Details", "order": "36", "role": "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails", "shortName": "Stockholders' Equity - Summary of Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Net Income Per Share - Schedule of Computation of Net Income Per Share (Details)", "menuCat": "Details", "order": "37", "role": "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails", "shortName": "Net Income Per Share - Schedule of Computation of Net Income Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i01530646309a47ebb06ba42eaf3c9466_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Net Income Per Share - Narrative (Details)", "menuCat": "Details", "order": "38", "role": "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails", "shortName": "Net Income Per Share - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i01530646309a47ebb06ba42eaf3c9466_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Income taxes (Details)", "menuCat": "Details", "order": "39", "role": "http://www.corcept.com/role/IncometaxesDetails", "shortName": "Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i6b288e08781f4663a3c0f394d5a113a7_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Subsequent Events - Lease Amendment (Details)", "menuCat": "Details", "order": "40", "role": "http://www.corcept.com/role/SubsequentEventsLeaseAmendmentDetails", "shortName": "Subsequent Events - Lease Amendment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "idd0fc8cd558849c6b25ccd28ec2c7b81_I20230401", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "ib5b0bfa9f5d84325861468aa5f219556_I20230306", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Subsequent Events - Tender Offer (Details)", "menuCat": "Details", "order": "41", "role": "http://www.corcept.com/role/SubsequentEventsTenderOfferDetails", "shortName": "Subsequent Events - Tender Offer (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "ib5b0bfa9f5d84325861468aa5f219556_I20230306", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "5", "role": "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnauditedParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i2edb853e76e74773b24dbc4d53acd9dd_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)", "menuCat": "Statements", "order": "7", "role": "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i2edb853e76e74773b24dbc4d53acd9dd_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Composition of Certain Balance Sheet Items", "menuCat": "Notes", "order": "9", "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItems", "shortName": "Composition of Certain Balance Sheet Items", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230331.htm", "contextRef": "i086283208bed42c9a9c574f3b91b1e78_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 35, "tag": { "cort_AccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Policies [Line Items]", "label": "Accounting Policies [Line Items]", "terseLabel": "Accounting Policies [Line Items]" } } }, "localname": "AccountingPoliciesLineItems", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "cort_AccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Policies [Table]", "label": "Accounting Policies [Table]", "terseLabel": "Accounting Policies [Table]" } } }, "localname": "AccountingPoliciesTable", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "cort_AccretionExpenseIncome": { "auth_ref": [], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accretion Expense (Income)", "label": "Accretion Expense (Income)", "terseLabel": "(Accretion) amortization of interest income" } } }, "localname": "AccretionExpenseIncome", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "cort_AccruedClinicalExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are associated with clinical research and related activities, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of clinical accrued liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Clinical Expenses Current", "terseLabel": "Accrued research and development expenses" } } }, "localname": "AccruedClinicalExpensesCurrent", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "cort_AccruedCompensationCurrent": { "auth_ref": [], "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Compensation, Current", "label": "Accrued Compensation, Current", "terseLabel": "Accrued compensation" } } }, "localname": "AccruedCompensationCurrent", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cort_AccruedGovernmentRebateCurrent": { "auth_ref": [], "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued government rebate current.", "label": "Accrued Government Rebate Current", "terseLabel": "Government rebates" } } }, "localname": "AccruedGovernmentRebateCurrent", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cort_AccruedLegalFeesCurrent": { "auth_ref": [], "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to legal services. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Legal Fees Current", "terseLabel": "Legal fees" } } }, "localname": "AccruedLegalFeesCurrent", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Available for sale securities and fair value measurements.", "label": "Available For Sale Securities And Fair Value Measurements [Abstract]", "terseLabel": "Available For Sale Securities And Fair Value Measurements [Abstract]" } } }, "localname": "AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract", "nsuri": "http://www.corcept.com/20230331", "xbrltype": "stringItemType" }, "cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Available for sale securities and fair value measurements disclosure.", "label": "Available For Sale Securities And Fair Value Measurements Disclosure [Text Block]", "terseLabel": "Available-for-Sale Securities and Fair Value Measurements" } } }, "localname": "AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "cort_AvailableForSaleSecuritiesIncludingCashEquivalents": { "auth_ref": [], "calculation": { "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available for sale securities including cash equivalents.", "label": "Available For Sale Securities Including Cash Equivalents", "terseLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesIncludingCashEquivalents", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "cort_DepositsForClinicalTrials": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deposits For Clinical Trials", "label": "Deposits For Clinical Trials", "terseLabel": "Deposits for clinical trials" } } }, "localname": "DepositsForClinicalTrials", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cort_EarningsPerShareBasicAndDilutedEPSAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnings Per Share, Basic and Diluted EPS", "label": "Earnings Per Share, Basic and Diluted EPS [Abstract]", "verboseLabel": "Net income per share attributable to common stockholders" } } }, "localname": "EarningsPerShareBasicAndDilutedEPSAbstract", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "cort_EmployeeStockPurchasePlanAwardHoldingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan, Award Holding Period", "label": "Employee Stock Purchase Plan, Award Holding Period", "terseLabel": "Award holding period" } } }, "localname": "EmployeeStockPurchasePlanAwardHoldingPeriod", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "cort_IncreaseDecreaseInAccruedClinicalExpenses": { "auth_ref": [], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in accrued clinical expenses.", "label": "Increase Decrease In Accrued Clinical Expenses", "terseLabel": "Accrued research and development expenses" } } }, "localname": "IncreaseDecreaseInAccruedClinicalExpenses", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "cort_InventoryCurrentNoncurrent": { "auth_ref": [], "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total inventory.", "label": "Inventory Current Noncurrent", "totalLabel": "Total inventory" } } }, "localname": "InventoryCurrentNoncurrent", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails" ], "xbrltype": "monetaryItemType" }, "cort_InventoryFinishedGoodsCurrentAndNoncurrent": { "auth_ref": [], "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails": { "order": 2.0, "parentTag": "cort_InventoryCurrentNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory, finished goods, current and noncurrent.", "label": "Inventory Finished Goods Current And Noncurrent", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsCurrentAndNoncurrent", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails" ], "xbrltype": "monetaryItemType" }, "cort_InventoryWorkInProcessCurrentAndNoncurrent": { "auth_ref": [], "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails": { "order": 1.0, "parentTag": "cort_InventoryCurrentNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory, work in process. current and noncurrent.", "label": "Inventory Work In Process Current And Noncurrent", "terseLabel": "Work in progress" } } }, "localname": "InventoryWorkInProcessCurrentAndNoncurrent", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails" ], "xbrltype": "monetaryItemType" }, "cort_LongLivedTangibleAssetAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "LongLivedTangibleAssetAxis", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "cort_LongLivedTangibleAssetDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "LongLivedTangibleAssetDomain", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "cort_LongTermMarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Marketable Securities [Member]", "label": "Long Term Marketable Securities [Member]", "terseLabel": "Long-term marketable securities" } } }, "localname": "LongTermMarketableSecuritiesMember", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "cort_LossContingencyAccrualOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss Contingency Accrual, Other", "label": "Loss Contingency Accrual, Other", "terseLabel": "Other losses for contingent liability" } } }, "localname": "LossContingencyAccrualOther", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "cort_LossContingencyAccrualProvisionOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss Contingency Accrual, Provision, Other", "label": "Loss Contingency Accrual, Provision, Other", "terseLabel": "Other provisions for a loss contingency" } } }, "localname": "LossContingencyAccrualProvisionOther", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "cort_MarketableSecuritiesMaximumMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable securities maximum original maturity period.", "label": "Marketable Securities Maximum Maturity Period", "terseLabel": "Maximum maturity period" } } }, "localname": "MarketableSecuritiesMaximumMaturityPeriod", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails" ], "xbrltype": "durationItemType" }, "cort_MarketableSecuritiesWeightedAverageMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable securities weighted-average maturity period.", "label": "Marketable Securities Weighted Average Maturity Period", "terseLabel": "Weighted average maturity period" } } }, "localname": "MarketableSecuritiesWeightedAverageMaturityPeriod", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails" ], "xbrltype": "durationItemType" }, "cort_MelucciMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Melucci", "label": "Melucci [Member]", "terseLabel": "Melucci" } } }, "localname": "MelucciMember", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non Cash Transaction, Recognition Of Right Of Use Asset And Lease Liability", "label": "Non Cash Transaction, Recognition Of Right Of Use Asset And Lease Liability", "terseLabel": "Recognition of right-of-use asset and lease liability" } } }, "localname": "NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "cort_NumberOfCompounds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Compounds", "label": "Number Of Compounds", "terseLabel": "Number of compounds (more than)" } } }, "localname": "NumberOfCompounds", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "cort_NumberOfSeriesOfSelectiveCortisolModulators": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Series Of Selective Cortisol Modulators", "label": "Number Of Series Of Selective Cortisol Modulators", "terseLabel": "Number of series of selective cortisol modulators" } } }, "localname": "NumberOfSeriesOfSelectiveCortisolModulators", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "cort_NumberOfStockOptionPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of stock option plans.", "label": "Number Of Stock Option Plans", "terseLabel": "Number of stock option plans" } } }, "localname": "NumberOfStockOptionPlans", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "cort_RestrictedStockAwardsRSAsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Awards (RSAs)", "label": "Restricted Stock Awards (RSAs) [Member]", "terseLabel": "Restricted Stock Awards (RSAs)" } } }, "localname": "RestrictedStockAwardsRSAsMember", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "cort_RestrictedStockUnitsAndStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units and Stock Options", "label": "Restricted Stock Units and Stock Options [Member]", "terseLabel": "Restricted Stock Units and Stock Options" } } }, "localname": "RestrictedStockUnitsAndStockOptionsMember", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Shares Repurchased In Net Settlement Of Cashless Option Exercise", "label": "Shares Repurchased In Net Settlement Of Cashless Option Exercise", "terseLabel": "Exercise cost of shares repurchased for net settlement of cashless option exercises" } } }, "localname": "SharesRepurchasedInNetSettlementOfCashlessOptionExercise", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "cort_ShortTermMarketableSecuritiesMaximumMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short Term Marketable Securities Maximum Maturity Period", "label": "Short Term Marketable Securities Maximum Maturity Period", "terseLabel": "Maximum maturity period, short-term securities" } } }, "localname": "ShortTermMarketableSecuritiesMaximumMaturityPeriod", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails" ], "xbrltype": "durationItemType" }, "cort_ShortTermMarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short Term Marketable Securities [Member]", "label": "Short Term Marketable Securities [Member]", "terseLabel": "Short-term marketable securities" } } }, "localname": "ShortTermMarketableSecuritiesMember", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "cort_TenderOfferMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tender Offer", "label": "Tender Offer [Member]", "terseLabel": "Tender Offer" } } }, "localname": "TenderOfferMember", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/SubsequentEventsTenderOfferDetails" ], "xbrltype": "domainItemType" }, "cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance", "label": "Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance", "terseLabel": "Unrecognized tax benefits that would be offset by a change in valuation allowance" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "cort_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted [Abstract]", "terseLabel": "Weighted-average shares outstanding used in computing net income per common share" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract", "nsuri": "http://www.corcept.com/20230331", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r219", "r220", "r221", "r222", "r260", "r381", "r392", "r400", "r401", "r411", "r415", "r421", "r463", "r475", "r476", "r477", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r219", "r220", "r221", "r222", "r253", "r260", "r286", "r287", "r288", "r357", "r381", "r392", "r400", "r401", "r411", "r415", "r421", "r456", "r463", "r476", "r477", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r219", "r220", "r221", "r222", "r253", "r260", "r286", "r287", "r288", "r357", "r381", "r392", "r400", "r401", "r411", "r415", "r421", "r456", "r463", "r476", "r477", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r261", "r446" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.corcept.com/role/SubsequentEventsLeaseAmendmentDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r157", "r261", "r429", "r446" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.corcept.com/role/SubsequentEventsLeaseAmendmentDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r157", "r261", "r429", "r430", "r446" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.corcept.com/role/SubsequentEventsLeaseAmendmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r13", "r420" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r197", "r198" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Trade receivables, net of allowances" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r1", "r94", "r102" ], "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r2", "r94", "r102" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Long-term accrued income taxes payable" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Total accrued and other liabilities", "totalLabel": "Total accrued and other liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedMarketingCostsCurrent": { "auth_ref": [], "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Marketing Costs, Current", "terseLabel": "Accrued selling and marketing costs" } } }, "localname": "AccruedMarketingCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r59", "r116" ], "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r22", "r24", "r25", "r122", "r388", "r397", "r398" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r21", "r25", "r86", "r347", "r393", "r394", "r435", "r436", "r437", "r443", "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r5" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r293", "r294", "r295", "r443", "r444", "r445", "r466" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r82", "r83", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operations:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r291" ], "calculation": { "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails": { "order": 2.0, "parentTag": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Allocated share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquityNarrativeDetails", "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Weighted average options excluded from the computation of diluted net income per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r412", "r448" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-Backed Securities [Member]", "terseLabel": "Asset-backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r93", "r101", "r118", "r141", "r185", "r188", "r192", "r203", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r316", "r320", "r330", "r420", "r461", "r462", "r473" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r112", "r124", "r141", "r203", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r316", "r320", "r330", "r420", "r461", "r462", "r473" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r50" ], "calculation": { "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r51" ], "calculation": { "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r200", "r210" ], "calculation": { "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r49", "r199", "r210", "r383" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Total marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails", "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]", "terseLabel": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r43", "r114", "r402" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r38", "r43", "r44" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, at end of period", "periodStartLabel": "Cash and cash equivalents, at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r38", "r91" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Shareholders Equity [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r17", "r96", "r106" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 4)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r61", "r216", "r217", "r399", "r460" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r443", "r444", "r466" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common\u00a0Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r4", "r68" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r4", "r420" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r26", "r129", "r131", "r135", "r384", "r389" ], "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r416", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Software" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r31", "r382" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r30" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Summary of the classification of available-for-sale securities in condensed consolidated balance sheets" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r296", "r297" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets, net" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r41", "r85", "r303", "r308", "r309", "r442" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "verboseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r41", "r183" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization of property and equipment" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r136", "r149", "r150", "r151", "r152", "r153", "r158", "r161", "r171", "r172", "r173", "r177", "r325", "r326", "r385", "r390", "r405" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income per share (in dollars per share)", "verboseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r136", "r149", "r150", "r151", "r152", "r153", "r161", "r171", "r172", "r173", "r177", "r325", "r326", "r385", "r390", "r405" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income per share (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r174", "r175", "r176", "r178" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r292" ], "calculation": { "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails": { "order": 1.0, "parentTag": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Amount Capitalized", "terseLabel": "Stock-based compensation capitalized in inventory" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options to Purchase Common Stock", "verboseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails", "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r68", "r110", "r132", "r133", "r134", "r144", "r145", "r146", "r148", "r154", "r156", "r179", "r204", "r250", "r293", "r294", "r295", "r304", "r305", "r324", "r331", "r332", "r333", "r334", "r335", "r336", "r347", "r393", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r232", "r329", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimate of fair value measurement" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r232", "r254", "r255", "r256", "r257", "r258", "r259", "r327", "r354", "r355", "r356", "r409", "r410", "r412", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r89", "r90", "r232", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r232", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r232", "r254", "r259", "r327", "r354", "r412", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r232", "r254", "r259", "r327", "r355", "r409", "r410", "r412", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r232", "r254", "r255", "r256", "r257", "r258", "r259", "r354", "r355", "r356", "r409", "r410", "r412", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r201", "r202", "r205", "r206", "r207", "r208", "r209", "r211", "r212", "r213", "r233", "r247", "r322", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r408", "r450", "r451", "r452", "r483", "r484", "r485", "r486", "r487", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r27", "r92", "r97", "r108", "r185", "r187", "r191", "r193", "r386", "r407" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r214", "r215" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r142", "r299", "r301", "r302", "r306", "r310", "r312", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r143", "r155", "r156", "r184", "r298", "r307", "r311", "r391" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax expense", "terseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.corcept.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r40" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r40" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade receivables" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": { "auth_ref": [ "r438" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.", "label": "Increase (Decrease) in Accrued Taxes Payable", "terseLabel": "Long-term accrued income taxes" } } }, "localname": "IncreaseDecreaseInAccruedTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r40" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r438", "r470" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r40" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Accrued and other liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r40" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r162", "r163", "r164", "r173", "r263" ], "calculation": { "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Dilutive effect of employee stock options and unvested RSUs (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InsuranceRecoveries": { "auth_ref": [ "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.", "label": "Insurance Recoveries", "terseLabel": "Insurance recoveries" } } }, "localname": "InsuranceRecoveries", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableCurrent": { "auth_ref": [ "r432" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Interest Receivable, Current", "terseLabel": "Interest receivable, current" } } }, "localname": "InterestReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r123", "r403", "r420" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails_1": { "order": 2.0, "parentTag": "cort_InventoryCurrentNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "verboseLabel": "Total inventory classified as current" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r431" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails_1": { "order": 1.0, "parentTag": "cort_InventoryCurrentNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "negatedLabel": "Less strategic inventory classified as non-current", "terseLabel": "Strategic inventory" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of information of leases asset and liabilities" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of future minimum lease payments under non-cancelable operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r345" ], "calculation": { "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r472" ], "calculation": { "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2023 (remainder)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r345" ], "calculation": { "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Extended lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/SubsequentEventsLeaseAmendmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r14", "r141", "r203", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r317", "r320", "r321", "r330", "r406", "r461", "r473", "r474" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r9", "r95", "r104", "r420", "r441", "r453", "r467" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r16", "r113", "r141", "r203", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r317", "r320", "r321", "r330", "r420", "r461", "r473", "r474" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Payment awarded to other party" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "terseLabel": "Litigation settlement, expense" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r62", "r63", "r218", "r219", "r220", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "auth_ref": [ "r218" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.", "label": "Loss Contingency, Accrual, Current", "terseLabel": "Accrued settlement related to Melucci litigation (Note 4)", "verboseLabel": "Accrued liability, litigation" } } }, "localname": "LossContingencyAccrualCarryingValueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.corcept.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyReceivableCurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected within one year or the normal operating cycle, if longer. For example, an insurance recovery receivable.", "label": "Loss Contingency, Receivable, Current", "terseLabel": "Insurance recovery receivable related to Melucci litigation (Note 4)", "verboseLabel": "Insurance recovery receivable" } } }, "localname": "LossContingencyReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.corcept.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Short-term marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Long-term marketable securities" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Marketable Securities, Unrealized Gain (Loss)", "terseLabel": "Other comprehensive income (loss), net of tax" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r139" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r139" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r38", "r39", "r42" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r28", "r42", "r98", "r107", "r111", "r128", "r130", "r134", "r141", "r147", "r149", "r150", "r151", "r152", "r155", "r156", "r169", "r185", "r187", "r191", "r193", "r203", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r326", "r330", "r407", "r461" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited", "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r149", "r150", "r151", "r152", "r158", "r159", "r170", "r173", "r185", "r187", "r191", "r193", "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net income attributable to common stockholders, basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r160", "r165", "r166", "r167", "r168", "r170", "r173" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net income attributable to common stockholders, diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r34" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Interest and other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r185", "r187", "r191", "r193", "r407" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r468" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expenses", "verboseLabel": "Rent expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/LeasesNarrativeDetails", "http://www.corcept.com/role/SubsequentEventsLeaseAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r339" ], "calculation": { "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "verboseLabel": "Present value of operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r339" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Short-term operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.corcept.com/role/SubsequentEventsLeaseAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r340", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r338" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.corcept.com/role/SubsequentEventsLeaseAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r439" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Non-cash amortization of right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r344", "r419" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r343", "r419" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r117" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r125", "r126", "r127" ], "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Unrealized gain (loss) on available-for-sale investments, net of tax effect of $(192) and $323, respectively" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r20" ], "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation gain (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "auth_ref": [ "r23", "r126" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax", "verboseLabel": "Unrealized gain (loss) on available-for-sale investments, tax expense (benefit)" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "terseLabel": "Purchase price of stock repurchase" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/SubsequentEventsTenderOfferDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r137" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants", "terseLabel": "Payment tax withholding share-based payment arrangement" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r48" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r35" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at fair value measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r3", "r420" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r433" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r36" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Proceeds from issuance of common stock under our incentive award plan, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r111", "r128", "r130", "r138", "r141", "r147", "r155", "r156", "r185", "r187", "r191", "r193", "r203", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r315", "r318", "r319", "r326", "r330", "r386", "r407", "r417", "r418", "r437", "r461" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r58", "r115" ], "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r60", "r105", "r387", "r420" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r84", "r109", "r481" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards (RSAs)" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails", "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails", "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r6", "r75", "r103", "r396", "r398", "r420" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r110", "r144", "r145", "r146", "r148", "r154", "r156", "r204", "r293", "r294", "r295", "r304", "r305", "r324", "r393", "r395" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r181", "r182", "r186", "r189", "r190", "r194", "r195", "r196", "r251", "r252", "r382" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Product revenue, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r342", "r419" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in connection with new operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of other accrued liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails", "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of available-for-sale securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r52", "r53", "r54", "r55", "r56", "r57", "r99", "r100" ], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-Sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails", "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of computation of net income per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r79", "r81" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of stock-based compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r0", "r10", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of composition of inventory, current" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.", "label": "Schedule of Inventory, Noncurrent [Table Text Block]", "terseLabel": "Schedule of composition of inventory, noncurrent" } } }, "localname": "ScheduleOfInventoryNoncurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r65", "r66", "r67", "r69", "r70", "r71", "r72", "r73", "r74", "r75", "r119", "r120", "r121", "r180", "r234", "r235", "r236", "r238", "r242", "r247", "r249", "r411", "r428", "r440" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r33" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SettledLitigationMember": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.", "label": "Settled Litigation [Member]", "terseLabel": "Settled Litigation" } } }, "localname": "SettledLitigationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r40" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Grants in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r275", "r276" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "ESPP maximum employee subscription rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r267", "r268" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "terseLabel": "Stock options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "terseLabel": "Shares issued in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails", "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/SubsequentEventsTenderOfferDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/SubsequentEventsTenderOfferDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "auth_ref": [ "r290" ], "calculation": { "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "totalLabel": "Total stock-based compensation" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises (in shares)", "terseLabel": "Shares withheld for tax withholding obligation (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r18", "r68", "r110", "r132", "r133", "r134", "r144", "r145", "r146", "r148", "r154", "r156", "r179", "r204", "r250", "r293", "r294", "r295", "r304", "r305", "r324", "r331", "r332", "r333", "r334", "r335", "r336", "r347", "r393", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r144", "r145", "r146", "r179", "r382" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r3", "r4", "r68", "r75", "r272" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Issuance of common stock upon exercise of options (in shares)", "verboseLabel": "Common shares issued upon exercise of options (in share)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r18", "r68", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Number of shares repurchased (in shares)" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/SubsequentEventsTenderOfferDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r4", "r7", "r8", "r47", "r420", "r441", "r453", "r467" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r78", "r140", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r248", "r250", "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/SubsequentEventsLeaseAmendmentDetails", "http://www.corcept.com/role/SubsequentEventsTenderOfferDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r337", "r349" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/SubsequentEventsLeaseAmendmentDetails", "http://www.corcept.com/role/SubsequentEventsTenderOfferDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r337", "r349" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/SubsequentEventsLeaseAmendmentDetails", "http://www.corcept.com/role/SubsequentEventsTenderOfferDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r337", "r349" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/SubsequentEventsLeaseAmendmentDetails", "http://www.corcept.com/role/SubsequentEventsTenderOfferDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r337", "r349" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/SubsequentEventsLeaseAmendmentDetails", "http://www.corcept.com/role/SubsequentEventsTenderOfferDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r348", "r350" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Composition of Certain Balance Sheet Items" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItems" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r201", "r202", "r233", "r247", "r322", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r450", "r451", "r452", "r483", "r484", "r485", "r486", "r487", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Common stock repurchased, average price (in dollars per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/SubsequentEventsTenderOfferDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Number of treasury shares outstanding (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r19", "r76", "r77" ], "calculation": { "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "negatedLabel": "Treasury stock" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r4", "r68", "r75" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury stock shares acquired (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/SubsequentEventsTenderOfferDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r404", "r412", "r482" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government agency securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r404", "r412", "r414", "r482" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.", "label": "Unrecognized Tax Benefits, Period Increase (Decrease)", "terseLabel": "Unrecognized tax benefits, period increase" } } }, "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r160", "r173" ], "calculation": { "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average shares used to compute diluted net income per share (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r158", "r173" ], "calculation": { "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average shares used to compute basic net income per share (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r422": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r423": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r424": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r425": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r426": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r427": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r434": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r449": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 61 0001628280-23-015236-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-015236-xbrl.zip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end